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THESIS SUMMARY 
Prostate cancer is the second highest cause of cancer death in men and its transformation to 
an untreatable state depends on the loss of the cells' requirement for androgen. 
Metalloproteinases such as matrix metalloproteinases (MMPs), a disintegrin and 
metalloproteinases (ADAMs) and a disintegrin and metalloproteinase with thrombospondin 
motifs (ADAMTSs) are implicated in prostate cancer. Tissue inhibitor ofmetalloproteinase 
(TIMP) is a family of 4 inhibitors whose major functions are to regulate the activity of 
metalloproteinases. TIMP-3 inhibits ADAMTSs, MMPs and ADAMs, and independently 
inhibits angiogenesis. 
The aims of this research were to investigate the expression and modulation of TIMP-3 in 
prostate stromal and cancer cells in order to better understand its role(s) in prostate cancer. 
The effects of androgen, growth factors and cytokines on TIMP-3 expression in prostate 
stromal and cancer cells were analysed. Co-culture analyses were employed to investigate 
the effect of cell-cell contact on TIMP-3 expression. RNAi experiments were carried out to 
study the effects of TIMP-3 inhibition on biological functions. Tissue micro array analyses 
were carried out in order to investigate correlation of TIMP-3 expression with prostate 
cancer malignancy. 
TIMP-3 expression was higher in prostate stromal cells than cancer cells. Co-culture 
analyses showed up-regulation of TIMP-3 in stromal cells and down-regulation in cancer 
cells. Immuno-staining in prostate tissues demonstrated higher TIMP-3 staining normal and 
benign tissues compared to malignant tissue. The modulation of TIMP-3 expression 
observed by androgen was cancer-cell-specific and by growth factors/cytokines was 
stromal-cell-specific. RNAi-mediated down-regulation of TIMP-3 in cancer-associated 
stromal cells resulted in increased migration and invasion. ECM lysates from transfected 
stromal cells demonstrated reduced MMP-2 inhibition. 
Overall, these results show the interplay of the stromal and tumour compartments in 
modifying the activity of prostate tumour, and suggest that TIMP-3 is important in 
modulating the migration and invasive potential. 
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1.1. THE PROSTATE GLAND 
In humans, the male reproductive system comprises internal and external organs, all of 
which work together for reproduction. The external organs are the penis and the scrotum 
and the internal organs are the testes, vas deferens, epididymis, seminal vesicle, Cowper 
glands and the prostate gland (Benoit et aI., 1993). The prostate gland surrounds the urethra 
and is located behind the bladder and in front of the rectum (Figure 1.1). It participates in 
the production of semen, in conjunction with the testes, seminal vesicles and Cowper 
glands and also plays an important role in the transportation of spenn out of the penis 
(Kumar and Majumder, 1995). The prostate is small, walnut-shaped and measures about 3 
cm in diameter and weighs about 20 - 25 g. The prostate secretes prostatic fluid which 
makes up about 35% of the total semen (Aumuller and Seitz, 1990). The seminal vesicle 
also secretes viscous fluid into the prostate and mixes with the prostatic fluid to fonn 
seminal fluid. The testicles are based within the scrotum and they secrete the male honnone 
- testosterone that facilitates the production of spenn - this is further transported by the vas 
deferens into the prostate and this mixes with the seminal fluid to fonn semen. The prostate 
is responsible for contracting and expelling the semen into the penis by the action of the 
smooth muscle cells contained in the prostate gland (Aumuller and Seitz, 1990). 
The prostate is divided into three zones (Figure 1.1): 
• Peripheral zone 
• Transitional zone 
• Central zone 
The peripheral zone is located at the posterior of the prostate and is the largest zone in the 
gland while the transitional zone is located at the anterior of the prostate. The central zone 
can be found between the anterior and the posterior of the prostate and this is the zone 
connected to the seminal vesicle (McNeal, 1997). 
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Figure 1.1: The Anatomy of the Male Reproductive System. 
This diagram shows both the external and internal organs that are in the male reproductive 
system. The three zones o/the prostate gland are highlighted in red. This image is used and 
modified lvith the permission 0/ the copyright owner: Nucleus Medical Images (see 
Appendix/or more information). 
Alterations in the rate of growth of epithelial cells within the peripheral region results in 
majority of tumours of the prostate, while overgrowth of predominantly stromal and 
fibrobla t cells within the transitional zone and, to a lesser extent, the overgrowth of 
epithelial cells in the transitional zone, results in the majority of benign prostatic 
hyperplasia (BPH) (McNeal, 1978). 
1.2 BENIGN PROSTATIC HYPERPLASIA (BPH) 
BPH is a disorder which occurs as a result of overgrowth of the stromal fibroblast and 
smooth muscle cells within the transitional zone of the prostate (Figure 1.2) (McNeal, 
1978). This is an occurrence that increases with age (Altwein and Orestano, 1975). In BPH, 
there is an altered balance in the homoeostasis of ECM turnover, in favour of increased 
accumulation of ECM. This is mediated my several growth factors, including fibroblast 
growth factors (FGF), insulin-like growth factors (IGF) and transforming growth factor 
beta (TGF-~) (Eaton, 2003). The overgrowth is benign and, if sufficiently large, results in 
con triction of the pro tatic urethra. The outcome of this constriction is blockage of the 
passage of urine from the bladder to the peni , leading to symptoms of urinary retention 
and the need for frequent urination, otherwise known as lower urinary tract symptoms 
(LUTS) (Robert, 1994). If unchecked, these symptoms could develop into infection of the 
19 
urinary tract, fonnation of bladder stones in the bladder a a re ult of accumulation of alt 
from urine inside the bladder, and, more serious, failure of the kidney (Reynard and 
Abrams, 1994). 
Bladder ---
Prostate gland 
Urethra 
Enlarged 
prostate gland 
Constricted ----fo\_; 
urethra 
Normal Prostate Anatomy 
BPH Prostate Anatomy 
Figure 1.2: The Normal and BPH Prostate Anatomy. 
This diagram illustrates the conformation of the prostatic urethra in normal prostate and 
its constriction in an enlarged prostate in BPH. Thi image is u ed with the permi ion of 
the copyright owner: Nucleus Medical images (. ee Appendixfor more information). 
The occurrence of clinical BPH is most common in men above the age of 50 and a much 
as one third of men have BPH by the age of 50. Thi percentage increa e to ab ut 5% by 
the age of 90 (McVary, 2006). As at 2010, about 30 million ca e of BPH had been 
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recorded worldwide, with the highest percentage of cases recorded within the U.S.A. 
(Gabuev and Oelke, 2011). 
The role of androgen in the form of dihydrotestosterone in the manifestation of BPH cannot 
be overlooked. The main androgen produced in the prostate is testosterone and this is 
converted to an active dihydrotestosterone by the enzyme 5-a-reductase (Silver et aI., 1994, 
Russell and Wilson, 1994). Up regulation of both circulating DHT and 5-a-reductase levels 
have been reported in BPH cases (Silver et aI., 1994) and this led to the use of 5-a-
reductase inhibitors such as finasteride for management of BPH (Seftel, 2005). These 
inhibitors are used either for monotherapy or alongside alpha-adrenergic blockers such as 
Tamsulosin as combinatorial therapy for patients that do not respond to 5-a-reductase 
inhibitors only and require alpha blockers to relax the smooth muscle cells in the prostate 
and relieve the pressure on the urethra (Shakir et aI., 2001). The presence of elevated levels 
of growth factors other than DHT in the prostate has also been implicated in the 
progression of BPH. The accumulation and formation of stromal fibroblasts in the benign 
growth in the prostate has been shown to result in an increase in the secretion of cytokines 
such as TGF-~ which can then trigger several signalling pathways such as the MAPK 
pathway and activate transcription factors that drive continuous growth of the fibroblasts 
and ECM synthesis within the prostate (Macoska, 2011). TGF-~ transforms fibroblasts to 
myofibroblasts, which make smooth muscle actin, ECM matrix and proteinases (Border 
and Noble, 1994, Border et aI., 1994) and is pivotal to many cancers where the progression 
is enhanced as a result of stromal fibroblasts producing more matrix and proteinases 
(Kohrmann et aI., 2009, Duffy and McCarthy, 1998). Stromal fibroblasts can also regulate 
the growth of epithelial cells by the secretion of growth factors such as IGF-l (McLaren et 
aI., 20 II, Crescioli et aI., 2002), which plays a cellular proliferative role and can lead to an 
increase in both the stromal compartment and glandular epithelial compartment of the 
prostate and subsequent enlargement of the size of the prostate and LUTS. Thus, the 
epithelial and stromal interaction within the prostate is very important in the progression of 
BPH. 
Diagnosis of BPH is initially by digital rectum evaluation (ORE) of the size of the prostate 
via the rectum and blood test to measure the levels of prostate-specific antigen (PSA; 
kallikrein-related peptidase 3; hK3;) (Uno, 1995). PSA is a serine proteinase secreted by 
epithelial cells in the prostate into the lumen of the prostatic ducts and forms part of the 
seminal fluid (Wang et aI., 1979).These tests are also used for the diagnosis of prostate 
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cancer (as well as BPH) and a high level of PSA in serum is indicative of elevated eminal 
fluid levels and subsequent escape into the blood. Histological examination of prostate 
tissue will confinn the presence or absence of malignancy and will differentiate whether the 
increase in prostate size is as a result of development of prostate cancer or BPH. It will also 
show a larger stromal compartment relative to nonnal prostate tumour (see Figure 1.3). 
Normal Prostate Tissues 
Primary Prostate Cancer Tissues 
(GS 6) 
BPH Tissues 
Figure 1.3: Immuno-histochemical Analyses of Prostate Tissues. 
Normal, primary prostate cancer and BPH tissues were donated by Dr Colby Eaton 's 
group at the University of Sheffield, u.K. Haematoxylin and Eosin Staining was carried out 
according to methods described in Section 2. I 7. Normal prostate tissues are characterised 
by the presence of intact glandular structures (red arrows) while erosion of basement 
membrane and disruption of glandular structures are present in primary prostate cancer 
tissue (blue arrows). In BPH, there is an increase in the surrounding stroma (green 
arrows) and this distinguishes the BPH tissue from prostate cancer tissues. The images 
were obtained using an inverted microscope and black bar represents size of I 00 11M 
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1.3 PROST A TE CANCER 
1.3.1 Pathophysiology of Prostate Cancer 
Prostate cancer is a malignant tumour that occurs predominantly in the peripheral region of 
the prostate gland and has metastatic potential i.e. it can spread to surrounding tissues and 
organs. It begins as a form that is treatable particularly among the elderly (Hemminki et aI., 
2005) but often progresses to become untreatable. Prostate cancer is a multifactorial disease 
and the aetiology is not completely understood. The most prominent phenotype is the loss 
of androgen-dependence on cell growth and survival within the prostate. Androgen is the 
main growth hormone in the prostate and normal prostate epithelial cells require constant 
levels of DHT to survive and this survival mechanism is regulated by the presence of the 
androgen receptor (Veldscholte et aI., 1990). In prostate cancer, the tumour cells bypass 
this androgen signalling pathway via alternative means, the most common of which is 
androgen receptor mutation, and therefore are able to multiply unchecked (Trapman and 
Brinkmann, 1996, Craft et aI., 1999, D'Antonio et aI., 2010). Several mutations in the AR 
have been identified - replacement, addition or deletion of amino acids can lead to 
alteration of the protein function (Rajender et aI., 2010, Rajender et aI., 2007, Zhao et aI., 
1999) and therefore render the AR unable to regulate the levels of DHT. The increase in 
circulating DHT levels results in the increase in epithelial cell growth and is an initiating 
factor for growth of malignant tumours. The intricacies of androgen receptor signalling are 
discussed at length in Chapter 4: Section 4.1 of this report. 
1.3.2 Epidemiology of Prostate Cancer 
Prostate cancer is the most common cancer in men and accounts for 24 out of every 100 
cases of male cancers in the U.K (Ferlay et aI., 2010). It is the most common cancer in 
males and is the second highest cause of cancer death in males in the U.K. and the U.S.A, 
exceeded only by lung cancer (Hsing and Chokkalingam, 2006) (Ferlay et aI., 2010). Its 
occurrence is usually linked to age and ethnic background (Parker et aI., 2011), genetic pre-
disposition, environmental factors (Wu et aI., 2009b, Ekman et aI., 1999) and even diet 
(Kenfield et aI., 2007, Wolk, 2005, Mills et aI., 1989). As with BPH, prostate cancer is 
prevalent in men over 50 (Ferlay et aI., 2010) and can remain non-progressive, undetected 
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and undiagnosed for several years. Prostate cancer is prevalent in Europe and Africa, and 
not so much in Asia (Ferlay et aI., 2010). There is a greater prevalence in black-Africans 
compared to Caucasians, and the least number of cases have been reported in Asians. In the 
U.K. alone, the number of prostate cancer cases in men over 50 years of age is 155 out of 
100,000 men - this rate increases with age and the incidence increases to 510 out of 
100,000 in men over the age of 60 and 750 per 100,000 in men over the age of 70. The rate 
of diagnosis is higher in developed regions of the world such as Europe, Australia and 
North America, with the lowest rate in Asia (Ferlay et aI., 2010). Although black Africans 
have a higher risk of prostate cancer, under-diagnosis and late presentation are quite 
common (Heyns et aI., 2003) as a result of almost non-existent PSA screening and 
reluctance of patients to seek medical advice when presenting with symptoms (Kehinde, 
1995) reviewed in (Olapade-Olaopa et aI., 2008). Therefore the data collated from regions 
such as West Africa are already biased as a result of these factors (Chu et aI., 2011). The 
mortality rate is usually lower than the incidence rate (as shown in Figure 1.4) in developed 
countries as a result of better screening regimes and availability of resources for disease 
management. Developing and under-developed regions, on the contrary, have a higher 
proportion of mortality in cases presented and almost 1: 1 ratio of incidence to mortality 
ratios. This is not surprising, given the lack of management resources available in these 
regions. 
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Figure 1.4: Rates of Incidence and Mortality of Prostate Cancer Worldwide. 
These data were culled from the GLOBOCAN database, as compiled by the International 
Agency for Research on Cancer (2010) (Ferlay, Shin et aI, 2008). The raw dala are also 
available from http://globocan.iarc.fr 
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1.3.3 Staging of Prostate Cancer 
The size of a tumour and the extent of its migration and invasion can be described using the 
TNM system of classification of cancer. This system was first described in 1942 and has 
since been adapted by the Union for International Cancer Control (UICC) as a standard 
method of classification of the severity of several cancers, including prostate cancer 
(Wallace et al., 1975). The acronym stands for: 
• T = size of the Iumour 
• N = degree of spread of tumour to proximal lymph Nodes 
• M = degree of distal tumour Metastasis 
Usually, a letter X denotes the absence of any of the above occurrences and numbers denote 
the size of the tumour (T) or the extent of local spread (N) or distal metastasis of the tumour 
(M). The different stages are described below: 
• T 
o Tx: primary tumour cannot be evaluated 
o TO: no apparent sign of tumour 
o Tl, T2, T3 or T4: size and extension of the primary tumour 
• N 
o Nx: lymph nodes cannot be evaluated 
o NO: primary tumour cells absent from regional lymph nodes 
o N 1: regional lymph node tumour metastasis present in small number of 
lymph nodes or lymph nodes closest to primary site of tumour 
• 
o N2: tumor spread to an extent between Nt and N3 
o N3: regional and distal lymph node tumour metastasis or tumour present in 
numerous lymph nodes 
o 
o 
o 
M 
Mx: distant metastasis of primary tumour cannot be evaluated 
MO: no distant metastasis 
M 1 : metastasis to distant organs (beyond regional lymph nodes) 
The stage of prostate cancer is usually assessed by a combination of ORE, imaging and 
surgical evaluation. ORE identifies the palpable size of the tumour and imaging techniques 
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such as x-rays, computed tomography scan (CT scan) and magnetic resonance imaging 
(MRI) can inform the physician about the location of the tumour both in the primary and 
any secondary sites (Quintens et aI., 1990, Khoo et aI., 1999). In instances whereby surgery 
has been utilized as a management regime, the surgeon is able to report any proximal or 
distant metastasis of the tumour away from the primary site. All of the information 
collected enables the patient to be assigned a stage e.g. prostate cancer TINOMO is cancer 
with small palpable tumour and no lymph node or distal metastasis away from the primary 
site (see Figure 1.5). 
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TNM Staging 
Tumor is NOT palpable by 
digital rectal exam (ORE) 
Tumor extends out of 
capsule to seminal vesicles 
but no other organs 
Tumor spreads to 
lymph nodes 
Tu"",," 
Tumor is palpable by 
digital rectal exam (ORE) 
T4 Stage 
..-~-....., 
Tumor spreads to tissues 
around the prostate 
Cancer metastasizes to 
distant lymph nodes 
and organs 
Figure 1.5: The TNM Staging in Prostate Cancer. 
The T stages Tl - T4 are represented, with Tl being the small prostate confined tumour, T2 
is the enlarged prostate confined tumour that is palpable by DRE and restricted only to the 
peripheral zone of the prostate, T3 is showing tumour extending to the central and 
transitional zones of the prostate and neighbouring seminal vesicles while T4 is showing 
the tumour enlarged, filling the three prostate zones and spreading to tissues around the 
prostate, constricting the neighbouring bladder and rectal muscles. N stage depicts the 
spread of the tumour into neighbouring lymph nodes and M stage depicts the distant 
metastasis of the tumour to secondary sites such as the brain. Copyright permission 
grantedfor the use of the image (see Appendix). 
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1.3.4 Grading of Prostate Cancer 
The Gleason system was developed in 1977 and has been widely accepted as a standard for 
grading of prostate tumours (Gleason, 1977). This system is based solely on morphology 
and histochemical analyses of the tumour. Prostate tissue biopsy samples are sent to the lab 
for analysis by a pathologist. Microscopic examination of the biopsy specimens reveal 
tumour patterns ranging from well-differentiated, small glands to poorly differentiated 
sheets or cords of malignant cells. Five distinct glandular patterns are graded progressively 
from most to least differentiated. This is referred to as the Gleason Grade (GG) of the 
tumour and range from GG of 1 (well differentiated) to GG of 5 (poorly differentiated). The 
GG of the two predominant patterns present in a biopsy specimen are added to yield the 
final Gleason Score (GS) (see Figure 1.6). GS correlates well with other known prognostic 
factors, such as tumour size, presence of pelvic lymph-node metastasis, and PSA level 
(Baker AH et aI., 2002) The lower the GS, the better the patient's prognosis and vice versa. 
Together with the TNM staging, the degree of malignancy of a tumour can be reported. 
The occurrence of prostatic intra-epithelial neoplasia (PIN) is characteristic of pre-
malignant tumours and is commonly detected in prostate tissue biopsies collected for 
examination to diagnose prostate cancer (Bostwick et aI., 1995, Gaudin et aI., 1997). PIN is 
characterised by the presence of abnormally formed epithelial cells contained within the 
glandular ducts. The cells form abnormally shaped glands that appear enlarged and sheet-
like and erode into the surrounding stroma (Egevad et aI., 2006, Algaba Arrea et aI., 1997). 
PIN is a precursor to prostate cancer and many patients with detectable PIN in their tissue 
biopsy specimen go on to develop prostate cancer (Zlotta and Schulman, 1999) (Dickinson, 
2010) (see Figure 1.7). 
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Figure 1.6: The Gleason Grading of Prostate Cancer. 
The Copyright permission granted by Elsevier/RightsLink for the use of the image (see 
Appendix). Gleason grade (GG) of 1 is assigned to tissue that is well differentiated and 
retains the glandular structures and is very similar to the glandular conformation ob erved 
in normal tissue. GG of 2 is assigned to tissue that is still differentiated but les so, in 
comparison to GG 1 tissue. GG of 3 is assigned to tissue with signs of glandular 
disintegration and can be mild to moderate (A), moderate (B) or prominent (C) glandular 
disaggregation within the tissue. GG of 4 is assigned to tissue with poor differentiation and 
invasion of surrounding stroma, with the formation of non-distinct shaped cell rna e and 
can range from tissues with minimal glandularity (A) to no glandularity (B). GG of 5 is 
assigned to tissues with no existing glands and the formation of infiltrating sheets of cells 
that can range from moderately flat sheets (A) to flat sheets (B). 
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Prostate can cer ti ssu es 
High Grade PIN lissues 
Normal Prostate lissues 
Figure 1. 7: Immuno-histochemical Analyses of Prostate Tissues. 
Prostate cancer, high-grade PIN and normal prostate tissues were donated by Dr Colby 
Eaton's group at the University of Sheffield, u.K. Haematoxylin and Eosin Staining was 
carried out according to methods described in Section 2.17. Normal prostate tissues are 
characterised by the presence of intact glandular structures (red arrows) while erosion of 
basement membrane and disruption of glandular structures are present in primary prostate 
cancer tis ue (blue arrows). In high-grade PIN tissues, there is formation of abnormally 
shaped glands and glandular infiltration of surrounding stroma (green arrows). The 
images were obtained using an inverted microscope and black bar represents size of 100 
pM. 
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1.3.5 Symptoms of Prostate Cancer 
Many people with prostate cancer experience no symptoms but some patients have 
symptoms, which include: 
• Difficult and painful urination 
• Blood in the urine 
• Hip and back pain 
• Frequent urination 
• Decreased force of urine stream (Miller et aI., 2003) 
The above symptoms are also characteristic of BPH. In metastatic prostate cancer, 
symptoms can include: 
• Weight loss 
• 
• 
• 
• 
Anaemia 
Weakness or paralysis due to compression of the spinal cord 
Pain in the bones and joints 
In some cases, kidney failure (Kufe et aI., 2003) 
1.3.6 Diagnosis of Prostate Cancer 
Prostate cancer progression is usually monitored by carrying out a prostate specific antigen 
(PSA) test. This involves measuring the serum levels of PSA, which is originally produced 
in the semen. PSA is a glycoprotein and a member of the kallikrein family of serine 
proteases (MEROPS ID: S01.162, http://merops.sanger.ac.uk). PSA is an androgen 
dependent marker for prostate cancer progression and can also be used during screening to 
identify those at risk of prostate cancer (Heinlein and Chang, 2004). However, this test is 
not a very good diagnostic marker as some patients with benign prostate enlargement also 
produce elevated levels of PSA (Baker AH et aI., 2002) Therefore, tissue biopsy specimen 
has to be collected and histologically analysed for a complete diagnosis of prostate cancer. 
In some cases, CT and MRI scans can also be carried out to detect any metastasis specific 
to malignancy only (Tzikas et aI., 2011). 
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1.3.7 Management of Prostate Cancer 
In patients at the early stage of the disease, where the tumour is still localised within the 
prostate and patients have low Gleason grades and PSA levels, patients may undergo 
surgical removal of the tumour and radiotherapy as curative measures, though not 100% 
efficient. However, the chances of eradicating the disease at this early stage are increased 
with surgery (Balk, 2002). In advanced stages of the disease where the cancer has spread to 
lymph nodes surrounding the prostate, androgen ablation therapy is employed as a method 
of treatment, whereby anti-androgen drugs such as flutamide (Higano et aI., 1996) and 
bicalutamide (See et aI., 2001) are given to patients with a view to controlling the growth of 
the tumour. By the time the disease advances to the distant metastatic stage, the majority of 
patients would have developed hormone-refractory prostate cancer, whereby tumour 
growth is independent of the presence of androgen and so anti-androgen drugs are 
ineffective (Balk, 2002). At this stage, the disease is untreatable. The loss of androgen 
sensitivity is thought to arise from a mutation in the androgen receptor a ligand-activated 
nuclear transcription factor that is important for the growth of prostate cancer and its 
response to hormone therapy (Taplin et aI., 2003). 
1.3.8 The Role of the Stromal compartment in Cancer 
The stroma is an important component of the cellular microenvironment, providing support 
and nutrition for growing cells. In the tumour microenvironment, the role of the stroma is 
particularly important because there exists alterations in the conformation of the epithelial 
cells, leading to a concomitant change in the stromal compartment as well (De Wever and 
Mareel, 2003, Bishop, 1991). There are several components of the stroma - these include: 
inflammatory cells, endothelial cells, fibroblasts and matrix components, all of which play 
crucial roles in the development of the tumour (Mareel and Leroy, 2003). 
The inflammatory cells comprise mast cells, macrophages and polymorphonuclear 
leukocytes (PMN), all of which work together to effect tissue response to injury or 
inflammation. The mast cells secrete soluble growth factors, proteinases and cytokines that 
mediate angiogenesis and proliferation of endothelial, fibroblast and tumour cells 
(Coussens et aI., 1999). Macrophages also produce several cytokines and pro-angiogenic 
factors that support stromal cell proliferation (Ono et aI., 1999). PMNs are immune-
response mediators and act as first line of defense in tissue invasion and inflammation. 
They recruit immune cells and secrete a host of cytokines and chemokines in response to 
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inflammation (Di Carlo et aI., 200 I). In the hypoxic conditions associated with the tumour 
microenvironment, the inflammatory cells produce cytokines and proteases that effect 
alterations in the ECM and guide both cell proliferation and cell killing (Di Carlo et aI., 
2001). 
The endothelial cells respond to the presence of a tumour by eliciting increased 
angiogenesis to supply blood to the growing tumour (Carmeliet and Jain, 2000). Also, the 
increase in tumour vasculature enables the tumour cells to metastasize out of the primary 
site - a phenomenon characteristic of several advanced cancers as reviewed previously 
(Folkman, 1995). Angiogenesis is mediated by secreted growth factors both from the 
tumour cells as well as the endothelial and inflammatory cells and these growth factors 
mediate endothelial cell growth and motility. One of the most important of these pro-
angiogenic factors is vascular endothelial growth factor (VEGF) which is primarily 
secreted by the endothelial cells and macrophages, and to some extent by the cancer cell in 
the tumour environment (Carmeliet and Jain, 2000). Endothelial cells also secrete 
endothelin-l (ET -1) which enables proliferation of endothelial cells (Unoki et aI., 1999). 
With increase in tumour size come increases in pro-angiogenic factors such as transforming 
growth factor beta (TGF-I3) and platelet-derived growth factor (PDGF), all of which 
modulate vascularisation and metastasis of the tumour (Lippman et aI., 1987, Jechlinger et 
al.,2006). 
The fibroblasts, also components of the stroma, play an important role in the tumour 
microenvironment. First there is a paracrine effect of the tumour cells on the fibroblasts -
an increase in the secreted levels of TGFI3 by tumour cells result in recruitment of 
fibroblasts to the tumour and subsequent activation of fibroblasts to myofibroblasts 
(Ronnov-Jessen and Petersen, 1993). ET-l from endothelial cells and PDGF from tumour 
cells also nourish and facilitate proliferation of myofibroblasts in the tumour 
microenvironment. Myofibroblasts act as a major 'supplier' of proteinases and proteinase 
inhibitors in the ECM (Knowles et aI., 2012, Ito et aI., 1995) and help to regulate their 
homeostasis. Fibroblasts also secrete other major components of the stromal matrix such as 
proteoglycans (Hassell et aI., 1992), collagen (Noel et aI., 1992), fibronectin (Clark et aI., 
1997) all of which contribute to the structural framework of the supporting ECM. They are 
also major secretors of matrix-degrading proteinases such as members of the MMPs 
(Stuelten et aI., 2005, Wandel et aI., 2000) as well as proteinase inhibitors such as TIMPs 
(Fernandez-Gomez et aI., 2011), both of which play regulatory roles in tissue homeostasis. 
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The importance of stromal cells to the growth and progression of tumours is clear and the 
ever-increasing evidence suggests that the cancer cells are not independent of their stromal 
compartments and that stromal cells even drive tumour progression via expression of 
matrix -degrading proteases. 
The summary of interactions of tumour and stromal cells is schematically represented in 
Figure 1.8. In light of these findings, it is important to better understand the proteases and 
their inhibitors and these will be discussed below. 
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Figure 1.8: The Interactions between Tumour and Stromal Cells. 
The stromal compartment comprises endothelial cells, inflammatory cells, fibrob last cells 
and ECM components. The autocrine secretion of growth factors by the tumour cells 
induces the proliferation of stromal cells and vice versa. Also, angiogenesis is mediated in 
the tumour microenvironment via paracrine signalling between the endothelial and tumour 
cells. The production of cytokines and growth factors by inflammatory cells also modulate 
tumour cell growth. Proximity of the tumour cells to fibroblasts also results in activation of 
fibroblasts to myofibroblasts and concomitant secretion of growth f actors, proteinases, 
proteinase inhibitors into the microenvironment - these are all recruited to the tumour cells 
and mediate their growth, migration and invasion. 
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1.4 PROT EASES 
Proteases or peptidases, as they are sometimes called, are a group of enzymes that function 
by cleaving peptide bonds formed by amino acids in proteins (Simpson, 2007). They are 
ubiquitously expressed in nature and function mainly by cleaving peptide bonds within a 
protein (endopeptidase), at the N- or c- terminal regions of a protein (exo-peptidases) and 
thus are generally classed on these characteristics. In humans, proteases are key players in 
biological processes such as digestion of food (e.g. pepsin), blood clotting (e.g. thrombin), 
growth and development of cells (e.g. PSA) and signalling pathways (e.g. the proteasome 
and caspases). The classification of proteases based on the type of peptide bonds they 
cleave (Bairoch, 1994), is described in Figure 1.9. 
Protelnases! 
Metalloprotelnases 
otelnases of unknown catalytic mechanism 
t-----IAmino-peptidases 
carboxy-peptidases 
Figure 1.9: Schematic Representation of the Super-family and Family of Proteinases 
According to the MEROPS Database of Proteinases and their Inhibitors. 
Also see MEROPS database available on http://merops.sanger.ac.uk (Rawlings et al., 
2010) 
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For the purpose of this report, only the endopeptidases will be discussed, with emphasis on 
metalloproteinases, as relevant to the research project. 
1.4.1 Serine Proteinases 
This is the most widely studied and largest class of proteinases and belongs to the E.C. 
3.4.21 class of enzymes according to the international union of biochemistry and molecular 
biology (IUBMB) (Bairoch, 1994). They act primarily by cleavage of peptide bonds within 
the core of the protein and this is mediated by a triad of amino acids (Ser 195, His 57, and 
Asp 102) located in the catalytic site of the proteinase. This triad of amino acids is 
collectively called the catalytic triad and is widely conserved amongst members of this 
family of enzymes, and is important in their mechanism of action (Hartley, 1970, 
Hedstrom, 2002, Kraut, 1977). Serine proteinases are broadly divided into 12 clans and 79 
families - only 8 of these families are found in humans. Mammalian serine proteinases 
participate in diverse biological functions such as digestion (e.g. trypsin); blood clotting 
(e.g. thrombin, plasmin), signal pathway processing (e.g. signal peptidase I, furin, the 
proteasome) and reproduction (e.g. kallikrein 3). According to the MEROPS database of 
proteinases, members of the serine proteinases are denoted by a prefix "S" followed by a 
specific number, which defines the family. 
1.4.2 Cysteine Proteinases 
This is a class of proteinases that is ubiquitously expressed in plants and animals and play 
diverse roles in physiology and pathophysiology in mammals (Leung-Toung et aI., 2002). 
They are widely grouped into 8 clans and 96 families - only 11 of the families are found in 
humans. Their enzymatic activity is mediated by a catalytic triad in their active site 
comprising a cysteine, aspartate and histidine residue, located close to each other (Nishihira 
and Tachikawa, 1999). In mammals, cysteine proteinases comprise some cathepsins, 
cal pains and caspases, all of which play important roles in biological processes e.g. 
cathepsin K plays a major role in bone resorption and skeletal muscle integrity (Inaoka et 
aI., 1995), caspase 8 plays a major role in programmed cell death alongside caspase 3 
(Denault and Salvesen, 2002, Salvesen, 2002) and calpain 1 has been shown to be involved 
in cell cycle progression (Janossy et aI., 2004). They belong to the E.C. 3.4.22 class of 
enzymes according to IUBMB and are denoted by "C" followed by the family number. 
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1.4.3 Aspartic Proteinases 
This class of proteinases belong to the E.C. 3.4.23 class of enzymes according to IUBMB 
and members are denoted by "A" followed by a number, according to MEROPS. They are 
widely grouped into 5 clans and 16 families - only 2 of the families are found in humans. 
Their enzymatic activity is largely dependent on two conserved aspartate residues in their 
catalytic domain (Pearl, 1987). In mammals, their main function is digestion, with pepsin A 
found predominantly in gastric secretions (Baxter et aI., 1990) and cathepsin E in 
endosomes where it is implicated in antigen processing (Marie et aI., 1994, Chain et aI., 
2005) 
1.4.4 Threonine Proteinases 
This is a relatively small class of proteinases, in comparison to serine proteinases and 
belongs to the E.C. 3.4.25 class of enzymes according to IUBMB and is denoted by "T" 
followed by a number, according to MEROPS. They are widely grouped into 6 families, 2 
of which are found in humans. The catalytic site of this family contains a threonine residue 
necessary for its enzymatic activity (Seemuller et aI., 1995). Members of this family 
include polycystin-l that plays an important role in renal tube fonnation in kidneys 
(Scheffers et aI., 2000) and are also found in the proteasome. The N-tenninal threonine 
residues of some of the beta subunits are the nucleophiles in catalysis (Seemuller et aI., 
1995). 
1.4.5 Metalloproteinases 
This class ofproteinases belongs to the E.C.3.4.24 according to IUBMB and are denoted by 
'M' followed by the family member, according to the MEROPS database. They constitute a 
family of metal ion-dependent enzymes, with a zinc-binding site in their catalytic domain 
(Stocker and Bode, 1995, Stocker et aI., 1995). The zinc-binding domain is well conserved 
in this family, with the sequence x-x-x-H-E-x-x-H-x-x. They are also commonly called the 
"metzincins" because of their conserved zinc-binding domain (Rawlings and Barrett, 1995, 
Hege and Baumann, 2001). They are widely grouped into 16 clans and 86 families - only 
11 of these families are found in humans. 
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1.4.5.1 Matrix Metalloproteinases (MMPs) 
In many biological processes such as development, wound healing and in many 
pathological processes, there is extracellular matrix (ECM) breakdown resulting from an 
increase in proteinase activity. Some of the proteinases implicated include the matrix 
metalloproteinases (MMPs) otherwise known as the matrixins. The MMPs belong to the 
family MIO subfamily MIOA of proteinases, according to the MEROPS database. These 
enzymes are secreted by cells as inactive pro-enzymes or zymogens that become activated 
via initial cleavage of the signal peptide post-translationally in the endoplasmic reticulum, 
followed by furin cleavage of the pro-peptide giving rise to an active neutral 
metalloproteinase that depends on water molecules bound to the Zn2~ binding site for its 
activity (Visse and Nagase, 2003). There are 24 known MMPs in mammals, majority of 
which are responsible for the degradation of components of the ECM (Nagase and 
Woessner, 1999b, Bode et aI., 1999). They have been implicated in several degenerative 
disorders, including arthritis and cancer, with correlation between MMP activity and 
invasion and metastatic potential observed in various cancers as previously reviewed 
(Folgueras et aI., 2004). 
The basic structure of MMPs consists of a preceding signal peptide at the N-terminal 
domain followed by a pro-peptide, a furin cleavage site and then a catalytic domain. The 
catalytic domain contains a Zinc binding region that is mandatory for the maintenance of 
the catalytic function of the metalloproteinase (Bode et aI., 1999). The zinc ion is bound to 
the catalytic domain via three histidine residues in the conserved zinc-binding motif: H-E-
x-x-H-x-x-G-x-x-H of the metallo-enzyme. The pro-peptide maintains the enzyme in its 
latent state via the cysteine residue in a conserved motif P-R-C-G-x-P-D. The cysteine 
residue is able to associate with the zinc binding domain to prevent its catalytic function 
(Nagase and Woessner, 1999a). In some MMPs, the catalytic domain also contains 
fibronectin type 11 inserts, which play a role in the substrate specificity of the MMP e.g. 
gelatinase/MMP-2 (Murphy et aI., 1985). In the C-terminal region, the haemopexin-like 
domain is a tetrad structure, which is essential for the interaction of MMP with other 
proteins and is a determinant of most MMPs specificity for their substrate (Murphy et aI., 
1985) (see Figure 1.10). 
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Figure 1.10: Schematic Diagram Representing the MMPs and MT-MMPs. 
The signal peptide, furin cleavage site, pro-peptide, catalytic domain and haemopexin-like 
domains are characteristic of most MMPs, with the exception of MMP-7 and MMP-26 that 
have no haemopexin domain. The trans-membranelGPI anchor and cytoplasmic domains in 
dotted circle is only present in MT-MMP. 
MMPs are further divided into subsets based on the organization of their domains. These 
subsets are: membrane-bound MMPs, collagenases, stromelysins, matrilysins, gelatinases 
and other MMPs (Vi sse and Nagase, 2003). 
The MT -MMP is a subset of the MMPs whose members are characteristically anchored to 
the cell membrane via a C-terminal trans-membrane or GPI-anchored domain, with an 
additional C-terminal cytoplasmic domain at the tail end of the enzyme (Zucker et a1., 
2003). Members include: MTI-MMP (MMP-14), MT2-MMP (MMP-15), MT3-MMP 
(MMP-16), MT4-MMP (MMP] 7), MT5-MMP (MMP-24) and MT6-MMP (MMP-25) 
(Zucker et aI., 2003). 
The collagenases subset comprises MMPs that cleave interstitial collagen molecules in the 
ECM. Their C-terminal region contains the tetrad haemopexin-like domain that enables 
them to carry out their collagenolytic function (Tam et aI., 2004). Members include: 
collagenase-l (MMP-l), collagenase-2 (MMP-8), collagenase-3 (MMP-13) and non-
mammalian collagenase-4 (MMP-18) (visse and Nagase, 2003). MMP-14 is also a very 
efficient collagenase (Tchetina et aI. , 2005 , Schneider et aI., 2008). 
The stromelysins subset comprises MMPs that share structural similarity to the 
collagenases in general, but lack the collagenolytic activity. Their members include 
stromelysin-l (MMP3) and stromelysin-2 (MMP-I0) both of which are able to cleave 
several non-collagen ECM molecules and are players in the activation of pro-MMPs (visse 
and Nagase, 2003). Stromelysin-3 (MMP-ll) is the third member of this subset but is 
structurally different from the other stromelysins because it contains a furin recognition site 
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at the C-tenninal of its pro-peptide, enabling intracellular cleavage and activation of the 
enzyme. Stromelysin-3 also has a weak affinity for ECM molecules but strong affinity for 
serpins (Gall et aI., 2001). 
The Matrilysins subset comprises MMPs that lack a haemopexin-like domain (Windsor et 
aI., 1997). The members include matrilysin-l (MMP-7) and matrilysin-2 (MMP-26). 
Matrilysin-l is characteristically secreted by epithelial cells and is able to degrade ECM 
molecules as well as some cell surface molecules like E-cadherin (Noe et aI., 2001). 
Matrilysin-2 is an intra-cellular enzyme that is capable of digesting ECM molecules like 
fibronectin and vitronectin (Noe et aI., 2001, Marchenko et aI., 2001). 
The gelatinases subset comprises MMPs that have the haemopexin-like domain in their C-
tenninal region as well as fibronectin inserts in the N-tenninal catalytic domain. This 
enables them to bind to ECM components like gelatin, elastin and collagen to effect 
digestion of these molecules (Allan et aI., 1995, Patterson et aI., 2001). Members include 
gelatinase-A (MMP-2) and gelatinase-B (MMP-9). 
In addition to the above subsets, there are also other MMPs that have diverse functions. 
Members include macrophage elastase (MMP-12) which is expressed in human alveolar 
macrophages and is capable of cleaving elastin (Shapiro et aI., 1993) and has been 
implicated in the development of emphysema (Haq et aI., 2011), rheumatoid arthritis 
synovial inflammation (MMP-19) which cleaves molecules of the basement membrane and 
is found in lymphocytes of rheumatoid arthritis patients (Sedlacek et aI., 1998, Kolb et aI., 
1997) and has also been identified as an anti-angiogenic tumour suppressor, (Chan et aI., 
2010). Enamelysin (MMP-20) possesses amelogeninolytic properties and is primarily 
found in the enamel of newly fonned teeth (Sulkala et aI., 2002). MMP-21 has gelatinolytic 
properties and is largely expressed in melanomas (Skoog et aI., 2006, Kuivanen et aI., 
2005) and squamous cell carcinomas (Boyd et aI., 2009). 
MMP-23 is a unique member of this subset of MMPs as a result of the different 
arrangement of its domains in comparison to other MMPs - it has no haemopexin-like 
domain but instead, contains a cysteine-rich domain. It also has a trans-membrane domain 
in its pro-peptide at the N-tenninal region (Pei, 1999). Next to the pro-peptide is a furin 
cleavage site, which enables the enzyme to be activated intracellularly or during secretion 
(Pei et aI., 2000). MMP-27 is the same enzyme as chicken MMP-22 (Yang and Kurkinen, 
1998) but the function remains unclear. MMP-28 is found in keratinocytes (Lohi et aI., 
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2001) and may also play a role in the epithelial to mesenchymal transition of lung cancer 
epithelial cells (Illman et aI., 2008). 
MMPs have been implicated in several developmental and pathological roles over the 
years. They are particularly implicated in cancers such as breast, colon, and prostate cancer 
as previously reviewed (Folgueras et aI., 2004) where their expression has been shown to 
positively correlate with disease progression. Several drugs have been manufactured as 
synthetic MMP inhibitors e.g. Prinomastat and Marismastat, but poor efficacies and 
tolerability has been reported due largely to the cytotoxic effect of the drug and its inability 
to improve survival rates of cancer patients has led to its discontinuation as therapy for 
cancer (Bissett et aI., 2005, Sparano et aI., 2004). 
1.4.5.2 A Disintegrin and metalloproteinase (ADAM) 
This is a subset of the adamalysin subfamily of metzincins and belongs to the M12B 
subfamily according to MEROPS. They share N-terminal sequence similarity to the MMPs 
in that they are synthesized as pro-enzymes and possess a signal peptide domain, pro-
peptide domain and a catalytic domain within their N-terminal region (Seals and 
Courtneidge, 2003). Also the H-E-x-x-H-x-x-G-x-x-H zinc-binding motif in the catalytic 
domain and the R-C-G-x-P-D conserved cysteine motif in the pro-peptide in MMPs are 
also conserved in ADAMs (Seals and Courtneidge, 2003). However, the difference lies in 
the C-terminal region of these proteinases, which contains a characteristic cysteine-rich 
domain, a disintegrin-like domain, an epidermal growth factor (EGF)-like domain, a trans-
membrane domain and a cytoplasmic domain, hence their alias of MDC (metallo-
proteinase-like, disintegrin-like, cysteine-rich proteins (Takeda et aI., 2006). The presence 
of the trans-membrane domain enables the enzyme to be membrane-anchored and therefore 
localized on the cell surface. The cysteine-rich domain and the disintegrin-like domain 
present in the extra-cellular region of the proteinase enable its interaction with ECM 
proteins in order to enforce its proteolytic function. The presence of an integrin-binding 
motif R-x-x-x-x-x-x-D-E-V -F in the disintegrin-like domain of the ADAMs enable them to 
bind to integrins in the ECM while the cysteine-rich domain has high affinity for ECM 
molecules like heparan sulphate proteoglycans (Seals and Courtneidge, 2003) (see Figure 
1.11). The role ofthe EGF -like domain is unclear. 
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The signal peptide, pro-peptide, furin cleavage site, catalytic domain, cysteine-rich domain, 
disintegrin-like domain, EGF-like domain, trans-membrane and cytoplasmic domains are 
characteristic of members of the ADAMfamily, with the exception of ADAM-8, ADAM-20, 
ADAM-28 and ADAM-30 that lack the furin cleavage site. 
ADAM metalloproteinases function as "Sheddases" with characteristic ability to clea e 
proteins from their membrane-bound form, and release them from the cell membrane with 
diverse biological consequences (Zhang et aI., 2000). 
There are 24 known human ADAMs (Klein and Bischoff, 20 II). In humans, the ADAM 
family is broadly divided into two subsets: ADAMs with no known proteolytic activity and 
ADAMs with known proteolytic activity. 
ADAMs with no known proteolytic activity include: ADAM-2, -3 , -6, -7, -11 , -16, -18, -
2] /-31 , -22, -23 , -27 and -29. 
ADAMs with known proteolytic activity includes: ADAM-I , -8, -9, -10, -12, -15, -17 -19, 
-20, -28, -30 and -33 . ADAMJ 0 and ADAM 17 are the most relevant to thi research and 
will be discussed further. 
ADAM-lOis also known as CD 156c and its pro-enzyme is also cleaved by proteolytic 
cleavage to release its active form which plays multifunctional roles; it hed chemokines 
and their receptors e.g. CXCL16 (Abel et aI. , 2004) as well as the membrane-bound form of 
F AS ligand, releasing soluble F AS which plays a major role in the regulation of cellular 
apoptosis (Kirkin et aI. , 2007, Liu and Chang, 20J 1). It was first identified due to its myelin 
basic protein-cleaving activity (Amour et aI., 2000). It promotes tumour migration and 
metastasis via its ability to shed CD44 (pro-migratory molecule) (Murai et aI., 2004). 
ADAM-J 0 also plays a role in shedding of HER2 in the HER2 ignalling pathway required 
in breast cancer (Liu et aI., 2006). 
ADAM-I7 is the most widely studied member of the ADAM and is al 0 known a TNF-
alpha converting enzyme (T ACE). It is produced as a pro-enzyme and activated by 
proteolytic cleavage (Moss et aI. , 1997a). Its major role is in the conversion of membrane-
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bound pro-TNF to soluble TNF (Moss et aI., 1997a). It also plays roles as a sheddase of L-
selectin which is important in cellular adhesion (Condon et aI., 2001), TGF-a, an important 
pro-inflammatory cytokine (Liu et aI., 2009), and epigen (Sahin and Blobel, 2007). It is 
also an important mediator of tumour formation and metastasis as evident in studies 
showing cells that had lost ADAM-17 were unable to form tumours and also unable to 
invade the surrounding environment (Franovic et aI., 2006). 
1.4.5.3 A Disintegrin and metalloproteinase with Thrombospondin 
Motif (ADAMTSs) 
This is a subset of the adamalysin subfamily of metzincins and belongs to the M 128 
subfamily according to the MEROPS database. They possess a signal peptide domain, pro-
peptide domain and a catalytic domain within their N-terminal region (Kaushal and Shah, 
2000). The H-E-x-x-H-x-x-G-x-x-H zinc-binding motif in the catalytic domain and the R-
C-G-x-P-D conserved cysteine motif in the pro-peptide in MMPs are also conserved in 
ADAMTSs. However, the differences lie in the C-terminal region of these proteinases, 
which contains a characteristic cysteine-rich domain, a thrombospindin type-1 domain, 
spacer region and several thrombospondin type-I repeats (Kuno and Matsushima, 1998), 
with the exception of ADAMTS-4 which has no thrombospondin repeats (Kashiwagi et aI., 
2004). The ADAMTSs also bear structural similarity to the ADAMs in their N-terminal 
region, with the presence of the furin cleavage site between the signal peptide and the pro-
peptide (Apte, 2004) (see Figure l.12). Another unique characteristic that distinguishes 
them from the ADAMs is that although they are secreted proteins, they are localized 
predominantly in the ECM (Tang, 2001). 
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Figure 1.12: Schematic Diagram Representing the ADAMTSs. 
ADAMTS 
The signal peptide, pro-peptide, furin cleavage site, catalytic domain, thrombospondin 
repeats and cysteine-rich domain are characteristic of members o/the ADAM/amily, 
Figure 1. 12 shows the conserved domains pre ent in all ADAMT member . They undergo 
signa l peptidase processing to remove the ignal peptide co-tran lationally and proteolytic 
cleavage to activate the enzymes. There are 19 known ADAMTSs in the human genome, 
which are classified based on their proteolytic propertie : the ' orphan ' ADAMT who e 
functions remain more-or-Iess obscure, and the known proteolytic ADAMTS. The 
'orphan' ADAMTSs include: ADAMTS -6, -7, -10, -17, -18, -19 and -20 and the known 
proteolytic ADAMTSs include: ADAMTS -1 , -2, -3 , -4, -S (-II), -8, -9, -12, -13 , -14, -15 
and -16 (Porter et aL, 2005). 
The aggrecanases include ADAMTS -I , -4, -S , -9 and -IS and have been hown to break 
down predominantly aggrecan and homologous large aggregating proteoglycan ( aga e 
and Kashiwagi, 2003). ADAMTS-I is also known as METH-I and ha al 0 been hown to 
break down versican (Nakamura et aL, 200Sb). ADAMTS-4 is al 0 known a aggrecana e 1 
and A DAMTS-S is also known as aggrecanase-2 - both cleave brevi can, (proteoglycan that 
is expressed in the CNS) and versican (Matthews et aL , 2000, Kuno et aL , 2000). 
ADAMTS - J, -4 and -8 possess anti-angiogenic properties (Dunn et aL , 2006 H u et aL , 
2012), and ADAMTS-8 is expressed at low levels in breast carcinoma (Porter et aL , 2004). 
ADAMTS-9 has been reported to also cleave versican (Kern et aL 20 I 0) while the role of 
ADAMTS-IS is not very clear and recent studies may indicate that it i protecti e again t 
prostate cancer progression (Molokwu et aL , 2010). 
The pro-collagen-N-proteinases include ADAMTS -2, -3 and -14 and their role i in the 
conversion of pro-collagens to collagens via removal of the pro-peptide in the N-terminus 
of the proteins. ADAMTS-2 has the widest catalytic profile, with reported activity on pro-
collagens 1, 11 and III (Colige et aL , 1997). ADAMTS-3 has been reported to cleave pro-
collagen 11 (Fernandes et aL , 2001) while ADAMTS-14 cleaves pro-collagen-I ( olige et 
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aI., 2002). ADAMTS-2 has also been reported to inhibit angiogenesis via mechanisms that 
are independent of its collagenolytic functions (Dubail et aI., 2010) 
The GON-ADAMTSs include ADAMTS -9 and -20. They are so named because of the 
sequence similarity they bear to the ADAMTS gene gon-J found in C elegans (gon-l is 
responsible for gonadal development). They both have an additional gon domain in their C-
terminal region as well as 14 thrombospondin repeats adjacent to their cysteine-rich domain 
(Somerville et aI., 2003). The role of these ADAMTSs in human gonadal development has 
not been shown, despite the similarity of their C-terminal region with the well-
characterized C e/egans gon-J gene. ADAMTS-9 mRNA has been shown to be elevated in 
metastatic head and neck cancer (Demircan et aI., 2009) and in a rat model of stroke (Reid 
et aI., 2009). 
The von-Willebrand factor cleaving and activating enzyme is ADAMTS-13 and is so 
named because its main substrate is von-Willebrand factor - a protein that plays an 
important role in haemostasis through interactions with Factor VllI and platelets (Sadler, 
1998). Mutations in the ADAMTS-J3 gene have been shown to result in thrombotic 
thrombocytopenic purpura, which results in renal failure, neurological dysfunction and 
anaemia (Fontana et aI., 2004). 
Some of the orphan ADAMTSs have variable expression patterns in pathological processes 
e.g. ADAMTS-J6 gene expression is up regulated in osteoarthritis (Kevorkian et aI., 2004) 
and ADAMTS-12 expression in breast cancer (Porter et aI., 2004). 
1.5 PROTEINASE INHIBITORS 
Proteinase inhibitors are proteins that inhibit proteinases and are ubiquitously expressed in 
nature. They are mainly classified into super families according to the type of proteinase 
they inhibit. These are: 
• Serine proteinase inhibitors 
• Cysteine proteinase inhibitors 
• a-2-Macroglobulin 
• Metallo-proteinase inhibitors 
There are 415 known proteinase inhibitors m the human genome, compared to 698 
proteinases (MEROPS). To date, there are 91 families of proteinase inhibitors. 
47 
1.5.1 Serine Proteinase Inhibitors 
Whilst this is not the best name for this group of inhibitors, their characteristic ability to 
inhibit S I and S8 families of serine proteinases (Dufour et aI., 1998) have earned them this 
nickname. There are over 500 members of this inhibitor family identified to date. They also 
inhibit family CI (Irving et aI., 2002) and family CI4 (Komiyama et aI., 1994) of cysteine 
proteinases. They exert their inhibitory property by irreversibly binding to the active 
catalytic region on the proteinase thereby causing conformational distortion of and 
subsequent inactivation of the enzyme (Silverman et aI., 200 I). They are also commonly 
known as Serpins although this term rightly refers to the 14 family of serine and cysteine 
proteinase inhibitors. Serpins are sub-divided into 36 clades, 29 of which are inhibitory and 
7 of which are non-inhibitory (Silverman et aI., 200 I). 
The non-inhibitory clades of serpins include: Serpin A2, All, A12, A13, BIO, BII and 
BI2 while the inhibitory clades include: Serpin AI, A3, A4, A5, A6, A 7, A8, A9, AIO, BI, 
B2, B3, B4, B5, B6, B7, B8, B9, B13, CI, DI, EI, E2, FI, F2, GI, HI, NI and N2. 
1.5.2 Cysteine Proteinase Inhibitors 
This super-family of inhibitors comprises inhibitors from the 14, 125, 127 and 132 of 
inhibitors according to MEROPS. They inhibit C I, C2 and C 14 families of proteinases and 
include the stefins, cystatins, calpastatins, survivin and kininogens (Muller-Esterl et aI., 
1985a) 
The stefins are largely intracellular and include cystatin A and cystatin B; cystatin A is 
expressed by neutrophilic granulocytes and epithelial cells (Jarvinen et aI., 1987) while 
cystatin B is expressed during embryonic development (Afonso et aI., 1997). 
The cystatin family is largely extracellular and includes cystatin C, cystatin D and cystatin 
S. Cystatin C has a wide distribution (Nagai et aI., 2008). Cystatin D is expressed in saliva 
(Freije et aI., 1991) while cystatin S is expressed in tears, urine, saliva, pancreas, bronchi 
and gall bladder. 
Calpastatins inhibit calpains 1 and 2 of the C2 family ofproteinases (Todd et aI., 2003) and 
to a lesser degree, cal pain 3. 
Survivin is an inhibitor of the caspases in C 14 family of proteases and plays a major role in 
cellular survival and homeostasis (Guzman et aI., 2009, Chandele et al., 2004, Shankar et 
al.,2001). 
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The kininogen family comprises H-kininogen and L-kininogen, both of which are 
expressed as extracellular proteins in plasma. Their roles include inhibition of C 1 proteases 
including cathepsin L and are also involved in blood clotting processes (Muller-Esterl et at., 
1985b). 
1.5.3 a-2-Macroglobulin 
This is an inhibitor of most proteinases that was first discovered in 1973 (Barrett and 
Starkey, 1973). It has a unique mode of action (Salvesen & Barrett, 1980) and is produced 
in the liver and is abundant in the blood. It is also expressed by fibroblasts (Boel et aI., 
1990) and macrophages (Hussaini et aI., 1990). 
1.5.4 Metalloproteinase Inhibitors 
In humans, there are several metalloproteinase inhibitors, including: a-2-macroglobulin 
(see Section 1.5.3), ~-amyloid precursor protein (inhibition of MMP-2) (Hashimoto et at., 
2011) and reversion-inducing cysteine-rich protein RECK (inhibition of several MMPs 
including MMP-9, MMP-2) (Dh et aI., 2001, Takeuchi et aI., 2004). However, the most 
widely studied metalloproteinase inhibitors are members of the TIMP family and these will 
be discussed further. 
1.6 TISSUE INHIBITOR OF METALLOPROTEINASES 
The tissue inhibitor of metalloproteinases are a family of metalloproteinase inhibitors that 
are ubiquitously expressed in a variety of tissues and biological systems (Fata JE et aI., 
2001). They belong to the 135 family of inhibitors according to the MEROPS database. In 
humans, this family consists of four family members TlMP-1, -2, -3 and -4, and these 
TIMPs are all secreted proteins (Apte et aI., 1994). By virtue of their MMP-inhibitory 
activity, the TIMPs have a major role in regulation of matrix composition and therefore 
affect a wide range of physiological processes such as growth, invasion, migration, 
angiogenesis, transformation and apoptosis (Lambert et aI., 2004). The human TIMPs 
possess sequence identity of about 40% and contain 12 cysteine residues that are conserved 
in all members that form 6 disulphide bonds (Apte SS et aI., 1995) (see Figures. 1.14 and 
1.15). The N-terminal region of all TIMPs is highly conserved across all members and 
takes up about 2/3 of the entire protein (Murphy et aI., 1991). As well as inhibiting the 
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MMPs (Vi sse and Nagase, 2003), TIMPs also inhibit most of the proteolytic ADAMs 
(Klein and Bischoff, 2011) and the ADAMTS aggrecanases (Porter et aI., 2004). The 
TIMP: proteinase binding consists of a unique I: I stoichiometry thus maintaining 
homeostasis and proteolytic regulation in tissue physiology. Alteration in the balance in 
favour of the proteinases often results in pathological conditions (Nagase and Woessner, 
I 999a). 
1.6.1 TIMP-l 
TIMP-I comprises 207 amino acids, with 23 amino acids in its signal peptide and 184 
amino acid residues in its mature protein structure. Its relative molecular mass in its 
unglycosylated form is about 21kDa and has 2 known N-glycosylation sites (Okada et aI., 
1994). Its X-ray crystal structure has been solved and demonstrates binding of the N-
terminal domain of TIMP-I to the catalytic domain of MMP-I thus eliciting an inhibitory 
function (Iyer et aI., 2007). TIMP-I has also been reported to inhibit ADAM-I 0 (Schelter et 
aI., 2011, Amour et aI., 2000). TIMP-I is mainly expressed as a soluble protein and has 
been reported to confer proliferative advantages to cells such as fibroblasts (Welgus et aI., 
1979). 
1.6.2 TIMP-2 
TIMP-2 comprises 220 amino acids, with 26 amino acids in its signal peptide and 194 
amino acid residues in its mature protein structure and has a relative molecular mass of 
22kDa (Fridman et aI., 1992). There are no known glycosylation sites in the protein 
(Wingfield et aI., 1999) and it is constitutively expressed as a soluble protein known to 
inhibit MMPs and ADAMs as previously reviewed (Brew and Nagase, 2010). It has 
proliferative functions as shown in its enhancement of the growth of fibroblasts and 
erythroid precursors as well as pro-apoptotic effects as shown in its inhibition of the growth 
of human T-Iymphocytes and colorectal cells (reviewed in (Brew and Nagase, 2010) 
1.6.3 TIMP-4 
TIMP-4 comprises 224 amino acids, with 29 amino acids in its signal peptide and 196 
amino acids in its mature protein structure. It has no known glycosylation sites and is 
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synthesized as a soluble protein with a relative molecular mass of about 22kDa (Bigg et aI. , 
1997). 
1.6.4 TIMP-3 
TlMP-3 is the main focus of the project. It comprises 211 amino acids, with 23 amino acids 
in its signal peptide and 188 amino acids in its mature protein (Apte SS et aI. , 1995). 
1.6.4.1 Structure of TIMP-3 
The TIMP-3 gene is large, compared to other members. It is about 30kbp in size and 
contains large introns and a long 3' untranslated region. Exon 1 of the gene contains the 5' 
untranslated region and also encodes the signal peptide as well as the N-terminal region of 
the mature protein. The translation tem1ination codon and the 3' untranslated region are in 
exon 5 (Figurel.13) (Apte SS et at, 1995). 
UTR 11 ~""""'""--- 3' 
Figure 1.13: Schematic structure of the timp-3 gene. 
The solid line represents the full length of the gene, both the translated and untranslated 
regions (UTR) . The translated region comprises 5 exons labelled EJ - E5 and 4 introns 
labelled 11 - 14. The size of exon 5 is variable, depending on polyadenylation signal (grey 
box) and has been denoted E5 +/- (A)n. 
TIMP-3 is also unique in that unlike other members of the family that become freely 
diffusible within the cellular microenvironment after secretion, TIMP-3 becomes tightly 
bound to the ECM via its C-terminus, although the basicity of the N-tenninus with Lysine 
residues at Lys 26,27, 30 and 76 (see Figure l.6.4.l.2) may also be a contributing factor to 
the molecule's affmity to the ECM (Langton et aI. , 1998). 
The stability of TlMP-3 in the ECM is a feature that is specified by the 3 loops comprising 
its C-tenninus, and studies showed that recombinant TJMP-3 lacking the COOH region was 
obtained from the medium used, and did not bind to the ECM (Baker AH et al.). The six 
disulphide bonds arise from the 12 conserved cysteine residues and these form the basis of 
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the 6-100p protein structure (see Figure 1.14); three of which make up the N-terminal 
domain and the other three make up the C-terminal domain (Apte SS et aI., 1995). 
The x-ray crystal structure of TIMP-3 is yet unknown. However, there is a postulated 
model based on its similarity to TIMP-l. The structure of N-TIMP-3 in complex with 
T ACE is shown in Figure 1.14 and the sequence similarity between TIMP-3 and other 
TIMPs is represented as a PRALINE multiple alignment format (Simossis and Heringa, 
2005) in Figure 1.15. The beta sheets and helices of N-TIMP-3 are super-imposed on the 
sequence alignment: 
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Figure 1.14: 3D Ribbon Structure of TA CE-N-TIMP-3 Interaction 
The 3D structure oj the complex Jormed by binding oj the catalytic domain oj TACE 
(green) to the -terminal domain oj TlMP-3 (orange). The TlMP-3 structure is based on 
the similarity oj TIMP-3 to TlMP-I, whose structure is well characterised and x-ray 
structure available. The 5 interrupted beta-sheets (sA - sE) and the 2 helices (h 1 - h2) of 
the -terminal TlMP-3 are shown. The Lysine residues (Lys26, 27, 30 and 76) that are 
important for ECM binding are shown as protruding orange and blue sticks. Copyright 
permi ion to reproduce image is detailed in Appendix. 
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Figure 1.15: PRALINE Sequence Alignment of the TIMPs Showing Similarity. The 
sequences of TIMPs 1-4 were imput into PRALiNE online software f or generation of 
colour-coded alignment and conserved motif identification. The key on the lower right side 
of the image shows colour coding for unconserved and conserved amino acids in the 
sequences, with blue representing least conserved amno acids and red representing most 
conserved amino acids ad scored/rom 1-10 likewise. H* " represents the alignment of the 
12 cysteine residues that make up the 6 disulfide bonds characteristic of TlMPs. The beta 
sheets sA - sE (blue arrows) and helices hi and h2 (blue cylinders) depicted in Figure 
1.6.4.1.2 are superimposed on the sequences. The black arrow indicates the end of the N-
terminal and the start of the C-terminal region ofTlMP-3. 
54 
1.6.4.2 Expression Profile of TIMP-3 
TIMP-3 is widely expressed in different tissue types and to different degrees. It is highly 
expressed in placenta, lung and retina of the eye (see Figure 1.16). The expression and 
relative amounts ofTIMP-3 transcripts in different tissues are represented below: 
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Figure 1.16: Expression Profile of TIMP-3 Transcripts in Different Tissues. 
These data were obtained using the free BIOGPS software available at http://biogps.com 
(Wu et al. , 2009a). Units represent relative quantification of TIMP-3 mRNA in tissue 
samples. Expression levels ofTIMP-3 mRNA in the prostate is highlighted in the black box. 
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1.6.4.3 Functions of TIMP-3 
1.6.4.3.1 Growth and Development 
TIMP-3 expression in foetal hair follicle and foetal kidney has highlighted its role in foetal 
development. This is mediated by the balance of homeostasis of proteinases and TIMP-3, 
thereby regulating tissue turnover and normal development of the foetus (Airola et aI., 
1998). 
1.6.3.4.2 Inhibition of Metalloproteinases 
TIMP-3 inhibits several metalloproteinases and this is summarised in tabular format below: 
Proteinase TIMP-3 Ki Value (nM) Literature References 
MMP-l 0.16 (Zhao et aI., 2004) 
MMP-2 NIR (Zhao et aI., 2004) 
MMP-3 NIR (Wetzel et aI., 2003) 
MMP-7 NIR (Woessner, 1996) 
MMP-8 NIR (Pavloff et aI., 1992) 
MMP-9 NIR (Negro et aI., 1997) 
MMP-13 NIR (Knauper et aI., 1996) 
MMP-14 (MTl-MMP) 0.16 (Zhao et aI., 2004) 
MMP-15 (MT2-MMP) NIR (Butler et aI., 1997) 
MMP-16 (MT3-MMP) 0.008 (Zhao et aI., 2004) 
MMP-17 (MT4-MMP) 10 (Amour et aI., 2002) 
MMP-19 0.005 (Stracke et aI., 2000) 
ADAM-IO 10 (Amour et aI., 2002) 
ADAM-12 100 (Amour et aI., 2002) 
ADAM-15 NIR (Maretzky et aI., 2009) 
ADAM-I 7 (TACE) 10 (Amour et aI., 2002) 
ADAM28 NIR (Mochizuki et aI., 2004) 
ADAMTS-l NIR (Rodriguez-Manzaneque et aI., 2002) 
ADAMTS-2 106 (Wang et al., 2006) 
ADAMTS-4 7.9 (Hashimoto et aI., 200 1) 
ADAMTS-5 NIR (Kashiwagi M et aI., 2001) 
Table 1.1: Proteinases Inhibited by TIMP-3 and the Inhibitory Constants (Xi). 
NR = not reported. 
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ADAM-17 IT ACE (TNF Alpha Convertase Enzyme) is responsible for processing 
membrane bound TNF to its soluble form. TIMP-3 controls TNF shedding by inhibiting 
T ACE, and thus regulating the levels of TNF both in tissue homeostasis and tissue response 
to injury. Mohammed et al (Mohammed et aI., 2004) demonstrated that TACE activity was 
up regulated in the livers of timp-3-1- mice, and that partial hepatectomy resulted in 
uncontrolled production of TNF (Wang et aI., 2006) by the recruited macrophages, which, 
in the absence of TlMP-3, resulted in hepatic necrosis and eventual morbidity in these 
mice. TlMP-3 can also inhibit ADAMTSs, some of which, like TlMP-3, are located in the 
ECM via interactions with sulphated glycosaminoglycans (GAG). Wang et al (Wang et aI., 
2006) demonstrated the inhibition of the pro-collagen N-proteinase ADAMTS-2 by TIMP-
3 and studies carried out by Kashiwagi et al (Kashiwagi M et aI., 200 I) have shown that the 
ADAMTSs -4 and -5 are inhibited by TlMP-3. In both studies, none of the other TIMP 
family members inhibited these ADAMTSs to the magnitude with which TIMP-3 did. 
1.6.4.3.3 Inhibition of Angiogenesis 
Qi et al (Qi et aI., 2003) demonstrated that TlMP-3 inhibited angiogenesis by binding to 
VEGFR2, thus competing with binding of the bioactive ligand, VEGF. Consequently, there 
is inhibition of the downstream signalling pathways imperative for endothelial cell 
differentiation. TlMP-I and TlMP-2 did not block VEGF binding in the above experiment, 
demonstrating that the interaction with VEGFR2 was TIMP-3-specific. Thus, TlMP-3 
over-expression suppressed primary tumour growth and metastasis by suppressing cell 
growth and survival, necessary for tumour progression. This feature is independent of its 
MMP-inhibitory activity, as demonstrated by this group. However, MMP inhibition would 
be expected to also inhibit angiogenesis, as some of the MMPs are pro-angiogenic (Basile 
et aI., 2007, Huang et aI., 2007). The mechanism of TlMP-3 inhibition of angiogenesis is 
illustrated in Figure 1.17: 
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Figure 1.17: Schematic Representation of Tumour Angiogene i and TlMP-3- :pecijic 
Inhibition of Angiogenesis. 
It is known that there is an increase in Ihe blood upply in establi hed lumour and the 
process of angiogenesis is mediated by VEGF binding to it receptor, VEGFR2. II ha been 
demonstrated that TIMP-3 is able to competitively bind to VEGFR2 to inhibit the mediation 
of angiogenesis by VEGF, and this anti-angiogenic property i independent of it MMP-
inhibitory activity (Qi et aI. , 2003). 
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1.6.4.3.4 Regulation of Apoptosis 
Fata et al (Fata JE et aI., 2001) demonstrated that TlMP-3 is a critical epithelial survival 
factor during mammary gland involution. According to their results, deficiencies in TlMP-3 
function led to excessive and unscheduled physiological apoptosis in the mammary 
epithelium. They demonstrated that TlMP-3 influenced mammary epithelial apoptosis 
during involution through its ability to inhibit ecto-domain shedding of apoptotic regulatory 
factors such as T ACE, which processes cell-bound TNF to its soluble, pro-apoptotic form 
Although their findings demonstrated an anti-apoptotic characteristic of TlMP-3, they 
concluded that the several effects of TIMP-3 on cell survival are largely dependent on the 
cell type, the cell microenvironment and the amount of TlMP-3 in the microenvironment. 
Also, recent studies by Mylona et al (Mylona et aI., 2006), showed a positive correlation 
between the anti-apoptotic Bcl-2, and TIMP-3, suggesting that this inhibitor may playa 
role in suppressing cell death. One study showed an increase in the levels of secreted T ACE 
and TlMP-3 in head and neck cancer, with expression positively correlating with lower 
survival rate in patients. As T ACE is required for initiation of cellular apoptosis and 
inhibited by TlMP-3, the inhibitor is functioning in an anti-apoptotic manner, and may be 
contributing to the progression of head and neck cancer (Kornfeld et aI., 2011). TIMP-3 
also plays pro-apoptotic functions in cells as demonstrated by studies which show increase 
in cellular death in cancer cells over-expressing TlMP-3 or a decrease in apoptosis in 
neuronal cells from timp-3 -1- mice following oxygen and glucose deprivation (Wetzel et 
aI., 2008, Finan et aI., 2006). Thus, TlMP-3 could be a risk factor for cancer as well as a 
"tumour suppressor", depending on which of its various activities predominates. A 
schematic diagram showing the TIMP-3 mediated inhibition apoptosis via T ACE inhibition 
is illustrated in Figure 1.18. 
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Figure 1.18: Schematic Representation of TlMP-3-specific Inhibition of Apoptosis. 
TNF is a multi-functional cytokine that is synthesized by cells as a pro-TNF that requires 
the TNF-a.-converting enzyme TACEIADAM-17 to cleave its pro-peptide and relea e 
soluble TNF. Soluble TNF can then bind to its receptor, TNFR1, a Iran -membrane 
receptor, to initiate the Fas-associated protein with death domain (FADD)-mediated 
apoptotic pathway. TlMP-3 is a known and potent inhibitor of TACE and can prevent its 
sheddase activity; thereby preventing the solubilisation of TNF and so plays an anti-
apoptotic role. 
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1.6.4.3.5 Inhibition of Tumour Growth 
Tumours frequently show an increase in MMP expression and/or a decrease in TlMP 
expression leading to a net increase in proteolytic activity, which may be necessary for 
tissue remodelling during tumour growth, angiogenesis, invasion, and metastasis. TlMP 
expression can suppress primary tumour growth, angiogenesis, invasion (in vitro and in 
vivo), and metastasis, whereas depletion of TlMPs can increase primary tumour growth, 
invasion, and metastasis, as demonstrated by Bachman et al (Bachman KE et at, 1999). 
They speculated that TlMP-3 expression may be critical for the normal growth of the 
kidney and brain, and that cancers, particularly from the kidney, have the highest frequency 
of timp-3 gene methylation - this methylation corresponds to the loss of TIMP-3 
expression, and is prevalent in many primary solid tumours. It is thought that loss ofTIMP-
3 may inhibit normal apoptotic programs, enhance primary tumour growth and 
angiogenesis, invasiveness, and metastasis and possibly, therefore, contribute to all stages 
of malignant progression (Airola et at, 1998, Baker AH et aI., 2002, Cruz-Munoz et aI., 
2006). 
1.6.4.4 Non-malignant Pathological Conditions 
Apart from the role(s) TIMP-3 plays in the development of several cancers via its 
proteinase-inhibitory properties, there are some disorders that have been associated with the 
over-expression or reduced expression of TlMP-3 in tissues and these include: 
1.6.4.4.1 Age-related Macular Degeneration 
Age-related macular degeneration is also known as AMD. Single nucleotide 
polymorphisms (SNPs) have been identified upstream of the TlMP-3 gene and about 24 of 
these occur in up to 90 % of AMD cases. The alteration of the TlMP-3 gene in the retinal 
pigment epithelium and Bruch's membrane in the eye result in abnormal matrix turnover 
and increase in muscular degeneration and subsequent dystrophy of the macula (Kamei and 
Hollyfield, 1999). 
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1.6.4.4.2 Myocardial Infarction 
The process of cardiac re-modelling is crucial to the repair of the heart following 
myocardial infarction. The existence of abnormal accelerated cardiac re-modelling in 
TIMP-3 knockout mice and an increase in the expression of matrix metalloproteinases and 
inflammatory cytokines has been demonstrated (Ikonomidis et aI., 2005). This suggests that 
TIMP-3 may be important for minimizing cases of myocardial infarction in heart attack 
patients if the levels ofTIMP-3 expressed in the myocardium could be up regulated. 
1.6.4.4.3 Sorsby's Fundus Dystrophy 
In Sorsby's fundus dystrophy, a mutation in the C-terminal region of TIMP-3 causes its 
accumulation in the Bruch's membrane of the eye, leading to blindness (Langton et aI., 
2005). The increased expression of TIMP-3 in the Bruch's membrane of SFD patients has 
been described and this has shed light on the aetiology of the disease whilst suggesting that 
therapeutic interventions that favour the reduction of TIMP-3 accumulation may prove 
beneficial for treating SFD patient (Chong et aI., 2000, Fariss et aI., 1998) 
1. 7 HYPOTHESIS AND AIMS OF THIS RESEARCH 
Hypothesis: DHT, TNF and TGF-f} regulate the amount of TIMP-3 present in prostate 
cancer and stromal cells, and that a loss of this inhibitor could enable the cancer cells to 
behave more aggressively and to grow and metastasize more efficiently. 
The aims of this research are to: 
• Investigate the expression ofTIMP-3 in prostate stromal and cancer cells 
• Study the factors that regulate the expression of TIMP-3. with a view to 
understanding the role of this inhibitor in prostate cancer progression. 
Some of the factors controlling cell behaviour include dihydrotestosterone (DHT), tumour 
necrosis factor (TNF) and transforming growth factor beta (TGF-f}) - these will be further 
discussed in Chapter 3, Section 3.1. DHT is a growth factor for prostate cancer cells 
(Burnstein, 2005) and elevated levels of the proinflammatory cytokine TNF have been 
observed in the serum of prostate cancer patients (Nakashima et aI., 1998). Also, the 
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expression levels of ECM proteins and TlMP-3 mRNA are up regulated in peri-tumoural 
stroma of the breast (Bryne et aI, 1995) and in prostatic stromal cells (Cross et aI, 2005) in 
vitro. In order to elucidate in vitro the possible role of this inhibitor in prostate cancer, I 
will also analyse the role of TIMP-3 in biological processes such as growth, migration, 
invasion, angiogenesis and apoptosis, as well as proteinase inhibitory functional assays. In 
addition, the expression pattern of TIMP-3 will also be analysed in available histological 
samples, with a view to identifying if localization and expression pattern correlate 
positively or negatively with prostate cancer staging. Together, all of these experiments will 
help us to understand the importance of TIMP-3 in the initiation and/or progression of 
prostate cancer. 
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CHAPTER 2: MATERIALS AND METHODS 
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2.1 TISSUES AND CELL LINES 
2.1.1 Prostate Tissues 
All the prostate tissues and tissue micro-arrays were obtained as formalin-fixed paraffin-
embedded slides from Dr. Colby Eaton, The Mellanby Centre; University of Sheffield 
Medical School. All tissues and primary cells obtained from patients were done in line with 
the Trent Multi Centre Research Ethics Committee approval, (REC reference 01/4/061 and 
STH reference SS02/196). The ethical approval was granted for the study titled: 
"Molecular mechanisms and the development of novel treatment strategies in progressing 
prostate cancer (ProMPT) with validity from January 2001 to January 2016. 
The prostate tissues used in this project include: 
• Normal Prostate Tissue 
• Benign Prostatic Hyperplasia (BPH) tissue 
• Primary Prostate Cancer Tissue 
2.1.2 Stromal Cells (Non-Malignant) 
2.1.2.1 Benign Prostatic Hyperplasia Stromal Cells: 
BPH stromal cells were obtained from patients undergoing routine trans-urethral 
resectioning of the prostate (TURP) for bladder outlet obstruction (Cross et al., 2005). All 
tissues had been previously independently identified as BPH by histopathology, and in all 
cases, no signs of cancer were present. Our collaborator, Dr. Colby Eaton, provided all 
BPH cell types used for the experiments. Their markers of stromal cell origin have been 
previously described in BPH cells (Cardoso et a1., 2004, True et a1., 2009). 
2.1.2.2 Prostate cancer associated fibroblasts (PCAF): 
PCAF cells are carcinoma-associated fibroblasts originally obtained from patients 
undergoing re-sectioning of the prostate and were kind gifts from Dr. Colby Eaton's team. 
They had been previously characterised prior collection for this project. 
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2.1.2.3 Non-cancer associated prostate fibroblasts 
WPMY -1 cells are prostate fibroblasts obtained from ATCC (Webber et aI., 1999). They 
express the fibroblast-specific markers vimentin and fibronectin), do not express PSA and 
have also been shown by the depositors to have no cancer cell phenotype. 
2.1.3 Cancer Cells 
2.1.3.1 Poorly Metastatic Prostate Cancer Cells 
LNCaP cells were obtained from cultures that were initially isolated from a needle 
aspiration biopsy of a lymph node metastatic lesion from a male caucasian prostate cancer 
patient (Sobel and Sadar, 2005a). The cell line was previously confirmed to be androgen-
sensitive as a result of its expression of the androgen receptor (AR) and androgen-mediated 
up-regulation of prostate-specific antigen (PSA). 
2.1.3.1 Highly Metastatic Prostate Cancer Cells: 
The PC3 cell line was obtained from cultures that were initially isolated from a lumbar 
vertebral metastasis in a male Caucasian prostate cancer patient (Sobel and Sadar, 2005b). 
This cell line is known to be androgen-independent in its growth and does not express AR. 
2.1.4 Cell Culture and Media Preparation 
2.1.4.1 Serum-containing Media 
All cells were routinely cultured in Dulbecco's modified eagle's medium (DMEM) 
(Invitrogen, 41965) supplemented with 10% (v/v) foetal calf serum, 100units/mL penicillin, 
100f.1g1mL streptomycin and O.25f.1g/mL amphotericin-B. This will be described as 
complete medium. The cells were incubated in a humidified incubator at 37°C with 5% 
C02 atmosphere. 
2.1.4.2 Serum-free Media 
For the purpose of cell treatment experiments, all cell lines were first cultured in complete 
medium, as described above, and after they had reached 90% confluence, were cultured in 
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serum-free DMEM, supplemented with antibiotics but without phenol red (Invitrogen, 
21063). The cell cultures were maintained in serum-free media for at least 48hours prior to 
cell treatments. 
2.1.5 Co-culturing of Cells 
Lentivirally-transfected green fluorescent protein(GFP)-expressing LNCaP cells were kind 
gifts from Dr. Colby Eaton's lab, for use in this project. They were confinned as GFP-
positive by fluorescence microscopy and fluorescence-activated cell sorting (F ACS) 
analysis. The stromal fibroblast cells were tagged with a cell membrane label; PKH26 
(Sigma, MINI26), making them fluoresce red. For the labelling, 4~M final concentration of 
PKH26 was introduced to 100,000 cells suspended in serum-free media and incubated at 
ambient temperature for 4 minutes. Addition of an equal volume of complete medium to 
the cell-dye suspension for another I minute stopped the reaction by greatly reducing the 
binding effect of the dye to the cell membrane. The mixture was centrifuged for 5 minutes 
at 400 x g. The supernatant was aspirated and fresh complete medium was added to the cell 
pellet and centrifuged for 5 minutes at 400 x g. This wash step was repeated 3 times in 
order to remove unbound dye. 100,000 red fluorescing stromal cells PCAF or 100,000 
WPMY -I were plated along with an equal number of LNCaP-GFP cells for 24 or 48 hours 
in wells of a 6-well plate. This gave a mixed cell layer of cells in physical contact with one 
another. 
2.2 COLLECTION OF CONDITIONED MEDIA FOR ASSAYS 
Complete medium was used to culture cells until they were 80% confluent. The medium 
was then removed; the cell monolayer washed twice with PBS and then serum-free medium 
was added to the cells. This was left for 24, 48 or 72 hours and collected. The medium was 
centrifuged at 400 x g for 5 minutes and the supernatant media collected and stored at -
70°C until further use, to prevent microbial contamination. 
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2.3 CELL TREATMENTS 
Cells were subject to treatment with androgens and cytokines in order to investigate 
modulation of gene expression post-treatment. The treatments used for this project 
included: 
2.3.1 OUT 
Cells were seeded at 50,000/well, into 12-well plates with 1 mL of complete medium. 
When the cells reached 60 - 70% confluence, the medium was changed to serum-free 
medium. The cells were allowed to adjust to the serum-free condition for 48 hours after 
which the medium was again changed to serum-free medium with 0 nM, 0.1 nM, 1 nM and 
10 nM DHT (Sigma, A8380), 1 J.lM flutamide - an androgen receptor antagonist, (Sigma, 
F9397), as well as a combination of 1 11M flutamide + 10 nM DHT. The physiological 
serum concentration of DHT in humans is 1 - 5 nM (Raivio et aI., 2002). The inhibitory 
constant of flutamide is 175nM (Kemppainen et aI., 1999) so an excess of this 
concentration, up to 1000nM was used in order to investigate the reversal of any 
androgenic effects that DHT might show. 100% ethanol was used as diluent and maintained 
in all the culture media at a final concentration of 0.1 % (v/v). The treated cell cultures were 
incubated for 24 hours at 37°C, prior to RNA extraction. 
2.3.2 TNF 
The cells were cultured as described in 2.3.1 except for the cell treatment where the serum-
free media contained 0 pglmL, 10 pglmL (0.57pM), 100 pglmL (5.71pM) and 10 nglmL 
(571 pM) of recombinant human TNF (Biosource, PHC3015) in a 0.1% (w/v) BSA in PBS 
to give a final concentration of 0.001 % BSA. This acts as a carrier molecule and prevents 
the loss of TNF onto the plastic surfaces of the culture plates. Treated cell cultures were 
again incubated for 24 hours at 37°C, prior to RNA extraction. As an experimental constant 
0.001% BSA was maintained in control and test experiments. 
2.3.3 TGF-p 
Stromal cells were seeded at 10,000 cells/well with 1 mL of complete medium inl2-well 
tissue culture plates. The cells were incubated at 37°C and 5% CO2 for 48 hours in order to 
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allow the cells to form mono layers at the base of each well. The medium was then changed 
to serum-free DMEM supplemented with 100 units/mL penicillin, 100 IlglmL streptomycin 
and 0.25 Ilg/mL amphotericin-B. The cells were allowed to adjust to the serum-free 
condition for 48 hours after which the medium was again changed to serum-free medium 
containing 0.05 nM, 0.5 nM or 50 nM of TGF-~1 (Gibco, PHG9204) diluted in PBS 
containing 0.1% (v/v) BSA. Treated cell cultures were incubated at 37°C and 5% C02 for 
24 hours prior to RNA extraction and 72 hours for protein extraction. 0.001% BSA was 
maintained in control and test experiments. 
2.4 RNA EXTRACTION 
Cells were lysed directly in the culture flasks using 1 mL of Tri Reagent (Sigma, T9424) 
per IOcm2 of culture flask surface area. The culture medium was removed and Tri Reagent 
was added and cell lysates were homogenised by repeated pipetting. 0.2 mL Chloroform 
was then added to homogenates, vortexed for 15 seconds and allowed to stand for 10 
minutes at ambient temperature. Resulting mixtures were then centrifuged at 2400 x g for 
15 minutes at 4°C in order to separate the various phases, the top aqueous phase being the 
one that contained RNA. Once the aqueous phase had been obtained, 0.5mL isopropanol 
per I mL Tri Reagent was used to precipitate the pellet by centrifuging at 2400 x g for 10 
minutes at 4°C. The resulting supernatant was then removed and the RNA gel-like pellet 
was washed with ImL 75% v/v ethanol per 1 mL Tri Reagent used. The mixtures were 
centrifuged at 1500 x g for 5 minutes at 4°C after which ethanol was removed and samples 
were dried at ambient temperature. Then 50 ilL of diethyl pyrocarbonate (DEPC)-treated 
water (RNAse-free water) was added to dried RNA pellets and repeated pipetting at 50°C 
for 10 minutes facilitated dissociation. The resulting RNA solutions were stored at -80°C. 
RNA thus obtained was assayed using the Bio-Rad Spectrophotometer; this was carried out 
to estimate the degree of RNA purity and quantity of RNA obtained. The absorbance of 40 
Ilg/mL of RNA at UV wavelength of 260 nm is 1. The RNA concentration of samples was 
measured by reading the absorbance of the diluted total RNA at wavelength of 260 nm. The 
values obtained were then multiplied by the dilution factor. The equation below was used 
for the derivation of RNA concentration: 
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RNA (f.tg/mL) = Absorbance at 260 nm x dilution factor x 40 f.tg RNAlmL 
Measuring the absorbance of the diluted samples at A280 and comparing the A260:A28o ratios 
also identified any protein contamination. The ratio should approach 2.0 if the RNA sample 
is free of protein contamination and generally a ratio of about 2.0 indicates good RNA 
(Glasel, 1995). 
2.5 REVERSE TRANSCRIPTION 
After RNA extraction, cDNA was prepared by reverse transcription using Superscript II 
Reverse Transcriptase kit (Applied Biosystems, 18064-014), which contains a modified 
version of Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV RT) designed 
for good thennal stability and low RNase H activity. The kit also contained 
deoxynucleotide triphosphates (dNTP) mixture. This was primed with random primers 
(Applied Biosystems, 48190-011). Reverse transcription was carried out using 20 f.tl 
reaction mixture per tube, consisting of: 
• 4 f.tL of 5 X first strand Buffer, 2 f.tL of 0.1 M dithiothreitol (DTT), 
• 0.5 f.tL of 10 nM each of deoxynucleotide triphosphates (dNTP) mixture of 
dA TP, dCTP, dTIP and dGTP 
• 1 f.tL of 100 ng random primers (these are hexamers that can simultaneously 
act as primers to reverse-transcribe all mRNAs) 
• 0.5 f.tL of 40 units/f.tL of RNAseOUT RNAse inhibitor (Applied Biosystems, 
10777-019) 
• 10.5 f.tL of DEPC-treated water 
• 1 f.tL of a 1 f.tg/f.tl RNA sample 
• 1 f.tL of 200 units/f.tL of Superscript II reverse transcriptase 
Each tube represented different treated and untreated samples. Control reactions were also 
set up with no Superscript reverse transcriptase. The tubes were placed in the GeneAmp® 
PCR System 9700 and set at the following temperatures: 
25°C for 2 minutes, for activation of the enzyme 
42°C for 50 minutes for annealing of the random primers and cDNA synthesis 
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70°C for 15 minutes, for inactivation of the enzyme. 
These parameters facilitated the reverse transcription process, after which the tubes were 
stored at -20°C prior to use. 
2.6 REAL-TIME POLYMERASE CHAIN REACTION 
Real-time peR (qPCR) allows the monitoring of the PCR as it occurs, and so data are 
collected throughout the PCR process, rather than at the end of the PCR. Here, the relative 
quantification method of qPCR was used, whereby differences in the expression of a target 
gene between different samples were quantified, relative to another reference sample. In 
addition to the target sequence (TlMP-3, Versican or PSA), endogenous controls, 
glyceraldehyde phosphate dehydrogenase (GAPDH) and RNA polymerase 2 (RNAP11) 
were quantified as a means of correcting results that may be skewed due to differences in 
the cDNA quantities loaded into the reactions. GAPDH and RNAPll are constitutively 
expressed genes that remain fairly unaltered upon treatment of the cells with external 
stimuli or factors (Radonic et aI., 2004) and in these project experiments acted as references 
for the normalisation of the test results. With androgen-sensitive cell lines the expression 
levels of PSA were also analysed, as a positive control to confirm the activity of DHT used 
in the experiments, as previously reported (lilja, 1993). 
First, the cDNA samples were diluted by a factor of 0.5 with DEPC-treated water, after 
which 10 III of reaction mixture was set up in wells of 384-well plates, each comprising of 
the following: 
5 III of Taqman® Universal PCR Mastermix, no AmpErase® UNG (Applied 
Biosystems, 4324018) - this contains DNA polymerase capable of instant hot-
start PCR and does not require activation 
4.5 III of the diluted cDNA 
0.5 III of 20X Assay-on-Demand™ Gene Expression Assay mix (this contains 
pre-formulated primers and Taqman probes with a reporter dye, FAM, labelled 
to the 5' end of the probe and a non-fluorescent quencher at the 3' end of the 
probe). The pre-formulated primers targeted timp-3, PSAlhK-3, Versican, 
GAPDH or RNA Polymerase 11. 
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Table 2.1 below shows the sequence information for all assay used: 
Gene Name Assay ID Accession # Primer-Probe Seq. (5'-3') 
TIMP-3 HsOO165949_ml NM 000362 CCGACATCGTGATCCGGGCCAAGGT 
hK-3/PSA Hs00426859_g1 NM 001030047 GCCCACTGCATCAGGAACAAAAGCG 
Versican Hs00171642 ml NM 004385 GACTGTGGATGGGGTTGTGTTTCAC 
GAPDH Hs99999905 _ m 1 NM 002046 GGCGCCTGGTCACCAGGGCTGCTTT 
RNA Pol. II Hs00992801_ml NM 021974 TCAGACAACGAGGACAATTTTGATG 
Table 2.1: Sequence information of the assays ordered from Applied Biosystems. Assay 
ID, accession number and probe sequences for timp-3, hK-3/PSA, versican, GAPDH and 
RNA Polymerase 11. 
The PCR reaction exploited the 5' nuclease activity of the DNA polymerase to cleave a 
Taqman primer-probe during PCR. When the probe was intact, the proximity of the 
fluorescent reporter dye (F AMTM) to the non-fluorescent quencher resulted in repression of 
the reporter fluorescence. During the reaction, if the target sequence was present, the probe 
specifically annealed between the forward and reverse primer sites. If the probe hybridised 
to the target, the DNA polymerase cleaved off the probe and separated the reporter dye and 
the quencher dye, resulting in increased fluorescence of the reporter dye. The probe 
fragments were then displaced from the target, and strand polymerisation continued. 
The different treated and control samples were set up in triplicate wells and then wells were 
sealed tightly to prevent spillage. The ABI Prism 7900 HT Sequence Detector Platform was 
then set up for the real time PCR reactions by first connecting it to the computer. Then the 
probes containing F AMTM dye were added to all the well plates. The wells were labelled 
accordingly and the AB! system set at: 
(i) 95°C for 5 minutes for cDNA strand separation 
Then 40 cycles of: 
(ii) 95°C for 15 seconds for primer-probe annealing 
(iii) 60°C for I minute for polymerisation of DNA strands 
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2.7 PCR DATA ANALYSES 
qPCR data were analysed using SDS 2.0 Software (Applied Biosystems, U.K) and using 
the comparative delta Ct method as previously described (Livak and Schmittgen, 200 I). 
Baseline gene expression was first expressed as ~Ct, namely cycle threshold at which 
fluorescence was detectable above background for TIMP-3, minus Ct of endogenous 
control gene, e.g. GAPDH. The data obtained were then expressed as fold increase. Here, 
all ~Ct values for treated samples were standardised to the control for each experiment by 
subtracting them from the control/untreated sample. Fold increases were determined by 
applying the formula 2-MCt where 
~Ct = Ct of endogenous gene - Ct of test gene 
and 
~~Ct = ~Ct of test gene (treated) - ~Ct of test gene (untreated) 
2.8 PROTEIN EXTRACTION 
Total protein (i.e. cells plus ECM) was extracted from the cells using the Mammalian Cell 
Lysis Kit containing protease inhibitor cocktail (Sigma, MCL 1) or 0.1 % Triton-X-lOO 
containing protease inhibitor cocktail (Sigma, P8340), and following the manufacturer's 
protocol. The cell lysis buffer (CLB) made up from the kit contained 50 mL each of 250 
mM Tris-HCI, pH 7.5, 5 mM EDT A, 750 rnM NaCI, 0.5% SDS in water, 2.5% deoxycholic 
acid sodium salt in water, 5% Igepal CA-630 detergent in deionised water and 2.5 mL of 
protease inhibitor cocktail (Sigma) containing (4-(2-aminoethyl) benzenesulfonyl fluoride, 
pepstatin A, bestatin, leupeptin, aprotinin and L-trans-epoxysuccinyl-L-Ieucyl-amido (4-
guanidino )-butane (E-64). 
For the extraction of totallysates, the monolayer of cells was washed with PBS for I hour 
at 4°C and then 200 ~L of CLB was added per 106 cells. The mixture was centrifuged at 
2,500 x g for 10 minutes at 4°C. The supernatant was collected as the protein sample, and 
the pellet was discarded. The supernatant was stored at -20°C until needed. 
For the extraction of cellular proteins only, the cells were trypsinised from the wells or 
plates prior to addition of the CLB. The same procedures as above were carried out. 
For the extraction of extracellular matrix (ECM) proteins only, the cells were detached 
from the wells or plates using enzyme free Hanks Buffer (Invitrogen, 13150-016). This 
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contained EDT A that gently dissociated cells from each other and from their support 
substrates, leaving the ECM in the wells. The cells were counted for use in standardisation 
of amount of ECM loaded. Then loading buffer was made up and this consisted of: 
5 parts of 4X lithium dodecyl sulphate (LDS) sample buffer containing 106 mM 
Tris HCI, 141 mM Tris base, 2% LDS, 10% Glycerol, 0.51 mM EDTA, 0.22 
mM Coomassie blue G250 and 0.175 mM Phenol red (Invitrogen, U.K.) with a 
pH of8.5 
2 parts of 500 mM DTT at a lOX concentration (Invitrogen, U.K.) 
7 parts of water 
200 ilL of the loading buffer was added directly to the ECM in the wells and left at 4°C for 
1 hour, after which the solution was scraped off the base of the well or plate and pipetted 
into a tube. The solution, now containing the ECM proteins, was stored at -20°C prior to 
use. 
2.9 PROTEIN CON CENTRA TION ASSAY 
Protein concentration was assayed using the BCA (Bichinconinic acid) assay (Pierce, 
23225) and following the manufacturer's protocol. For this assay, a 96-well format was 
used. Serial dilutions of bovine serum albumin (Pierce, 23225) were diluted with CLB to 
give concentrations of BSA of 2000, 1500, 1000, 750, 500,250, 125,25 and 0 f.1g1mL. The 
working reagent (WR) was made up by diluting BCA by 1 :50. Then 25 f.1L of either BSA 
or diluted total or cell only protein was added to each well of a clear 96 well plate after 
which 200 ilL of WR was added to the samples, giving a sample to WR ratio of 1 :8. The 
plate was covered and incubated at 37°C for 30 minutes then for 15 minutes at ambient 
temperature. The absorbance of the mixtures was read off at 562 nm wavelength using a 
spectrophotometer. Standard curves were plotted using the absorbance of the BSA dilutions 
versus the concentrations of the BSA samples. The concentrations of the protein extracts 
were calculated from the BSA standard curve. 
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2.10 SDS-PAGE 
This was carried out in order to separate proteins from cell extracts, based on their 
molecular weight. This is in line with previously described protocols (Jovin, 1973a, lovin, 
1973b). The sulphate present in the anionic detergent (LOS) contained in the loading buffer 
(see Section 2.8) applies negative charges to proteins thereby linearising the protein. 
Loading them onto polyacrylamide gel and applying constant voltage to the gel separated 
the proteins. By using a combination of acrylamide and bis- acry1amide at a defined ratio, a 
gel matrix comprising of a network of pores was achieved. The negatively charged 
linearised proteins migrate through the gel matrix towards the positive electrode/anode. The 
speed of migration varies with the protein size; smaller proteins migrate faster than bigger 
ones, and appear as bands in the lower region of the gel. Bands in the upper region of the 
gel represent bigger proteins. 
12% resolving polyacrylamidelbis acrylamide gels were prepared by combining the 
following reagents in the order below: 
40% Acrylamide/Bis-acry1amide solution, 37.5:1 (Biorad, 161-0148) = 3.00 mL 
Resolving gel buffer, (1.5 M Tris-HC1, pH 8.8) (Biorad, 161-0798) = 2.50 mL 
Water = 4.35 mL 
10% (w/v) SOS (Biorad, 161-0416) 
100 mglmL Ammonium Persulphate/APS (Biorad, 161-0700) 
TEMEO (Biorad, 161-0801) 
= 0.10 mL 
=0.05 mL 
= 0.01 mL 
The first 4 components were mixed gently and both APS and TEMEO were added just 
before the mixture was introduced into a gel cassette assembly (the gel cassette assembly is 
made up of a spacer plate, a short plate and a casting frame, all components of Biorad Mini-
Protean 3 gel assembly system). APS and TEMEO are cross-linkers that increase the 
spontaneous polymerisation of acrylamide in the absence of oxygen. Some butan-2-01 was 
added to the top of the gel to smoothen it and prevent the introduction of 02 into the gel. 
The gel was left to polymerise at ambient temperature by placing it in the casting stand for 
40 minutes. Once dried, the butan-2-01 on top of the resolving gel was discarded and the gel 
was rinsed with water. The top of the gel was air-dried and placed back on the casting 
stand. 
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Stacking gel was made up and introduced to the top of the resolving gel to enable the 
protein bands to migrate slowly until they reach the top of the resolving gel. 10 mL of 
stacking gel was made up in the order below: 
40% Acrylamide/Bis-acrylamide solution, 37.5: 1 (Biorad, 161-0148) = 1.00 mL 
Stacking gel buffer, (0.5 M Tris-Hel, pH 6.8) (Biorad, 161-0798) = 3.00 mL 
Water 
10% v/v SDS (Biorad, 161-0416) 
100 mglmL Ammonium Persulphatel APS (Biorad, 161-0700) 
TEMED (Biorad, 161-0801) 
=6.84 mL 
= 0.10 mL 
=0.05 mL 
= 0.01 mL 
Immediately after adding the stacking gel, moulded combs (also part of the mini-protean 3 
system) were introduced into the gel before allowing polymerization at ambient 
temperature for 40 minutes. Once done, the combs were gently removed from the gel and 
the gel cassette sandwich was removed from the casting frame and inserted into the 
electrode assembly. When running only one gel, a buffer dam was placed in the other side 
of the electrode assembly clamped shut. The electrode assembly was placed into the 
clamping frame, making up the inner chamber assembly. This assembly was inserted into 
the mini tank. 
For electrophoresis, running buffer was made up, which consisted of 25 mM Tris/192 mM 
Glycine/O.l% SDS, pH 8.3 (Biorad, 161-0732). The inner chamber assembly was filled 
with running buffer and care was taken to prevent overfilling and spillage. The protein 
samples were prepared as described in Section 2.8, and heated at 70 degrees for 10 minutes. 
The samples were left to cool at ambient temperature and loaded into individual wells. 
Protein dual colour molecular weight standards (Biorad, 161-0374) were loaded on to one 
lane to monitor band migration and determine approximate molecular weights. Also, 
recombinant human full length TlMP-3 (R & D Systems, 973-TM) was loaded alongside 
proteins as a positive loading control of known molecular weight. Running buffer was 
added to the lower buffer chamber. The mini tank was covered with the tank lid and the set 
up was connected to a power supply and constant current of 20 rnA applied for 60 minutes 
for separation of proteins through the gel. 
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2.11 WESTERN BLOTTING 
Before the electrophoresis was complete, transfer buffer was made up. This consisted of 60 
mM Tris/40 mM CAPS buffer containing 15% methanol, pH 9.6 (Biorad, 161-0778) 
Once proteins were separated, the gel was removed from the gel sandwich and equilibrated 
in transfer buffer for 15 minutes. Blotting pads were also soaked in transfer buffer for 15 
minutes and blotting paper was lightly wet with transfer buffer. A PVDF membrane was 
soaked in methanol for 60 seconds and then equilibrated in transfer buffer for 15 minutes. 
The blotting sandwich was set up using the above materials and in the order below: 
Clear side down -> blotting pad -> blotting paper -> PVDF membrane -> gel -> blotting 
paper -> blotting pad -> Black side up. 
The sandwich was clamped shut with the attached white clip and inserted into the mini-
trans-blot module (Biorad) with the black side of the sandwich next to the black side of the 
module cassette. The inner part of the module was filled with transfer buffer, up to the 
white clip and outer chamber of the module was filled to the top. The module was closed 
with its lid and inserted into a container filled with ice (to prevent temperature increase) 
and connected to a power supply. The proteins were then transferred to the membrane by 
applying a constant voltage of 20 V for 2 hours. 
After transfer, the protein-binding sites on the PVDF membrane were blocked in blocking 
buffer consisting of TBS containing 1 % (w/v) casein (Bio-Rad, 161-0782) with 0.05% v/v 
Tween-20. This incubation was carried out for 60 minutes at ambient temperature whilst 
rocking the membrane gently on a rotor. Afterwards, the membrane was washed 3 times at 
5 minutes each, with the prepared TBS-casein buffer (Biorad, 170-6435) and protein bands 
were detected with the following primary antibodies diluted in blocking buffer: 
1 ""glml (50 nM or 1:500 dilution of 500 ""glml stock) of mouse monoclonal 
anti-TlMP-3 antibody, raised against residues 24 - 211 of recombinant human 
TlMP-3 (R&D Systems, MAB973) 
1 ""glml (50 nM or 1 :200 dilution of 200 ""g/ml stock) of rabbit polyclonal anti-
TlMP-3 antibody raised against the C-terrninal region of TlMP-3 (Sigma, 
T7812) 
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0.1 /lglml (5 nM or I: 10,000 dilution of 1 mg/ml stock) of rabbit polyclonal 
anti-GAPDH antibody (Sigma, G9545). This was used for GAPDH detection, as 
a loading control when loading total cell lysates. 
The primary antibody was incubated with the membrane overnight at 4°C. The membrane 
was then washed 3 times for 5 minutes each. The membrane was probed with HRP-
conjugated secondary antibodies, depending on the primary antibody used for initial 
membrane probing: 
1: 1 000 dilution of HRP-conjugated goat anti-mouse IgG (Dako, P0447) 
I: I 000 dilution of HRP-conjugated swine anti-rabbit IgG (Dako, P0399) 
The membrane was incubated for 60 minutes at ambient temperature with gentle rocking 
and then washed 3 times for 5 minutes each. 
The ECL plus western blotting detection reagent (GE Healthcare, RPN2132) was used for 
the detection of blotted proteins. This reagent is made up of lumigen PS-3 acridan substrate 
that produces highly luminescent acridinium ester intennediates upon reacting with 
peroxidase found in the HRP-conjugated secondary antibodies. The result of this reaction is 
the production of chemiluminescence that can be exposed to autoradiography films to be 
visualised as bands on the film. The ECL plus solution was applied onto the membranes for 
5 minutes and removed from the membranes. The membranes were drained of any excess 
reagent and placed into a thin cling film to prevent adherence of contaminants, and then 
exposed to x-ray films (GE Healthcare, RPN2103) in a dark room. 
2.12 DENSITOMETRIC ANALYSIS OF WESTERN BLOTS 
Western blots were scanned and the blots were analysed using the Bio-Rad Quantity One 
software. This measures the pixels of the blot in comparison to the background pixels to 
generate a value for the blot with optical density x area as the unit (OD mm2). It can also 
compare one blot to another, and correct the values using the same background so that there 
is unbiased quantification. The higher the value obtained, the higher the protein content of 
that particular blot, and vice versa. With this, semi-quantification of proteins can be 
achieved using the values obtained. 
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2.13 DOWN-REGULATION OF GENE EXPRESSION USING siRNA 
Commercially available siRNA to TlMP-3 (Ambion, AM1670S), GAPDH (Ambion, 
AM4655) and non-targetting control siRNA (Ambion, 4611) were obtained from Applied 
Biosciences/Ambion, U.K. This commercial TIMP-3 siRNA was designed to target ex on 5 
of timp-3 gene. The 5' --> 3' sequences of the siRNA are: 
Sense: GGAACUACAAGAGAGUCGGtt 
Anti-sense: CCGACUCUCUUGUAGUUCCtt 
Several methods of transfection were employed in order to determine the optimal protocol 
for introducing siRNA into the cells. These included: 
(i) Calcium Phosphate transfection 
(ii) Lipid-based Dharmafect transfection and 
(iii) Electroporation. 
(iv) 
For all protocols, silencer siRNA to TIMP-3 and a housekeeping gene GAPDH, and non-
targeting siRNA were used. GAPDH knockdown served as a positive experimental control 
as all actively metabolising cells express GAPDH. The sequence of the GAPDH siRNA 
was not supplied by Ambion but is proprietary. Non-targeting siRNA acted as a negative 
control and did not target any known human gene sequence. Again, this sequence was not 
supplied but is proprietary. Mock-transfection controls were also set up, where no siRNA 
was added to the transfection complexes. Untransfected cells were also plated and analysed 
alongside transfected and mock-transfected cells so as to monitor any differences observed 
in expression levels due to the transfection reagent only. 
2.13.1 Calcium Phosphate Transfection Method 
This is based on the formation of a calcium phosphate-RNA precipitate as a by-product of 
the addition of calcium chloride to Hepes buffered saline (HBS), which contains 
Na2HP04;2H20 as one of its components (Invitrogen, K27S0-01). 
Reaction: 
Na2HP04 + CaCh -~ 2NaCI + CaHP04 
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The calcium phosphate thus fonned facilitates RNA binding to the surface of the cell and 
subsequent introduction into the cytoplasm via endocytosis. This method has previously 
been described (Graham and van der Eb, 1973). First, the cells were trypsinised, complete 
DMEM medium containing antibiotics and serum was then added to neutralise the trypsin, 
and the cell suspension centrifuged at IS00 X g for S minutes. The cell pellet was re-
suspended in antibiotic-free DMEM and the cells were counted using a coulter counter (as 
described in Section 2.16). A total of 3X 1 04 cells were re-suspended per 80 III of antibiotic-
free medium. 
I.S III of a 20 IlM TIMP-3 silencer siRNA stock concentration (Ambion) was mixed with 
I.S III of 2 M CaCh and the volume made up to IOfll in a test tube labelled (a). To another 
tube labelled (b), 10 fll of 2 X HBS was added. Using a sterile pipette, the contents of (a), 
was slowly introduced into (b) whilst bubbling air into (b) using another pipette. At this 
point, there was fonnation of a calcium phosphate complex, which enables endocytosis to 
occur. The mixture of (a) and (b) was incubated at ambient temperature for 30 minutes. 
Then 400 III of the antibiotic-free medium was introduced into 48-well plates and the 80 III 
of cell suspension was also added to this. After the 30-minute incubation, the mixture of (a) 
and (b) was then introduced, drop-wise, into the wells containing the suspended cells. This 
is a process known as reverse-transfection or neo-transfection, and it allows more contact 
between the siRNA-CaCh-HBS mixture and the surface of the cells, resulting in more 
efficient transfection, relative to the traditional transfection protocol, where the cells are in 
monolayer and part of the surface area is unavailable for complete siRNA binding. The 
final siRNA concentration in the complex/culture was 60 nM. The plates were incubated at 
37°C/S%C02 for 16 hours, after which the transfection complex-media was removed (to 
prevent cell toxicity) and replaced with fresh medium for another 32 hours prior to RNA 
extraction. 
2.13.2 Lipid-Based Transfection Method 
This method also employs the neo-transfection technique but instead, utilises a liposome 
complex that entraps the siRNA and transports it into the cell via endocytosis. The cells 
were trypsinised, counted and re-suspended in antibiotic-free medium, as above. 3XlO4 
cells/60 III of antibiotic-free medium was prepared and added into 48-well plates already 
containing 100 III of antibiotic-free medium per well. The transfection complex comprised 
10 fll of a 2 flM siRNA concentration diluted in 10 III of antibiotic- and serum-free medium 
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in one tube labelled (a) and 0.4 III of Oharmafect-2 transfection reagent 
(Oharmacon/Thermo Fisher Scientific, T2002) diluted in 10 III of antibiotic and serum-free 
medium in tube (b). The contents of both (a) and (b) were mixed together by careful 
pipetting and then incubated for 20 minutes at ambient temperature prior to careful 
pipetting of the complex into the cell suspension in the wells. The final siRNA 
concentration in culture was 100 nM. The plates were incubated for 16 hours at 
37°C/5%C02 after which the transfection complex was removed because according to the 
manufacturer's protocol, Dharmafect-2 is toxic to cells if maintained for more than 16 
hours in culture. The medium was replaced with fresh antibiotic-free medium and 
incubated for another 32 hours prior to RNA extraction for analysis. 
2.13.3 Electroporation 
This method entails subjecting the cells to electric shock, which temporarily opens up pores 
in the lipid bilayer and allows the entry of highly charged molecules such as 
polynucleotides (Neumann et aI., 1982). Again, the cells were trypsinised, counted, and re-
suspended, this time, into 100 III of Nuc1eofector R reagent (Amaxa, VCAI001) at ambient 
temperature, at 1 X 106 cells/l 00 III of reagent. Then 2 Ilg of siRNA was introduced into the 
mixture and the entire mixture was transferred into an Amaxa-certified cuvette with a lid 
on. The cuvette was then inserted into the Amaxa nuc1eofector machine and the program 
set at T -09 for electroporation, according to manufacturer's recommended protocol. The 
cell mixture was immediately removed from the cuvette after electroporation and 
transferred into 37°C pre-warmed antibiotic-free OM EM containing 10% v/v serum, and 
pre-plated into 6-well plates. The final siRNA concentration in culture was 100nM. The 
plates were incubated at 37°C/5%C02 for 48 hours, prior to RNA extraction because 
according to the manufacturer's protocol, the nuc1eofector reagent is not toxic to cells and 
did not need to be removed post-transfection. 
2.14 F ACS SORTING OF CELLS 
Cells to be sorted were trypsinized, harvested and counted (as described in Section 2.18.1). 
They were then suspended in DMEM media with 0.5% FCS and taken to the University's 
F ACS (fluorescence activated cell sorting) facility (students were not allowed to operate the 
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FACS equipment and had to submit samples for analysis by trained technicians). FACS is a 
technique that employs the use of light to sort specific populations of cells from a mixed 
population based on the fluorescence emitting from cells. 
Cells were sorted either by inherent fluorescence as in the case of stably-GFP-transfected 
LNCaP cells, or by membrane fluorescence as in the case of PKH26-labelled cells. The 
different cell populations were sorted and collected into different tubes. Non-
transfectedlnon-Iabelled cells also had to be submitted for standardisation and optimisation 
of the F ACS sorter. Data reported by the technicians include: 
• Total cell number 
• Percentage of fluorescent cells 
• Percentage of non-fluorescent cells 
• Percentage of cell debris or dead cells 
The sorted cells were further analysed for timp-3 mRNA expression by qPCR or protein 
expression by western blotting (as described in Sections 2.6 and 2.11). 
2.15 FUNCTIONAL ASSAYS 
Several assays were carried out in order to assess whether there were any changes in 
biological functions of the cells after down-regulation of the TIMP-3 transcript. They 
include: 
2.15.1 Proliferation Assays 
2.15.1.1 Coulter Counter Method 
This is based on cell counting using the Beckman Coulter Z2 particle count and size 
analyser. It allows a threshold particle diameter to be set, such that the counts obtained will 
exclude any dead cells and cell debris that will fall under this threshold. Different cell types 
have different sizes and so the coulter counter first analyses the particle size and gives an 
approximate diameter of the cells, then counts the cell number. The diameters of the cell 
lines used in this project were determined as follows: 
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• PC3:-7~m 
• LNCaP: -9 ~m 
• PCAF: -12 ~m 
• WPMY-I: - 9 ~m 
• BPH45: - 12 ~m 
Cells were trypsinised and harvested as normal (see Section 2.2) and suspended in 10 mL 
of complete medium. The cell suspension was diluted by a factor of 20 in isotonic solution 
such as saline, by adding 0.5mL into 9.5 mL diluent, and placed in the counting chamber 
to be counted. Resulting counts were multiplied by the dilution factor of 20 and then by 2 
to give the total number of cells per ImL of cell suspension. This allowed for comparison 
of cell numbers between untreated and treated cells as an indication of the rate of 
proliferation of the cells. Any modulation of cell growth by treatment was indicated by cell 
number changes. 
2.15.1.2 Haemocytometer Method 
This method of counting uses a conventional haemocytometer. The cells were harvested 
and suspended in complete media such that they were sparsely diluted. Then the cells were 
further diluted I: I in trypan blue which stained the dead cells blue. When counting the cells 
under the microscope, any cells stained blue were excluded. Counts were obtained from 5 
sections out of the nine sections of the haemocytometer: the four edges and the central 
section. The total count was divided by 5 and then multiplied by 2 and again by 10,000 in 
order to give the total number of cells per mL of cell suspension i.e. 
Total cell count per mL = (haemocytometer countl5) x 2 (for trypan blue dilution) x 104 
This gave a measure of changes in rates of cell proliferation pre- or post-treatment. 
2.15.2 Migration Assays 
This is based on the Boyden chamber construct placed into a well of a 24-well plate. The 
cells are able to migrate through a membrane from the outer into the inner part of the 
chamber. 5,000 cells were suspended in 100 1-11 media and introduced into the outer part of 
the chamber. Over 24 hours or 48 hours (depending on cell type), the cells migrated 
through the pores of the membrane via chemotaxis into the inner part of the membrane i.e. 
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to the membrane that is in contact with the media inside the well. The non-migrated cell 
on the outer part of the membrane were removed by wabbing with a clean cotton bud and 
the membrane was fix-stained with crystal violet in 70% v/v ethanol and migrated cell 
were counted. This assay required the presence of a chemo-attractant such a growth factor 
or nutrient-rich media in the lower chamber (see Figure 2.5). With thi as ay, compari on 
was made between migratory potential of un-trans fee ted and TLMP-3-down-regulated cell . 
-+-------... Boyden chamber 
.-l~---""" 1'\-.......-.........-:"1=+-----..... Cell suspension 
0.2~-pore membrane 
~-____ ... Media with chemo-
attractant in well 
Figure 2.1: Transwell-migration assay. 
The cells are seeded into the Boyden chamber and allowed to migrate towards the lower 
chamber over 48 hours. Number of cells on surface of membrane facing the lower chamber 
with the media and chemo-attractant are counted 
2.15.3 Invasion Assays 
This is also based on a Boyden chamber set-up and i similar to the 3-D migration a ay 
(Section 2.15 .2) . However, the membrane in the chamber wa fir t coated with 50 )lL of 
growth factor reduced matrigel (BO Bio ciences, 354230), which wa allowed to 
polymerise for about 30 minutes at ambient temperature. Matrigel is routinely u ed a a 
semi-solid medium for promoting adherence of cells to surface in vitro , mimicking the 
basement membrane naturally found in vivo (Ondate et aI. , 1996). Thi added layer 
therefore represents a basement membrane-like ECM a it al 0 contain collagen IV, 
laminin and heparan sulphate proteoglycans that are normal component ba ement 
membranes. The cell uspension wa eeded on top of the matngel and inva i e cell had 
the opportunity to degrade the matrigel and pa through the membrane to the inner part of 
the membrane in the Boyden chamber, where they were tained with cry tal iolet in 70% 
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v/v ethanol and counted. Again, this assay was used to compare the changes in invasive 
potential of TlMP-3-down-regulated cells to their un-transfected or non-targeted controls. 
2.15.4 Apoptosis Assay 
This assay uses Annexin-V -FITC/Propidium Iodide (PI) staining of dead or necrotic cells 
and measures the amount of stained cells as a percentage of total number of cells assayed. 
This protocol was first described in 1995 by Vermes et al (Vermes et aI., 1995). The 
Annexin-V -FlTC and PI kit was bought from BO Biosciences (catalogue no. 556570) and 
the test kit contained Annexin-V binding buffer (made up of 10 mM Hepes/NaOH, 140 
mM NaCl and 2.5 mM CaCh pH 7.4). One of the changes that symbolizes the occurrence 
of early apoptosis in cells is the translocation of a component of the cell membrane; 
phosphatidyl serine (PS), from the inner part of the membrane to the outer surface. 
Annexin-V has a strong affinity for PS and will, in the presence of high Calcium 
concentrations, bind to PS. Propidium iodide (PI) is a fluorescent nucleic acid intercalator 
that fluoresces upon binding to DNA or RNA. As PI is impermeable to cell membranes, it 
can be used to detect cells with ruptured cell membranes. Used in combination with 
Annexin-V -FlTC, dead cells and necrotic cells can be excluded from a cell population by 
flow cytometry. The excitation wavelength for both Annexin-V-FITC and PI are 488nm 
and the emission wavelengths are 518 nm (detected in the FL 1 channel) and 617 nm 
(detected in the FL2 channel) respectively. 
For the apoptosis assay, cells were harvested by trypsinisation, counted and diluted to 1.0 x 
106cells/mL. Cells were washed with cold PBS by centrifugation at 1500 x g for 5 minutes. 
100 ilL of cell suspension was re-suspended in cold PBS, centrifuged at 1500 x g for 5 
minutes and re-suspended in 100 ilL of 1 X annexin-V binding buffer in a small Eppendorf 
tube. 5 III of Annexin-V-FlTC antibody and 5 ilL of PI was added to the cell suspension 
and vortexed gently for 10 seconds. The mixture was incubated at ambient temperature for 
15 minutes. Additional 400 ilL of 1 X binding buffer was added to each tube and the cells 
were analysed by flow cytometry for percentage of cells positive for Annexin-V as a 
measure of the percentage of the cell population that is apoptotic. 
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2.16 PROTEINASE INHIBITION ASSAY 
The total MMP-inhibitory activity of cell Iysates, ECM Iysates and conditioned medium 
from LNCaP, PCAF, WPMY -I and BPH45 cells was assayed using a quenched 
fluorescence substrate (QF); this is based on the ability of MMPs to break down a quenched 
fluorescence substrate at its Leu-Gly bond (Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) that 
contains a linked quencher and fluorophore (Bachem). Mca (7-methoxycoumarin-4-yl) is a 
derivative of 7-methoxycoumarin and is highly fluorescent. Dnp is a dinitrophenyl group, 
which acts as an internal quencher. This substrate was originally described by Knight el 01 
(Knight et aI., 1992). For the assay, 3 J.lL of 5 mM of the QF substrate was diluted in 3 mL 
of assay buffer (5 J.lM final concentration) containing 100 mM Tris-HCI, 100 mM NaCl, 10 
mM CaCh and 0.2% Triton-X-100, pH 7.5 and used to zero the LS-50B fluorimeter 
(Perkin-Elmer) prior to assaying for MMP activity and MMP-inhibition. The fluorescent 
peptide, which is released by the action of MMPs, Mca-Pro-Leu-OH, was used to 
standardise the fluorimeter such that at a concentration of 500 nM (10% substrate 
hydrolysis) gave a reading of 1000F. 
The excitation and emission wavelengths were set at A328 nm and A.W3 nm. Then 3 J.lL of 5 
J.lM of either MMP-2 or MMP-9 (final concentration of 5 nM) was added to fresh assay 
buffer-substrate mixtures and fluorescence was measured and stored in real time using the 
Flusys software package (Rawlings and Barrett, 1990). The linear rate of substrate 
conversion was followed for about 100 minutes and recorded as (V 0). Then, 10 J.lL of 
protein extracts or 3 J.lL of 5 J.lM stock of recombinant human TIMP-3 (control) was added 
to the reaction and the new linear rate was recorded (Vi). YiN 0 was calculated as the 
amount of matrix metalloproteinase proteolysis. If the value was less than I, MMP 
inhibition was occurring but if it was greater than or equal to I, then MMP activity was 
present in the sample. 
2.17 IMMUNOSTAINING OF CELLS AND TISSUES 
Cells were grown on glass slides for 24 houTS. Then the slides were rinsed briefly in PBS 
and cells fixed by submerging slides in 4% paraformaldehyde in PBS, pH 7.5, for 15 
minutes at ambient temperature. Afterwards, the slides were washed twice with ice-cold 
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PBS and then incubated with blocking buffer for 1 hour at ambient temperature, as used in 
western blotting (Section 2.11). The slides were then incubated in 50 nM of monoclonal 
TlMP-3 antibody (R&D Systems, MAB973) at 4°C overnight. This monoclonal antibody 
was used as it gave the best conditions for protein detection in previous optimisation 
experiments (see Section 2.13). The next day, the slides were removed from the antibody 
solution, washed with Tris buffered saline with 0.05% tween-20 (TBST) five times at 5 
minutes per wash. Then the slides were incubated in 1: 1000 dilution of a fluorescent 
secondary antibody; Alexa-Fluor 488-conjugated goat anti-mouse IgG (Invitrogen, 
AIIO)l) - this bound to the TlMP-3 mouse monoclonal antibody and fluoresced green 
with excitation and emission wavelengths of 485-495 nm and 520 nm respectively. The 
antibody reaction was carried out in the dark, as the fluorescent Alexa-Fluor-488 antibody 
is light sensitive. The cells were counter-stained by immersing the slides in 1 ~glmL DAPI 
nuclear stain (Thermo Fisher, U.K.) for 5 minutes at ambient temperature. DAPI is a very 
pure form of diamidino-2-phenylindole dye that is fluorescent and has high affinity for 
DNA. It binds to nuclear DNA where its fluorescence increases in its bound state 
(Lawrence and Possingham, 1986). The slides were then rinsed with PBS, allowed to dry 
and coverslips were mounted on the slides using a drop of mounting medium (DPX 
mounting medium, BD Biosciences). The coverslips were sealed onto the slides using nail 
varnish in order to prevent drying and movement under the microscope. The slides were 
stored in the dark until microscopic examination was carried out. 
Tissue samples were obtained as formalin-fixed and paraffin-embedded sections on glass 
slides. Before IHC staining, the sections were de-paraffinised by immersion twice in xylene 
for 5 minutes. The sections were then rehydrated by immersion into descending ethanol 
solutions; 99% for 10 minutes, 95% for 5 minutes, 70% for 5 minutes, and finally into 
distilled water for I minute. This was followed either by H&E staining or antibody 
incubation, as appropriate. For TIMP-3 antibody, the same protocol as cell immunostaining 
(above) was used. 
H&E is a common histological stain used to differentiate between the nucleic acid 
components and the cytoplasmic components of cells in a tissue section. Haematoxylin 
stains nucleic acid blue while eosin stains the intracellular and extracellular proteins found 
in the cytoplasm and basal laminae red/pink/orange. For H&E staining, the slides were 
immersed in Gill's II haematoxylin (Sigma Aldrich) for 90 seconds and then into distilled 
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water for 3 minutes. The slides were immediately immersed in I % aqueous eosin (Sigma) 
for 5 minutes and then into distilled water for 30 seconds. The slides were then fixed by 
immersion into ascending ethanol concentrations; 70% for 10 seconds, 95% for 10 seconds, 
99% for 1 minute and finally into xylene for 4 minutes. Coverslips were mounted with 
DPX mounting medium (BD Biosciences) and images captured using a fluorescent 
microscope at several objectives. 
Dr. Colby Eaton's group kindly donated the prostate tissue microarray samples. Figure 2.2 
shows the properties of the tissue microarray used: 
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Sheffield TMA 121 
LH006597/2002?y G3+3 PSA? 100cOaCS'3 OOCY3 acro OOcOnd LH0187nl20021y G1+1 PSA? 100001 000' 000 000 LH02683512002 1y G3+3 PSA7 E 000 3 0003 000 000 LH02036912002?y G3+3 PSA? 000 3 0003 000 LH00547612003?y G2+2 PSA? 000 2 0002 000 
LHOO376512003?y G2+2 PSA? 000 2 0002 000 LHOO358l12003?y G3+2 PSA? 0002 0003 000 000 LH02626l12002?y G3+3 PSA? 0003 0003 000 000 
LH02043612002?1 G3+3 PSA? 0003 0003 000 LHOO329112003 ?y G3+3 PSA ? 0003 0003 000 000 
LH02'52212002?y G3+3 PSA? 0003 0003 000 000 LH01571012002 ?y G3+3 PSA7 000 3 0003 000 000 LH01563112002?y G2+2 PSA ? 0002 0002 000 LH01563112002?y G3+2 PSA ? 000 3 0002 000 LHOO6794/1997?:i. G4+3 PSA ? 000 3 000 4 000 000 
Figure 2.2: Tissue M icro-array M ap: 
Each row included the samples from a single patient who had been treated by a radical 
prostatectomy. The clinical data in the first box consisted 0/ two unique identifier numbers 
from Sheffield internal coding, the age of the patient in years at the time of prostatectomy, 
the overall Gleason score for the whole tumour and the PSA level at presentation (if 
available). The array was orientated by two cores of marker tissue (either liver or spleen) 
at the beginning of the first two rows (shown as grey shaded circles on the template). The 
samples from the specimens were in triplicates with all 3 samples adjacent to each other. 
The first three cores were samples from cancer pattern 1 of the tumour and the Glea on 
grade of that area was given after the three circles. The next three cores were samples from 
cancer pattern 2 of the tumour and the Gleason grade of that area was given after these 
three circles. Usually these cancer samples represented the two main areas in the overall 
Gleason score given in the patient data but sometimes were sample from a tertiary or lesser 
pattern with a different Gleason grade. The next three cores were from areas ofhigh grade 
PIN if these were present in the specimen, if no PIN was present samples were not taken 
and the circles were absent from the template. The final three cores were from an area of 
morphologically normal background prostate epithelium in the specimen. 
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2.18 STATISTICAL ANALYSES 
Several types of statistical analyses were carried out depending on the type of data that 
needed to be analysed. Parametric analyses were carried out where several repeats of an 
experiment were carried out as there was sufficient sample number to immediately 
detennine a nonnal distribution. Non-parametric analyses were done where the data 
distribution was unknown andlor where sample number was low. The tests used in this 
project include: 
2.18.1 Student t-test 
This type of parametric statistical analysis was carried out where the number of 
experimental repeats was greater than I 0 and when distribution was detennined to be 
nonnal. The paired t-test was carried out to compare differences in paired samples and 
unpaired t-test for unpaired means of 2 data clusters. P ~ 0.05 was considered to be 
statistically significant. Microsoft excel was used for these calculations. 
2.18.2 Mann-Whitney Test 
The non-parametric Mann-Whitney two-tailed test was used to test for significant 
differences in between median values of control and individual samples. It is similar to the 
unpaired student's t-test but does not assume a nonnal data distribution. P ~ 0.05 was 
considered to be significant. These were carried out using Graph Pad Prism software. 
2.18.3 Wilcoxon Signed-Rank Test 
The non-parametric Wilcoxon signed-rank test was used to test for significant differences 
between median values of control and individual samples. It is similar to the paired students 
t-test but does not assume a nonnal data distribution, similar to the Mann-Whitney test. P ~ 
0.05 was considered to be significant. These were carried out using Graph Pad Prism 
software. 
2.18.4 Kruskal-Wallis Test 
This is also a non-parametric statistical analysis, which was used to compare 3 or more 
groups of data, unlike the Mann-Whitney and Wilcoxon tests, which could only compare 2 
groups of data at a time. It is similar to the parametric ANDY A test but instead of using the 
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means and variances for analysis, the Kruskal-Wallis test replaces it with ranks and reports 
the differences in the sum of the ranked data as P values. To correct for discrepancies in the 
ranked sums, a post-test was carried out based on whether the data was paired or unpaired: 
• Dunn's Post test for unpaired data sets i.e. extension of the Mann-Whitney test 
• Friedman's Post test for paired data sets i.e. extension of the Wilcoxon signed-rank 
test 
Again, P ~ 0.05 was considered to be a significant difference, as calculated by Graph Pad 
Prism software. 
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CHAPTER 3: EXPRESSION OF TIMP-3 IN 
PROSTATE CELLS AND TISSUES 
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3.1 INTRODUCTION 
The prostate tissue consists of different types of epithelial cells and a surrounding stromal 
component, separated from the epithelial component by a basement membrane. This 
stromal compartment consists of different types of cells such as smooth muscle cells, 
fibroblasts, nerve cells and lymphocytes, all embedded in the ECM-rich stroma (Wernert, 
1997). The basement membrane is semi-permeable and it consists of collagens, elastin, 
laminin and proteoglycans, all interwoven in a matrix that forms the membrane (Cunha et 
aI., 2002). In the androgen-refractive stage of prostate cancer, there is metastasis of tumour 
cells from the prostate primary site to other neighbouring and distal organs. This metastasis 
involves the breakdown of the basement membrane first, invasion of the stromal ECM and 
possibly co-migration of the cancer cells along with stromal fibroblasts to other organs 
where they home and form a secondary niche (Kaminski et aI., 2006). The process of 
migration and invasion is aided by proteases secreted by the tumour cells and these degrade 
substrates such as collagen and proteoglycans to enable passage of the tumour cells. The 
formation of secondary tumours is an indication of an aggressive cancer phenotype (Cobo 
Dols et aI., 2005, Plancke et aI., 1994). 
TIMP-3 is a metalloproteinase inhibitor that plays a major role in the regulation of ECM 
composition (Lee et aI., 2007). This leads to regulation of a wide range of physiological 
processes such as growth (Airola et aI., 1998, Baker et aI., 1998), apoptosis (Lee et at., 
2008, Fata et aI., 2001), migration, invasion (Baker et aI., 1998), transformation (Yang and 
Hawkes, 1992) and angiogenesis (Cruz-Munoz et aI., 2006). TIMP-3 is unique in that it is 
the only member of the TIMP family to strongly sequester itself in the ECM by interactions 
of both its N and C-terminal domains with ECM components (Lee et aI., 2007). The 
localisation of TIMP-3 has been associated with basal lamina and stroma of breast (Mylona 
et aI., 2006, Uria et aI., 1994) and prostate cells (Cross et aI., 2005). This is as a result of an 
abundance of ECM in stroma and basal lamina of these tissues as well as stromal cells 
(Huang et aI., 1998, Raga et aI., 1999). TIMPs regulates proteinase-mediated ECM and 
basement membrane degradation in several tumours (Hornebeck, 2003). Low expression of 
TIMP-3 has been demonstrated in the normal and malignant epithelial components of 
breast (Mylona et aI., 2006), and other tissues relative to the stromal components of the 
same tissues. This may indicate a negative correlation between TIMP-3 expression and 
93 
malignancy in-vitro, or may reflect a greater TIMP-3 expression by stromal as compared to 
epithelial cells. A higher level of expression of ADAMTS proteinases has been reported in 
malignant epithelial cells relative to expression in nonnal cells from benign prostatic 
hyperplasia (Cross et aI., 2005, Demircan et aI., 2009). This was concomitant with lower 
expression of the only tissue inhibitor of the ADAMTSs, TIMP-3, in the malignant 
epithelial cells (Cross et aI., 2005). Again, this in-vitro study supports the negative 
correlation of TIMP-3 with malignancy. In one study (Kotzsch et aI., 2005), lower 
expression of TIMP-3 was correlated with higher nuclear and histological tumour grading 
of breast cancer, implying that this reduced expression of TIMP-3 correlates with poorer 
prognosis. 
TIMP-3 expression has also been associated with clinical outcome and invasive potential of 
oesophageal squamous cell carcinoma (Miyazaki, Kato et al. 2004). This study also 
correlated TIMP-3 expression in tumours with disease stage and patient survival rate, 
highlighting the importance of TIMP-3 expression in favourable prognosis for patients. 
On the other hand, higher levels of TIMP-3 protein were positively correlated with tumour 
SIze In laryngeal cancer. Although the majority of TIMP-3 detected by 
immunohistochemistry in this study was epithelial, some expression was also localised in 
the stromal cells (Pietruszewska et aI., 2008). 
Also, methylation of the TIMP-3 promoter, associated with a reduction of TIMP-3 
expression, has been observed in oesophageal and gastric cancers (Gu et aI., 2008) as well 
as in hepatocellular carcinoma (Lu et aI., 2003). All these studies have, in one way or 
another, described TIMP-3 expression in tumour samples. 
The use of immunohistochemistry is in widespread use for analyses of expression of target 
protein in tissue samples. It is used extensively to identify expression patterns of known 
mediators of disease progression in tissue samples obtained from patients (Coons and 
Kaplan, 1950). It not only shows whether the proteins are expressed in the tissues but also 
indicates the localisation of the protein within the tissue under investigation. Localisation 
analyses can also be very infonnative in elucidating the particular roles that the protein may 
play in the initiation or progression of the disease. In cancer research, there have been 
several studies that show the pattern of expression of proteins in tissue samples from 
patients e.g. expression of PSA and androgen receptor in prostate cancer tissue (Grob et ai., 
1994, Gregory et aI., 1998), of oestrogen receptor in breast cancer (Yang et aI., 1991, 
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Yoshida et aI., 1997), to mention but a few. The collated infonnation has proven useful for 
improvement of therapeutic interventions in clinical management of the progression of 
cancers as well as identification of target patients for therapy based on the profile of their 
biopsies and the pattern of expression of the progression marker proteins (Yoshida et aI., 
1997). The other importance of immunohistochemical analyses of tissues is that it allows 
pathologists to identify the stage(s) at which the disease is present in the patient as well as 
giving a snapshot of the degree of tissue damage present, for instance as an indicator of the 
presence and extent of tumour metastasis that has occurred in the patient. This allows the 
pathologists to assign a grade to the tumour that allows the oncologists to interpret the 
immunohistochemical data accurately and proceed to diagnosis and treatment regimes and 
patient management. In prostate cancer, the use of both Gleason scoring and the TNM 
method of tumour classification is fundamental to correct grading of tumours from prostate 
cancer patients (see Section 1.3.3). 
TIMP-3 is expressed in different human cell types as described in Chapter 1, Section 1.6. 
Unique patterns of expression of its transcript and protein have been reported in the 
literature e.g. TIMP-3 expression in breast (Mylona et aI., 2006), liver (Lu et aI., 2003), 
colon (Hilska et aI., 2007, Tanaka et aI., 2007), ovary (Goldman and Shalev, 2004, Lu et 
ai., 2003), breast (Uria et aI., 1994) and prostate (Cross et aI., 2005). 
One particular study by Su et af (Su et aI., 2001) looked at the expression of timp-3 mRNA 
in a large cohort of tissue samples by Affymetrix GeneChip analyses. Some of the tissue 
samples they analysed included: nonnal liver tissues, nonnal prostate tissues and primary 
prostate cancer tissues. The mRNA expression results from these 3 tissues were of 
importance to this project as these were the tissues available at the time for 
immunohistochemical analyses for the characterisation and localisation studies for TIMP-3. 
In the Su et al study, the fold increase in intensity of timp-3 mRNA over baseline in several 
tissues was reported (see Figure 3.1), along with expression data for several other genes. 
The results were analysed and reported in line with the GCRMA method for analyses of 
Affymetrix GeneChip array data (Gharaibeh et aI., 2008). The interesting and relevant part 
of the pool of results obtained, was the overall increase in the level of TIMP-3 expression 
observed in nonnal prostate tissue compared to primary prostate tissue as well as the higher 
levels of TIMP-3 expression seen in T2NOMO (larger) tumours compared to T3NOMO 
(smaller) tumours, according to the TNM classification of the tumour (see Figure 3.1 and 
Figure 3.2). 
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P rostat e 
Figure 3.1: Expression Profile oftimp-3 mRNA in Tissues. 
This is a bar chart obtained via the online BfOGPS gene expression analysis software (WU 
et al., 2009a). The data were obtained from results of Affimetrix GeneChip analyse of 
RNA extracts from various tumours and the results given as normalized fluorescence 
intensities, which correlate to the levels of timp-3 mRNA present in each sample. See 
Figure 3.2 for a close-up of the prostate data 
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Figure 3.2: Expression Profile oftimp-3 mRNA in Prostate Tissue Samples. 
These are also results obtained fi'om the Affymetrix GeneChip analyses as in Figure 3.1. 
The above represents only expression data fi'om prostate tissue samples, magnified from 
Figure 3.1. The individual bars above represent the different types of prostate tissue 
analyses. 'Pr ' means prostate, the following number is an identifier code specific for the 
tissue and set by the researcher and the letter following the number is an indicator of 
whether the tissue is a normal (N) or tumour tissue (T). M stands for the median fold 
increase in fluorescence intensity, 3XM is 3 times the M value, 5XM is 5 times the M value 
and 10XM is 10 times the median value. The results from the Su et al study showed greater 
timp-3 mRNA expression in normal prostate tissues in comparison to prostate tumour 
tissues (see red dots on bars above) overall. 
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Annotation l1ssue Histol CancerSta 
Pt1T postate ameer ~ 
Pr5T postate ameer 
Pr10T postate ameer ~ 
Pr11T pustate ameer 
Pr2!JT postate ameer ~ 
Pr4T postate ameer l3JNM) 
Pr8T postate ameer l2INMO 
Pr3T postate amcer l2INMO 
PI9T postate amcer l2INMO 
Pr31T postate ameer l2INMO 
Pr16T postate ameer l2INMO 
ameer 
Pr12T postate ameer 13N«M) 
Pr1l1'T postate ameer T.WaIO 
Pr138T pndaIe ameer T.WaIO 
PI22T postate ameer T.WaIO 
PI23T postate ameer l3ANMO 
PI26T postate ameer lWGMX 
Pr30T postate amcer l3IDIO 
Pr8T postate ameer l3INMO 
Pr19T postate ameer l3tOtO 
ameer 
Pr17T postate amcer 1lN1MO 
Pr2fT postate amcer llNMX 
Pr27T postate ameer llNMX 
Pr1N postate IIDIIII8II 
Pr5N postate IIDIIII8II 
A3N postate IIDIIII8II 
Pr4N pustaIe IIDIIII8II 
PI'2N pG!ItIle IIDIIIIII 
A8N postate IIDIIII8II 
A9N pustate IIDIIIIII 
Pr1CW IIDIIIIII 
L13N IIDIIII8II 
Table 3.1: Expression Data/or timp-3 mRNA in Prostate and Liver Tissue Samples.-The 
expression levels were obtained from the Su et al study. These are fold increase in 
expression levels over the baseline expression levels, measured using the 'GCRMA' method 
for background correction, normalising and summarisation 0/ results from Affymetrix 
GeneChip arrays. The annotations are as described in Figure 3.1. 
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It was therefore important to investigate whether this expression pattern of timp-3 mRNA 
seen in these tissues (as per the above study) translated to expression of the TIMP-3 protein 
in prostate cancer tissues and normal prostate tissues. To do this, Dr. Colby Eaton's group 
kindly donated a prostate tissue microarray sample that contained normal liver tissue as 
well tissue from primary prostate tumour, high grade PIN tumour and normal background 
prostate epithelium, all 3 tissue types obtained from the same patient. Information on the 
Gleason Score (GS) of the patients was also supplied. The map of the tissue array is as 
described in Chapter 2, Section 2.18. 
In this project, the first objective was to investigate the expression of TIMP-3 in prostate 
cells and tissues in order to be able to study its role in the progression of prostate cancer. 
Normal stromal cells (WPMY -1), prostate cancer-associated fibroblasts (PCAF), benign 
prostatic hyperplasia stromal cells (BPH45), androgen-dependent prostate cancer cells 
(LNCaP) and androgen-independent prostate cancer cells (PC3) were analysed for 
transcript and protein expression ofTIMP-3. The TIMP-3 mRNA expression was measured 
by qPCR and the data were analysed using the Applied Biosystems SDS 2.2.1 analysis 
software. Protein expression was analysed by western blotting and immuno-cytochemistry. 
The western blotting was optimised in order to determine the best conditions for analysing 
protein levels. 
The expression of TlMP-3 in normal prostate, primary prostate cancer and BPH tissues was 
also investigated. Tissues had been obtained from patients and formalin-fixed and paraffin-
embedded onto glass slides. Expression and localisation of TIMP-3 was determined by 
immuno-histochemistry using mouse monoclonal anti-TlMP-3 as the primary antibody 
(R&D Systems, MAB973) and Alexa-flour-488-conjugated goat anti-mouse secondary 
antibody (Invitrogen, All 00 1). The slides were examined using an inverted fluorescence 
microscope with the lOX objective and the excitation wavelength for observing the Alexa-
fluor-488 fluorescent dye was set at 488 nm and emission at 519 nm. 
Also, changes in TlMP-3 expression upon co-culturing prostate stromal and prostate cancer 
cells in vitro were investigated as described in Section 2.1.5. Changes in TlMP-3 mRNA 
expression were analysed by qPCR and protein expression by western blotting. It has been 
suggested that during migration of cancer epithelial cells from their primary site, they co-
migrate with stromal fibroblasts after proteolysis of the basement membrane and ECM in 
the stromal compartment and co-habit a secondary niche (Kaminski et aI., 2006). If TIMP-3 
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expression is important for metastasis, my hypothesis is that there will be modulation of its 
expression in coculture. 
3.2 RESULTS 
3.2.1 Optimisation of Western Blotting 
During the course of this project, some protein bands obtained by SOS-PAGE and western 
blotting were of a higher molecular weight than expected, suggesting post-translational 
modifications such as glycosylation of proteins or cross-reactivity of antibodies with other 
non-specific proteins. Several experiments were carried out in order to determine the source 
of the problem(s). These included: deglycosylation of protein Iysates and immune-
precipitation of test protein with specific antibody to eliminate cross-reactivity. Therefore, 
experiments were designed to address these issues, and they are detailed below: 
3.2.1.1 De-glycosylation of protein samples 
The first possible trouble-shooting experiment was to remove any N-linked glycosyl 
residues from the proteins. To do this total cell Iysates were subject to de-glycosylation 
using the manufacturer's protocol. N-glycanase (Peptide-N-Glycosidase F) was obtained 
from Prozyme, UK. N-glycanase releases N-glycans from glycoproteins and so can be used 
to detach covalently bound sugars (glycosyl groups) from a target protein. First, 20 III (100 
Ilg) of protein extract was added to 25 ilL of reaction butTer (consisting of 100 mM sodium 
phosphate and 0.1 % sodium azide, pH 7.5) (Prozyme) totalling 45 ilL of reaction mixture. 
Then 2.5 ilL of denaturation solution (consisting of 2% SDS, I M p-mercaptoethanol) 
(Prozyme) was added. The mixture was maintained at 100°C for 5 minutes and then 
allowed to cool to ambient temperature. Then 2.5 ilL of detergent solution (consisting of 
15% NP-40) (Prozyme) was added to the mixture, left for 5 minutes and then 2 ilL of N-
glycanase stock was added and incubated overnight at 37°C. The next day, sample buffer 
(as described in Section 2.10) was added to the mixture and the sample was subject to SOS-
PAGE and western blotting for protein separation and detection (as described in Section 
2.11) This was done for all samples and when not used immediately, was stored at -20°C 
prior to use. This process of deglycosylation has been previously described (Chu, ) 986, 
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Tarentino et aI., 1985, Plummer et aI., 1984). Unfortunately, the N-glycanase alone was 
cross- reacting with antibody and showing as a -30 kD band (see Figure 3.3). 
NG NG+L L NG+B B NG+P P MWS 
Figure 3.3: Treatment of Proteins with N-Glycanase. 
75kD 
50kD 
37kD 
25kD 
20kD 
G = -Glycanase only, L = Total LNCaP extract, B = Total BPH45 extract, P = Total 
PCAF extract, MWS = molecular weight standards. For immunoblotting, anti-C-Terminal-
T1MP-3 antibody (Sigma) was used as described in Section 2.11. 100 f.-tg protein was 
loaded per ~1-'ell. 
3.2.1.2 Protein AlG Immunoprecipitation 
1 next attempted immunoprecipitation of the protein using target antibodies. Protein A/G 
ultralink wa obtained from Pierce, UK. Protein A/G binds to all the IgG subclasses with a 
high affmity and so it has a wider range of binding than either protein A or protein G alone. 
A protein-antibody complex can therefore be pulled out of solution using Protein A/G 
bound to Sepharo e bead. In this way, I hoped to be able to pull out TIMP-3 specifically 
from the protein e tracts before analysis by western blotting. 
For the e experiment, protein A/G resin was first diluted 1:2 with immunoprecipitation 
(IP) buffer (con i ting of 25 mM Tris, 150 rnM NaCI, pH 7.2) (Pierce, 28379). Then, 50 lAg 
of protein extract wa incubated with 250 lAg of anti-TIMP-3 mouse monoclonal antibody 
(R&D y tern , MAB973) made up in IP buffer. The mixture was incubated on a rotor 
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overnight at 4°C. The next day, 100 ~L of the gel suspension was added to the protein-
antibody complex and incubated for 2 hours at ambient temperature with gentle mixing. 
Then 0.5 mL of IP buffer was added to the mixture and centrifuged for 3 minutes at 2500 x 
g. This step was repeated 3 times after which the gel was washed with 0.5 mL of H20 by 
centrifugation at 2500 x g for 5 minutes. The supernatant was discarded and the immune 
complex was eluted by adding 50 ~I to the gel for 5 minutes and further centrifugation at 
2500 x g for 3 minutes. 50 f-lL of loading buffer (as described in Section 2.10) wa added to 
the gel and heated for 15 minutes at 70°C. The resulting supernatant was collected by 
centrifugation at 2500 x g for 5 minutes and cooled to ambient temperature before 
subjecting to SDS-PAGE and western blotting (as described in Section 2.11) using rabbit 
anti -TlMP-3 antibody. Unfortunately, this procedure did not resolve the problem and still 
gave bands of >23 kD molecular weight. It also resulted in non-specific bands across the 
gel (see Figure 3.4). 
37kD 
25kD 
20kD 
R R+AG B x B+AG L L+AG 
Figure 3.4: lmmuno-precipitation of Proteins using Protein AlG Ultralink Beads. 
R = recombinant human T1MP-3 only, B = Total BPH45 extract, L = Total LNCaP 
extract, X = blank well (gel imperfect in this region so well unused). For immunoblotting, 
anti-C-Terminal-T1MP-3 antibody (Sigma) was used as described in Section 2.13. 10 ng of 
recombinant human TlMP-3 was loaded - this was seen as - 24 kD as expected. 50 f.-lg of 
protein extracts was used for immuno-precipitation. Protein AIG beads were cross-reacting 
with antibody. 
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3.2.1.3 Monoclonal vs. Polyclonal TIMP-3 Antibody 
The problem of potential non-specific bands showing on the western blotting films was still 
to be tackled and another trouble-shooting experiment was to compare the antibody that I 
had been using previously (Anti-C-terminal-TIMP-3 from Sigma) for immunoblotting with 
a mouse monoclonal antibody (R & D systems, MAB973). Total and ECM only proteins 
were extracted as described in Section 2.10 and subject to SDS-PAGE and western blotting 
as described in Section 2.11. The results obtained showed the mouse monoclonal anti-
TIMP-3 antibody detecting TIMP-3 at -23 kD (see Figure 3.6) compared to the higher 
bands seen with the rabbit anti-TIMP-3 antibody (see Figure 3.5) and so led me to the 
decision to continue other experiments with the antibody since it gave no apparent non-
specific bands and TIMP-3 was detected at the correct size. It also buttressed the suggestion 
in literature (Langton et aI., 1998) that TIMP-3 is sequestered predominantly in the ECM, 
and that the non-specific bands were due to intracellular proteins. It therefore made sense 
that the better results were seen with loading of ECM proteins and not total proteins. Based 
on results of this experiment, it was decided to analyse ECM proteins for TIMP-3 
expression in all other experiments and to use 50 nM of the anti-TIMP-3 antibody from 
R&D Systems (MAB973). 
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37kD 
25kD 
MWS x R TL EL TB EB 
Figure 3.5: Immuno-blotting of Protein Extracts using Rabbit Anti-C-terminal-TIMP-3 
antibody . 
MWS = molecular weight standards, X = blank well, R = recombinant human TlMP-3, TL 
= total lysate from LNCaP cells, EL = ECM extract from LNCaP cells, TB = total lysate 
from BPH45 cells, EB = ECM extract f rom BPH45 cells. lOng of recombinant human 
TlMP-3 was loaded - this was seen as - 23 kD as expected. For total extracts, 50 J-lg 
protein was loaded per well and for ECM extracts, 100,000 cells ' worth of ECM was 
loaded per well. For immunoblotting, anti-C-Terminal-Tl MP-3 antibody (Sigma, T7812) 
was used as described in Section 2.13. This antibody did not detect TlMP-3 at the right size 
of - 23 kD but showed non-specific bands at - 45 kD and other bands at - 35 kD. 
25kD 
20kD 
MWS X R X TL EL X TB EB 
Figure 3.6: Immuno-blotting of Protein Extracts using Mouse Anti-TIMP-3 antibody . 
For immunoblotting, anti-TlMP-3 antibody (R&D Systems, MAB973) was used as 
described in Section 2.13. 100 ng of recombinant human TIMP-3 was loaded - this was 
seen as - 24 kD as expected. For total extracts, 50 J-lg protein was loaded per well and for 
ECM extracts, 100,000 cells' worth of ECM was loaded per well. This antibody detected 
single TIMP-3 band at - 21 kD in BPH45 ECM extract, closer to its known molecular 
weight of 22 kD. 
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3.2.2 TIMP-3 mRNA Expression in Prostate Cells 
The relative expression of TlMP-3 mRNA in WPMY-l, PCAF, BPH45, LNCaP and PC3 
cell lines was analysed. Total RNA was extracted from cells and quantified as described in 
Section 2.4. These were reverse-transcribed to make complementary DNA by reverse 
transciption as described in Section 2.5. mRNA was synthesized from cDNA by qPCR as 
described in Section 2.6. Results were analysed as described in Section 2.7 using the 
comparative L\Ct method (Livak and Schmittgen, 200 I). 
Amplification plots of the different Ct values obtained from qPCR analyses of the 
expression data are shown in Figure 3.7. BPH45 had the lowest Ct value and highest TlMP-
3 mRNA expression, followed by PCAF then WPMY-I then LNCaP. PC3 had the highest 
CT value and lowest TlMP-3 mRNA expression. The Ct values were all normalised to the 
Ct of RNA Polymerase II as a control 'house-keeping' gene. 
As summarised in Figure 3.8, all the prostate stromal cells that were analysed expressed 
significantly higher amounts of TlMP-3 mRNA relative to PC3 cells; about 100,000 -
200,000 fold higher expression (p=0.0079 for PCAF, WPMY-I and BPH45, Mann-
Whitney). The androgen-sensitive LNCaP cells produced about 100-fold higher expression 
of TlMP-3 mRNA than the androgen-resistant PC3 cells but this was also statistically 
significant (p=0.012, Mann-Whitney). The expression levels of TlMP-3 mRNA did not 
vary significantly between the cancer-associated PCAF and normal WPMY -I stromal cells 
but expression level were about 1.5-fold higher in the benign prostatic hyperplasia cells 
(BPH45) compared to PCAF cells (p=0.0079, Mann-Whitney) and about 2-fold higher in 
BPH45 compared to WPMY-l cells (p=0.0079, Mann-Whitney). The experiment was 
repeated 4 times. 
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Figure 3. 7: Amplification Plot of TIMP-3 mRNA expression in prostate cells. 
This is a logarithmic representation of the amplification plot of the mRNA expression in 
prostatic cells. LJRn is plotted on the y-axis and it represents the magnitude of the TI MP-3 
signal. During the initial cycles of qPCR, there are little or no changes in the fluorescence 
signal, imply ing no expression of TIMP-3 mRNA (i.e. between cycles 0 and 15) - thi is 
known as background. Afterwards, the linear and exponential phase of the amplification 
occurs, where fluorescence is detected, signifying TIMP-3 mRNA detection and 
amplification. The SDS 2.2.1 analysis software (see Section 2.6) was set to automatically 
determine a level of LJRn that is above the baseline and low enough to be within the 
exponential phase of the curve - this is known as threshold and is the line that inter ects 
with the amplification plot to determine the CT. The CT is defined as the cycle number at 
which the fluorescence signal passes the threshold, and these are indicated by the arrows 
in the plot. B = CT of TIMP-3 mRNA in BPH45, C = CT of TIMP-3 mRNA in PCAF, W = 
CT of TIMP-3 mRNA in WPMY-I, L = CT of TIMP-3 mRNA in LNCaP and P = CT of 
TIMP-3 mRNA in PC3 cells. Duplicate curves represent duplicate wells in the as ay . 
Results showed the lowest Cr value in BPH45 cells, indicating that this cell line has the 
highest TIMP-3 mRNA, followed by PCAF cells, then WPMY-1 , then LNCaP and finally 
PC3 cells with the highest Cr value and the lowest TIMP-3 mRNA expression of all the 
prostatic cells. n=4 
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Figure 3.8: TIMP-3 mRNA expression in prostate cells. 
100.000 cells were seeded into 6-well plates using complete DMEM media until they 
reached - 90% confluence. Total RNA was extracted from cells and cDNA synthesized by 
reverse transcription. TIMP-3 mRNA expression was measured by qPCR and normalised to 
a housekeeping gene. GAPDH. These procedures are as described in Section 2.6 - 2.9. 
Columns and bars represent the median and range of values (n=4) y-axis has been 
segmented to show fold differences between all cell lines relative to expression in PC3 
cells. * p<0.05 and ** p<O.Ol. Mann-Whitney non-parametric test used to generate p 
values. 
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3.2.3 TIMP-3 Protein Expression in Prostatic Cells 
TIMP-3 protein expression was analysed by western blotting of total cell and ECM Iysates, 
separately obtained from all cancer and stromal cells (described in Section 2.11) 
As discussed in Section 3.2.1, different antibodies gave different results and so had to be 
optimised for best TIMP-3 detection. Based on these experiments, anti-TIMP-3 antibody 
(R&D Systems, MAB973) was chosen for immuno-blotting and ECM Iysates were 
extracted instead of total cell Iysates. 
For western blotting experiments, 50 nM (l :500 dilution) of anti-TIMP-3 antibody was 
used for primary incubation. The protocol is as described in Section 3.2. I. As loading 
control, I x 105 cells' worth of ECM was loaded per well since the protein concentration 
could not be measured by BCA assay due to the presence of interfering (high) levels of 
DTT concentration on the ECM extraction buffer. This meant that the cells had to be 
counted once they had been uplifted from the ECM with enzyme-free buffer (Section 2.10). 
Higher levels of TIMP-3 were found in the ECM of the prostate stromal cells BPH45, 
PCAF and WPMY, compared to very low levels observed in the cancer cells LNCaP 
(Figure 3.9). This corroborated the mRNA results (Figure 3.8). Densitometric analysis of 
the blots suggested that BPH45 ECM contained the highest levels of TIMP-3 followed by 
PCAF ECM and then WPMY-I ECM. LNCaP ECM had the least amount ofTIMP-3. It is 
important to mention that LNCaP cells did not appear to produce as much ECM as the 
prostate stromal cells. It was decided not to extract ECM from prostate cancer cells PC3 as 
they produced negligible levels of TIMP-3 transcripts (Figure 3.8) and also only appeared 
to produce small amounts of ECM. 
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Figure 3.9: TIMP-3 protein expression in ECM lysatesfrom Prostate Cells. 1 x 1rf cells' 
worth of ECM protein was subjected to electrophoresis and transferred onto a PVDF 
membrane as described in Sections 2.10 - 2.11. The membrane was probed with 1:5000 of 
monoclonal anti-TlMP-3 overnight at 4°C and afterwards in 1:1000 goat anti-mouse HRP-
conjugated secondary antibodies for 1 hour at ambient temperature. ECL delection reagent 
was applied to the membrane and exposed to x-ray films. TIMP-3 bands were observed as 
~ 23 kD bands (red arrow). There also appeared some non-specific bands at about 50kD 
(green arrow). 1n row 1, MWS = molecular weight standards, X - blank lane, W = ECM 
from WPMY-1 cells. B = ECM from BPH45 cells, P = ECM ji-om PCAF cells and L = 
ECM from LNCaP cells. Semi-quantitative analyses of the bands were carried out by 
densitometry using the Quantity One software (see Section 2.12). The result of adjusted 
densitometric volume for each band is reported in row 2. 
Prostate cells were also fixed onto slides and immuno-stained for TlMP-3 as described in 
Section 2.16. For this, 1 :500 (SOn M) of mouse monoclonal anti-TlMP-3 was used for 
primary detection and counter-stained with 1: 1 000 of Alexa-fluor-488 goat anti-mouse 
antibody. A lOX or 20X objective on a fluorescence microscope was used for image 
capture. There was high TIMP-3 staining in stromal cells and low staining in LNCaP cells 
(Figure 3.10). 
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Figure 3.10: TIMP-3 Immunolocalisation in Prostate Cells. 
Cells were fixed onto slides as described in Section 2.17. 50 nM (1 :500) of mouse 
monoclonal anti-TlMP-3 antibody and 1:1000 0/ Alexa-jluor-488 goat anti mouse 
secondary antibody were used for detection of TlMP-3 in the slide-jixed cells. The slides 
were incubated overnight at 4 °C in primary antibody, washed with TBS buffer containing 
0.05% Tween-20, and then incubated in secondary antibody in the dark at ambient 
temperature for 1 hour, then washed and counter-stained with DAPI for 5 minutes before 
mounting the coverslip and visualisation under the microscope. Images from (A) Phase 
contrast (B) DAPI only (C) Alexa-jluor-488-T1MP-3 staining (D) Super-imposed pha e 
contrast+DAPl +Alexa-fluor-488-TlMP-3 images were taken using a Leica inverted 
fluorescence microscope and setting to l OX objective (for PCAF and WPMY-1 cell) or 
20X objective (for LNCaP cells). Scale bar for PCAF and WPMY-1 = 100 um and for 
LNCaP = 250 urn. 
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3.2.4 TIMP-3 Protein Expression in Prostatic Tissues 
Prostate tissues were obtained as fonnalin-fixed sections on glass slides. 
Immunohistochemical analyses of the samples were carried out as described in Section 
2.16. Tissues sections were stained with both haematoxylin and eosin (H&E) stains or with 
mouse anti-TlMP-3 and Alexa-fluor-488 goat anti mouse secondary antibody. 
Haematoxylin and eosin (H&E) staining is used routinely to distinguish between the 
different tissue types and distinguish the nuclear staining from the intracellular and 
extracellular staining of cytoplasmic and ECM proteins respectively. Haematoxylin dye 
stains the nuclei of cells blue/violet while eosin stains cytoplasmic and extracellular regions 
of the cells red/pink. 
Images were taken using the Leica inverted fluorescence microscope. Fluorescence was 
detected at excitation and emission wavelengths of 488 nm and 518 nm respectively. In 
instances where extra tissue samples were available, control staining was also carried out 
with the use of only the secondary antibody. 
There was pronounced eosin staining in BPH tissue, compared to nonnal and primary 
prostate cancer tissue - this indicates a bigger stromal compartment in BPH tissue, and this 
feature is characteristic of this benign disease (Figure 3.11). There also appears to be 
glandular infiltration of the extracellular region of the primary prostate tissue characterised 
by H&E staining in undefined regions - both haematoxylin (nuclear) staining and eosin 
(intracellular and extracellular protein) staining are evenly distributed in all parts of the 
tissue section and the tissue has lost much of its glandular structure. In contrast, the 
haematoxylin staining appears to be defined in the nonnal prostate and BPH tissue. In 
these two, the glandular structures have been retained. 
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IA) BPH TISSUE 
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IC) PRIMARY PROSTATE CANCER TISSUE 
Figure 3.11: H&E Staining in Prostate Tissues. 
Staining was performed as described in section 2. i 7. Images were taken using an inverted 
microscope. Eosin staining of intracellular and extracellular proteins (red arrow) and 
haematoxy lin staining of cell nuclei (blue arrow) were observed in all tissues with varying 
levels of each stain. (A) BPH tissue shows high eosin staining as a result of enlarged 
extracellular stroma and haematoxylin staining allows visualization of the intact glands in 
the tissue. (B) In normal prostate tissues, there is moderate level of staining of both 
haematoxylin and eosin staining and the glands appear intact. (C) in primary prostate 
cancer tissue, there is heterogenous distribution of both stains, and no apparent glandular 
structure. Scale bar = 100 um. 
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Slides of tissue sections were also stained with 500 nM (1 :50) of mouse monoclonal anti-
TlMP-3 antibody and incubated overnight at 4°C. The slides were washed with TBS buffer 
containing 0.5% Tween-20 and incubated with secondary goat anti-mouse Alexa-Fluor-488 
antibody for 1 hour at ambient temperature. Tissues were counter-stained with DAPI 
nuclear stain and covered with cover slips. Images were taken using an inverted 
fluorescence microscope at lOX objective. 
High expression levels of TIMP-3 were apparent in BPH tissue (Figure 3.12) compared to 
normal tissue (Figure 3.13) and primary prostate cancer tissue (Figure 3.14). This is in line 
with the mRNA data from this project, showing higher levels of TIMP-3 mRNA in prostate 
stromal cells compared to prostate cancer cells (Section 3.2.2). In the primary prostate 
cancer tissue, the expression of TlMP-3 was generally low. 
As control, BPH tissue sections were stained with only secondary antibody so as to ensure 
that any fluorescence observed was as a result of the antigen-antibody complex formation 
with the mouse anti-TlMP-3 antibody. Results showed no fluorescence in tissue, 
confirming that there is no inappropriate staining without the primary antibody (Figure 
3.15). 
113 
(0 
Figure 3.12: TIMP-3 Staining in BPH Tissue. 
Samples were stained as described in section 2.17. (A) = phase contrast image (B) = DAPI 
staining (C) TlMP-3 staining (D) = super-imposed DAPI and TfMP-3 staining. 
Localization of TIMP-3 observed both in the extracellular (red arrow) and glandular 
region (white arrow) as seen in (D). 
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Figure 3.13: TIMP-3 Staining in Normal Prostate Tissue. 
Samples were stained as described in section 2.17. (A) = phase contrast image (B) = DAPJ 
staining (C) TlMP-3 staining (D) = super-imposed DAPI and TlMP-3 staining. 
Localization of TlMP-3 observed both in small proportion of the extracellular (red arrow) 
and glandular region (white arrow) as seen in (D). 
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Figure 3.14: T1MP-3 Staining in Primary Prostate Cancer Tissue. 
Samples were stained as described in section 2.17. (A) = phase contrast image (B) = DAPl 
staining (C) TlMP-3 staining (D) = super-imposed DAPl and T1MP-3 staining. 
Localization of TlMP-3 observed both in small proportion of the extracellular (red arrow) 
region as seen in (D). 
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Figure 3.15: Control Staining in BPH Tissue. 
Samples were stained as described in section 2.17. (A) = phase contrast image (B) = DAPI 
staining (C) No TIMP-3 staining (D) = super-imposed DAPI and TIMP-3 staining. No 
fluorescence observed i.e. no TlMP-3 staining. Scale bar = 100 um 
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For the tissue microarray analyses, the samples were first checked for their morphological 
accuracy and were counter-analysed by an in-house pathologist at the University, Dr. 
Simon Cross. This was to ensure that subsequent analyses were to be carried out using real 
prostate tissues and no errors were made during their characterisation for the purpose of this 
study. The pre-fixed tissues obtained were first subjected to haematoxylin and eosin 
staining, carried out as described in Section 2.17. The results from this research showed a 
clear difference between normal and prostate cancer tissue as well as difference between 
the morphology of high GS and low GS primary prostate cancer tissue (see Figure 3.16). 
All tissue sections were probed with anti-TIMP-3 antibody as described in Section 2.17. 
There was also a pair of normal liver sections included on the microarray slide and these 
were used as control sections. The liver sections showed the occurrence of minute amounts 
ofTIMP-3 expression (Figure 3.17) 
There was also a negative correlation between the GS of the prostate cancer tissue and the 
degree of TIMP-3 staining i.e. more intense staining was observed in tissue with GS of 4 
(Figure 3.18) than in tissue with GS of 7 (Figure 3.19). 
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Prostate Cancer Tissue GS 9 
Figure 3.16: Haematoxylin & Eosin (H&E) Staining for Morphological Assessment of 
Prostate Tissue Samples. 
The above sample tissues had been previously formalin-fixed onto glass slides and were 
stained with H&E as described in Section 2.17. The nuclei of the cells are stained 
blue/purple and cytoplasmic proteins and extracellular matrices are stained red/pink. Scale 
bar = 100 urn. 
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(A) Phase Contrast B) OAPI 
C) Anti-TIMP-3 Stain (0) Superimposition of (B) and (C) 
Figure 3.1 7: Expression ofTIMP-3 in Normal Liver 
The above sample tissues had been previously formalin-fixed onto gla s slides and were 
stained first with mouse anti-TfMP-3 antibody and then with secondary jluorescent alexa-
jluor-488-tagged anti-mouse antibody as described in Section 2.17. (A) hows the phase 
contrast image of the fixed normal liver (B) is the nuclei staining with DAP1, (C) is the 
greenjluorescence image for TIMP-3 staining and (D) is the superimposition of images (B) 
and (C). There was virtually no staining for TfMP-3 in both the cy toplasm and 
extracellular components of the tissue. Images were obtained using a jluorescence 
microscope and its 20X objective. 
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(A) Phase Contrast (8) DAPI 
(C) Anti-TIMP-3 Stain (D) Superimposition of (8) and (C) 
Figure 3.18: TIMP-3 Antibody Probing of Prostate Tissue Sample with GS of 4. 
The above sample tissues had been previously formalin-fixed onto glass slides and were 
stained first with mouse anti-TlMP-3 antibody and then with secondary jluorescent alexa-
jluor-488-tagged anti-mouse antibody as described in Section 2.17. (AJ shows the phase 
contrast image of the fixed primary prostate tissue with a GS of 4, (B) is the nuclei staining 
with DAPl, (C) is the green fluorescence image for TlMP-3 staining and (D) is the 
superimposition of images (B) and (C). There was detection of staining for TlMP-3 in both 
the cytoplasm and extracellular components of the tissue as indicated by the green staining 
in (D). Images were obtained using ajluorescence microscope and its 20X objective. 
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Figure 3.19: TIMP-3 Antibody Probing of Prostate Tissue Sample with GS of 7. 
The above sample tissues had been previously formalin-fixed onto glass slides and were 
stained first with mouse anti-Tl MP-3 antibody and then with secondary fluorescent alexa-
fluor-488-tagged anti-mouse antibody as described in Section 2.17. (A) hows the phase 
contrast image of the fixed primary prostate tissue with a GS of 7, (B) i the nuclei staining 
with DAPI, (C) is the green jluorescence image for TIMP-3 staining and (D) is the 
superimposition of images (B) and (C) . Some staining for TlMP-3 in both the cytoplasm 
and extracellular components of the tissue as indicated by the green staining in (D). Images 
were obtained using ajluorescence microscope and its 20X objective. 
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3.2.5 Changes in TIMP-3 Expression in Co-cultured Cells 
Stromal cells PCAF and WPMY -1 were co-cultured with androgen-dependent GFP-
transfected LNCaP cells after labelling the stromal cells with a fluorescent dye; PKH26 (as 
described in Section 2.1.5). The co-cultures were maintained for 48 hours after which 
F ACS was carried out to separate the cells into red stromal cells (PCAF and WPMY -1) and 
green LNCaP cells (see Section 2.14). The separated cells were then analysed by qPCR for 
changes in TlMP-3 mRNA expression (see Section 2.6) or by SDS-PAGE and western 
blotting (see Sections 2.10 and 2.11) for changes in protein expression. The rationale 
behind the co-culture experiments was that cell-cell contact or cell-derived soluble factors 
may modulate the expression of TlMP-3 in individual cell cultures and may influence the 
migratory and invasive pattern of the cancer cells in vivo. 
Figure 3.20 shows images of cells co-habiting in the same wells and expressing their 
fluorescent tags; 48 hours was enough time for the cells to settle in the wells and establish 
cell-cell contact. 
Figure 3.21 shows the scatter of co-cultured cells and the separation into different 
populations by FACS sorting. Only green fluorescent LNCaP cells and only red fluorescent 
stromal cells were collected from the technicians for further analyses. Cells that did not, or 
had lost their fluorescence, were excluded from analyses as there was no way to verify their 
cell type. As a control, mono-cultured cells were also subject to F ACS sorting to ensure 
that there were no other variables between mono-cultured and co-cultured cells other than 
the fact that the latter had been in contact with another cell type. 
Figure 3.22 shows the expression of TlMP-3 mRNA in cells pre- and post-co-culture. Total 
RNA was extracted from the cells immediately after cell sorting and timp-3 mRNA 
expression analysed by qPCR. Relative expression of timp-3 mRNA in cells post-sorting 
was normalised to expression levels in mono-cultured cells. There was an increase in 
TIMP-3 mRNA expression in both PCAF (p=0.027, Mann-Whitney) and WPMY-I 
(p=0.026, Mann-Whitney) cells 48 hours after culturing with LNCaP cells. In contrast, the 
relatively low expression of TlMP-3 mRNA in LNCaP cells (see Section 3.1) was lost after 
co-culture with PCAF cells (p=0.029, Mann-Whitney) and after co-culture with WPMY-l 
cells (p=0.05, Mann-Whitney). 
Figure 3.23 shows a representative CT plot for the data shown in Figure 3.22. Blue curves 
represent TlMP-3 mRNA expression in mono-cultured cells and green curves represent 
123 
TIMP-3 mRNA expression in co-cultured cells. A shift to the right of the plot indicates 
higher CT, which is indicative of lower gene expression while a shift to the left of the plot 
indicates lower CT and higher gene expression. 
Figure 3.24 shows the changes in expression of TIMP-3 in the ECM made by co-cultured 
cells in comparison to ECM made by mono-cultured cells. Densitometric analyses of the 
protein blots showed an increase in TIMP-3 expression in ECM from both co-cultured 
WPMY -I and PCAF cells when compared to ECM from mono-cultured cells. TIMP-3 was 
not detected in the lysate from LNCaP cells. 
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Figure 3.20: Co-cultured prostate stromal and cancer cells. 
1 x 1ri GFP-expressing LNCaP cells were co-cultured with 1 x 1ri PKH26-labelled PCAF 
or 1 x 105 PKH26-labelled WPMY-J cells for 48 hours at 37°CI5% CO2 (see Section 2.1.5). 
The images were taken with an inverted fluorescence microscope at J OX objective. Scale 
bar = 100 urn. 
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Figure 3.21: FA CS sorting results of co-cultured cells. 
After the images of cells had been taken, the cells were harvested and suspended in DMEM 
media with 1% FCS. Cell suspensions were submitted to the FACS technicians for sorting 
into GFP-positive and PKH26-positive cells. 
(A). (B) and (C) are results of sorting of the mono-cultured LNCaP-GFP. PCAF and 
WPMY-l. (D) and (E) are results of sorting of LNCaP-GFP cells from PCAF and WPMY-1 
respectively. As seen on the left hand side of the above representative diagrams, green 
scatter represents GFP-positive LNCaP-GFP cells and red scatter represents PKH26-
positive stromal cells. In the right-hand-side diagrams of (A) - (C). a single population of 
cells was observed in each case when passing the mono-cultured cells through the FACS 
sorter, indicating all cells present were fluorescing at the same excitation and emission 
wavelengths. In (D) and (E), 2 populations of cells were observed, indicating 2 different 
cell types fluorescing at different excitation and emission wavelengths. 
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Figure 3.22: Changes in TIMP-3 mRNA expression in co-cultured prostate stromal and 
cancer cells. 
The cells were sorted by FA Cs then collected and total RNA was extracted from them. 
eDNA was synthesized and mRNA transcribed as described in Sections 2.6 - 2.8. The data 
obtained was analysed as described in Section 2.9. All sets of data were analysed relative 
to datafrom mono-cultured cells. (n=3).There was a significant decrease in TlMP-3 mRNA 
in LNCaP cells after co-culture with both PCAF (p=O.029. Mann-Whitney) (A) and 
WPMY-J (p=O.05. Mann-Whitney) (B). There was about 3.5-fold higher expression of 
TIMP-3 mRNA in PCAF cells after co-culture with LNCaP cells (p=O.027. Mann-Whitney) 
(C) and about 4-fold higher expression in WPMY-J cells after co-culture with LNCaP (* 
p=O.026. Mann-Whitney) (D). 
128 
(A) 
, .. 
(8) i 
4 
f>1 
, r 
~ 
• 
,. 
C}/de 
129 
'.50' 
tellO 
t_lOt 
(C) i .. 
t_Sf 
,-., 
t_&4 
• S • 
,. ,. 
C\II'dt 
(0) 
Figure 3.23: Amplification Plot of TIMP-3 mRNA expression in mono-cultured vs. co-
cultured prostate stromal and cancer cells. 
The graphs labelled A-D are representative diagrams of the amplification ofTlMP-3. Both 
duplicate blue curves represent TlMP-3 mRNA expression in mono-cultured cells and the 
green curves represent TlMP-3 mRNA expression in co-cultured cells. The cycle at which 
the curves intersect the threshold (red line) is the Cr for each reaction; the higher the Cr, 
the more the curve shifts to the right and the lower the expression and vice versa. (A) = 
changes in TlMP-3 mRNA expression mono-cultured vs. PCAF-co-cultured LNCaP (B) = 
changes in TlMP-3 mRNA expression mono-cultured vs. WPMY-J-co-cultured LNCaP (C) 
= changes in T1MP-3 mRNA expression mono-cultured vs. co-cultured PCAF and (D) = 
changes in TIMP-3 mRNA expression mono-cultured vs. co-cultured WPMY-l . In both A 
and B, there is a Crshift to the right of the plot, indicating lower T1MP-3 mRNA expre ion 
and in C and D, the Cr shift is to the left, indicating higher T1MP-3 mRNA expres ion. 
These results are represented as columns with bar: in Figure 3.22. 
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Figure 3.24: Changes TIMP-3 expression in prostate stromal cells after-eo-culture with 
LNCaP cells. 
After 48 hours of either mono-culturing or co-culturing LNCaP cells with PCAF or WPMY-
1 cells, they were uplifted using enzyme-Jree buffer and counted. The ECM laid down by the 
cells was extracted as described in Section 2.9, using 100 fJL of loading buffer. 1 x 105 
cells' worth of ECM was loaded on the SDS-P A GE, gels run and proteins transferred onto 
PVDF membrane as described in Section 2.10 - 2.11. Mouse monoclonal anti-TIMP-3 was 
used for probing the membrane for TIMP-3. MWS = molecular weight standards, EPM = 
ECMfrom mono-cultured PCAF, EPC = ECMfrom co-cultured PCAF, EWM = ECMfrom 
mono-cultured WPMY-1 cells. EWC = ECM from co-cultured WPMY-1 cells. TL = Total 
cell lysate from mono-cultured LNCaP-GFP cells. Optical density (DIA) is in OD mml. 
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3.3 DISCUSSION 
To my knowledge, this is the first study demonstrating the expression ofTIMP-3 protein in 
the ECM of prostate cancer cells by western blotting. Other studies have demonstrated 
expression in breast cancer tissue (Mylona et aI., 2006), in stromal cells of squamous cell 
carcinomas (Airola et aI., 1998), in laryngeal cancer (Pietruszewska et aI., 2008), in normal 
CNS white matter (Haddock et aI., 2006), in oesophageal cancer (Miyazaki et aI., 2004), in 
endometrial cancer as well as benign endometrial tissue (Tunuguntla et aI., 2003) and in 
hepatocellular carcinoma (Lu et aI., 2003). 
Other studies have also analysed the expression of TIMP-3 mRNA in different cells and 
tissue types such as various human prostate cell lines (Karan et aI., 2003), in the Bruch's 
membrane of the eye (Bailey et aI., 2001), in normal, neoplastic and hyperplasic 
endometrium (Maatta et aI., 2000), in normal thyrocytes and thyroid carcinoma cell lines 
(Hofmann et aI., 1998), in developing bones, developing kidneys and hair follicles 
highlighting its importance in foetal development and hair growth cycle (Airola et aI., 
1998) and in normal colorectal mucosa and colorectal adenocarcinoma (Powe et aI., 1997). 
This highlights the ubiquitous expression of TIMP-3 in nature generally. It is also the first 
study to show localisation patterns of TIMP-3 in prostate tissue. This is of great importance 
as it enables the in-depth investigation of the role of this inhibitor in the progression of 
prostate cancer and raises the possibilities of TIMP-3-targeted therapy for management of 
the disease. 
The results obtained in this study demonstrated a significantly greater TIMP-3 expression 
mRNA and protein in prostatic stromal cells PCAF, WPMY-l and BPH45, relative to 
prostate cancer cells LNCaP and PC3. This correlates with similar findings by Mylona et 01 
(Mylona et aI., 2006) who showed that TIMP-3 is expressed abundantly in the stromal cells 
adjacent to the breast tumour, and with studies carried out by Cross et 01 (Cross et aI., 
2005) showing increased expression of TIMP-3 mRNA in stromal cells BPH31, -33, -44 
and -45, relative to the cancer cells PC3 and LNCaP. TIMP-3 is also expressed in cells 
during foetal development and cancer progression (Airola et aI., 1998). Karan et 01 (Karan 
et aI., 2003) also carried out analyses of TIMP-3 expression in prostatic stromal cells, 
prostatic cancer cells LNCaP-C33 (androgen-dependent) and LNCaP-C81 (androgen 
independent) - they demonstrated high expression of TIMP-3 in the stromal cells and 
undetectable expression in the cancer cells LNCaP-C33, LNCaP-C81, MDA PCa 2b, 
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LNCaP-C51, LNCaP-Pro5, LNCaP-Ln3, LNCaP-C4-2, PC3, and DU145 cells. Riddick et 
af (Riddick et aI., 2005) also obtained similar results when analysing the components of 
prostatic tissue that are associated with prostate cancer. Stromal cells are likely to be 
important in the control of proteolytic activity due to their increased expression of TlMPs, 
and as the stromal-epithelial ratio reduces in cancer, this control is less likely to be 
complete. 
It is important to understand how much of TlMP-3 is available in tissue as the disease 
progresses as it could be a potential marker for prediction of patient outcome. Due to time 
and financial constraints, the expression of proteinases could not be measured alongside 
TlMP-3. However, it must be borne in mind that there is homeostasis of proteinase and 
inhibitors in normal tissue and any modulation in favour of one over the other will lead to 
altered balance and tissue turnover. 
The sequestering of TIMP-3 in the surrounding stroma of many cancers may possibly be a 
host protective mechanism of preventing tumour migration out of the primary site since 
more TlMP-3 is available in the stroma to inhibit proteinase-induced degradation of ECM 
and possibly prevent basement membrane rupture as well. However, analyses of prostate 
tissue sections (Figures 3.12 - 3.14) demonstrated a reduced expression of TlMP-3 in 
prostate cancer compared to benign conditions. Thus, the barrier to proteolysis leading to 
cell migration may be reduced in prostate cancer. The morphology of tissue from prostate 
cancer samples demonstrated a reduced matrix component in comparison with normal and 
BPH tissue (Figure 3.11), which may potentially reduce the barrier further. 
The results from this project is similar to a study conducted with breast cancer tissue, which 
showed TlMP-3 staining in both epithelial and stromal compartments of the tissue (Vizoso 
2007). The presence of TlMP-3 in the epithelium is contrary to my in-vitro findings of 
higher expression in prostate stromal cells relative to prostate cancer cells (see Section 
3.2.2). It is possible that TIMP-3 synthesised by the stromal cells is binding to heparin 
sulphate proteoglycans in the epithelial compartment, which may be important for its 
function of inhibiting epithelial-derived metalloproteinases. 
Expression of TlMP-3 was very low in the liver marker tissue used as controls for the 
tissue microarray analyses (Figure 3.17). This is in line with the study by Su et af which 
showed several fold higher expression of TlMP-3 mRNA in prostate tissues in comparison 
to liver tissue (see Figure 3.1 and 3.3). 
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The apparent inverse correlation of TlMP-3 expression with GS seen in Figs. 3.18 and 3.19 
suggests that the loss of TlMP-3 may result in poorer prognosis and may even encourage 
disease progression. This finding is in line with studies by Vizoso et al (Vizoso et aI., 2007) 
which showed higher expression of TIMP-3 in ER-positive breast tissue obtained from 
patients with no metastasis (early stage breast cancer) compared to ER-negative tissues 
from patients with metastasis (late stage breast cancer). Another study on breast cancer 
showed higher expression of TlMP-3 in the stromal cells and mononuclear inflammatory 
cells of the ductal carcinoma (early stage invasive breast cancer) when compared to 
expression in the distal lobular and medullar carcinomas (late stage invasive breast cancer) 
(del Casar et aI., 2010) 
All these results suggest that TIMP-3 may be of use in predicting patient survival. This is 
buttressed by the results from a study in 2007 (Hilska) which reported strong staining for 
TIMP-3 in tissues obtained from rectal cancer patients with higher mean survival time and 
earlier Duke's rectal cancer stage. In another study on breast cancer by Del Casar et al (Del 
Casar et aI., 2009) the expression of TIMP-3 was reported to be higher in stromal 
fibroblasts obtained from within the breast tumour in comparison with fibroblasts obtained 
from the invasive front of breast cancer. They concluded that higher expression of TlMP-3 
was indicative of lower metastasis and vice versa and is predictive of more favourable 
prognosis. 
Lower expression of TlMP-3 in cancer has also been reported in breast cancer tissue of an 
aggressive phenotype - there was lower expression ofTIMP-3 and this correlated with high 
nuclear and histological grading of the tissue (Mylona et al., 2006). Also, TlMP-3 
expression has been correlated with oesophageal squamous cell carcinoma invasion and 
metastasis - immunohistochemical analyses of the carcinoma tissue showed reduced TlMP-
3 expression in tumours with higher depth of invasion and patients with lower tissue 
expression of TlMP-3 had lower survival rates and vice versa (Miyazaki et aI., 2004). 
An interesting and novel finding of my experiments was the apparent up-regulation of 
TIMP-3 expression both at mRNA transcript and protein level, in stromal fibroblasts 
following co-culture with tumour epithelial cells. Here, both normal stromal fibroblasts, 
WPMY -1 and prostatic carcinoma-associated fibroblasts, PCAF, had increased TlMP-3 
expression 48 hours after they had been cultured with prostate cancer cells LNCaP (see 
Figures 3.22 and 3.23). Other studies have demonstrated an increase in TlMP-3 mRNA 
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expression in stromal fibroblasts adjacent to head and neck cancer patients' tissue samples 
in comparison with fibroblasts adjacent to normal epithelia (Kornfeld et aI., 2011). Also, 
cancer cells co-migrate with stromal fibroblasts from their primary site of origin to distal 
organs where they form niches and co-habitate synergistically, with the fibroblasts 
producing growth factors that enable the cancer cells to home properly and proliferate in 
this secondary site (Kaminski et aI., 2006). 
TlMP-3 in the tissue of prostate cancer and other cancers plays a major role in the 
inhibition of many proteinases, and inhibits angiogenesis, both of which may contribute to 
the inhibition of cancer growth and metastasis. The molecule may prove a useful diagnostic 
tool for prediction of patient survival, disease progression and may enable targeted 
therapeutics for patients with prostate cancer as well as other cancers 
In conclusion, this study showed higher expression of TlMP-3 in prostate stromal cells and 
tissues relative to the prostate cancer cells and tissue as well as an increase in TlMP-3 
expression in the stromal cells upon contact with cancer cells. To further understand the 
impact of this interaction on disease progression, further experiments were designed to 
investigate changes in expression of TlMP-3 and these are described in subsequent 
chapters. 
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CHAPTER 4: MODULATION OF TIMP-3 BY 
ANDROGEN AND CYTOKINES 
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4.1 INTRODUCTION 
Androgens are steroid hormones that regulate the growth of the prostate and male fertility 
and they function by binding to androgen receptors (AR) to initiate a signalling cascade that 
tightly regulates the development of the male sexual organs (Hovenanian and Deming, 
1948, Yang et aI., 2005). In men, the most important form of androgen is testosterone - this 
is a circulating androgen that is secreted by Leydig cells found in the testes (Burnstein, 
2005). Testosterone is converted by 5-alpha-reductase, into a highly reactive form called 
dihydrotestosterone (DHT). DHT translocates into the cytoplasm and binds to the androgen 
receptor via displacement of AR-bound heat shock proteins (HSP) (Brinkmann et aI., 
1999). The DHT-AR complex becomes dimerized and this results in AR phosphorylation. 
This phosphorylated complex translocates into the cells' nuclei where they bind to 
androgen response elements (ARE) in the promoter region of androgen-regulated genes. 
Once the binding of dimerized AR to AREs occurs, there is a mobilisation of transcription 
co-regulators to the complex, resulting in the formation of a transcription complex and 
initiation of the androgen-regulated genes (Gobinet et aI., 2002). These genes are essential 
to the normal growth and development of the prostate. Some of the androgen-regulated 
genes include prostate specific antigen (KLK-3/PSA), prostate specific membrane antigen 
(PSMA), kallikrein-2 (hK-2), to mention a few (Xu et aI., 2001, Ngan et aI., 2009). A 
schematic representation of the AR signalling pathway is represented in Figure 4.1. 
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Figure 4.1: DHT Signalling in Prostate Cells. 
The above diagram is a schematic representation oj DHT signalling cascade in cell . 
Firstly, soluble circulating testosterone is translocated into the cell via the cell membrane 
where it is converted into dihydrotestosterone (DHT) by 5-alpha reductase enzyme (1) 
(Celotti et aI. , 1991). Binding oj DHT to the latent androgen receptor (AR) re ults in the 
displacement oj heat shock proteins (HSP) fro m the AR, activation oj the DHT-AR complex 
and subsequent phosphorylation of bound AR. This is Jollowed by dimerization oj bound 
AR (2, 3 & 4) (Nazareth and Weigel, 1996). The dimer complex i tran located in/o the 
nucleus (5) where it is capable oj binding to androgen re ponse element located on the 
promoter regions oj the DNA sequence oj target genes (6), initiating the tran ription of 
target genes such as PSA (7) (Lindzey et aI. , 1994). 
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Several mutations have been reported in the AR of prostate cancer patients. This results in 
the loss of specificity of the AR to androgen, thereby converting it into a promiscuous 
receptor that will become activated upon binding of other steroids like oestrogen (Yeh et 
aI., 1998) and even anti-androgens like flutamide or making the AR more responsive to 
DHT (Taplin et aI., 2003). There is a point mutation in the AR in the LNCaP cell line, -
this mutation is at codon 877 (change of threonine to alanine) located in the ligand-binding 
domain of the AR and it results in promiscuity of the AR in LNCaP cells (Suzuki et aI., 
1996, Gaddipati et aI., 1994, Suzuki et aI., 1993). On the other hand, the PC3 cell line has 
been reported to have no AR and hence is no longer dependent on androgen for growth and 
survival. Insertion of the androgen receptor back into the PC3 cells led to androgen-
dependence for their growth once again (Yu et aI., 2009, Marcelli et aI., 1995). This loss of 
AR expression has been reported in some hormone-refractive prostate cancer patients 
(Heinlein and Chang, 2004). 
Tumours are generally hypoxic, consisting of a highly metabolically active dense 
population of cells, which causes a local shortage of available oxygen (Phillips, 1998) 
(Wijffels et aI., 2008). The occurrence of tumours results in the initiation of an 
inflammatory response at the primary site, leading to recruitment of macrophages and 
subsequent release of cytokines (Murdoch and Lewis, 2005, Murdoch et aI., 2004). 
Cytokines are secreted proteins that are produced by immune cells, and other cell types 
such as endothelial cells, epithelial cells and fibroblasts. They function primarily by 
modulating cellular activities that mediate the inflammatory response and are involved in 
growth, proliferation, differentiation, survival and apoptosis (Rakesh and Agrawal, 2005, 
Lentzsch et aI., 2004, Benczik and Gaffen, 2004, Klein, 1997). There are different types of 
cytokines such as interleukins, lymphokines, interferons, colony-stimulating factors, 
chemokines, polypeptide growth factors and stress proteins. These different types of 
cytokines have various functions that have independent signalling pathways or inter-related 
pathways, all of which regulate cellular behaviour and can be grouped as pro-inflammatory 
or anti-inflammatory cytokines (Roitt I.M. and P.J., 2001). 
TNF is implicated in diseases such as rheumatoid arthritis and osteoarthritis (Zangerle et 
al., 1992), both of which are degenerative diseases of the skeletal system. Membrane-bound 
pro-TN F is cleaved by a disintegrin and metalloproteinase 17 (ADAM 17) also known as 
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TNF-alpha-converting enzyme (TACE). This results In the formation of soluble TNF 
(Black et aI., 1997, Moss et aI., 1997b). 
TNF binds to the extracellular domain of the TNF receptor (TNFRI) - this binding 
initiates recruitment of an adaptor protein; Tumour necrosis factor receptor type 1-
associated DEATH domain protein (TRADD) by the intracellular domain of TNFRI (Hsu 
et aI., 1995). TRADD recruits TNF receptor associated factor 2 protein (TRAF2) and 
receptor-interacting serine/threonine protein kinase (RIP) forming a 
TRADD+ TRAF2+RIP complex. This complex subsequently recruits inhibitor of kappa B 
kinase enzyme complex OKB). NF-KB is a transcription factor that initiates the 
transcription of genes involved in regulating the inflammatory response, cell proliferation 
as well as transcription of anti-a pop to tic factors (Roitt LM. and PJ., 2001). IkB is bound to 
NF-KB in the cytoplasm. When IkB is inactivated by phosphorylation it leaves nuclear 
factor kappa enhancer of activated B cells (NF-KB) free to trans locate to the nucleus (Baker 
and Reddy, 1996, Hsu et aI., 1996). The complex (TRADD+ TRAF2+RIP) can also activate 
the mitogen-activated protein kinase (MAPK) pathway and initiate transcription of pro-
apoptotic factors and genes involved in cell differentiation (Holvoet et aI., 2003). 
As an alternate pathway, TRADD can also bind to an adaptor protein known as fas-
associated protein with death domain (F ADD), which binds to caspase 8 - this reaction 
leads to the activation of caspase 3 and formation of the death inducing signalling complex 
and subsequent cell apoptosis (Hsu et aI., 1996). A schematic diagram summarising the 
TNF signalling pathways is represented in Figure 4.2. 
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Figure 4.2: TNF Signalling Pathway in Cells. 
The above diagram is a schematic representation of the TNF signalling pathway in cells. 
Soluble trimerised TNF binds to the extracellular domain of TNFRI (1) and initiates the 
recruitment of the TRADD+TRAF2+RlP complex by the intracellular death domain of 
T FRI (2). The complex binds to IKK (3), which activates NF-K13 (4) and results in its 
nuclear translocation (5). NF-K13 binds to the promoter region of survival genes to initiate 
their transcription (6). Alternatively, the intracellular death domain of the TNFRI can 
initiate the recruitment of a TRADD+FADD complex which binds to caspase 8 (7) and 
initiates caspase 3 (8), therefore leading to the formation of the death inducing signalling 
complex and subsequent apoptosis of cells (9). 
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Transfonning growth factors (TGF) are also secreted cytokines belonging to the 
polypeptide growth factor class of cytokines, which includes activins and bone 
morphogenic proteins. They are multi-functional cytokines and consist of two members; 
TGF-a and TGF-~ (Wahl, 1992). In particular, TGF-~ regulates cell adhesion (Han et aI., 
1993, Ogata et aI., 2007), cell differentiation (Moustakas et aI., 2002, Bouche et aI., 2000, 
Sells Galvin et aI., 1999) and ECM turnover by increasing the production of ECM proteins 
(Ballock et aI., 1993, Risinger et aI., 2010, Chen et aI., 2003), and decreasing the 
production of matrix-degrading proteases (Risinger et aI., 2010, Chen et aI., 2003) and 
increasing the production of inhibitors of matrix-degrading proteases (Wu et aI., 2000). 
In the canonical TGF-~ signalling pathway, the ligand, TGF-~, binds to its trans-membrane 
serine-threonine kinase receptor 2 (TGF~RlI) - the bound TGF~RlI activates and 
phosphorylates TGF~RI. Activated TGF~RI then phosphorylates intracellular proteins 
SMAD 2 and SMAD 3 and subsequently fonns a trimeric complex with SMAD 4. The 
SMAD2+SMAD3+SMAD4 complex translocates and accumulates in the nucleus to 
activate the transcription of its target genes (Ogata et aI., 1997, Roitt I.M. and P.J., 2001). A 
schematic representation summarising the TGF-~ signalling pathway is represented in 
Figure 4.3. 
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Figure 4.3: TGFf3 Signalling in Cells. 
The above diagram is a schematic representation of the TGF-f3 signalling pathway via the 
TGF-f3 receptors. TGF-f3 binds to its trans-membrane receptor TGF-f3R2 (1) leading to an 
activation of a signalling cascade and phosphorylation of TGF-f3R1 (2) and subsequent 
TGF-f3 receptor-mediated phosphorylation of SMAD2 and SMAD3 (3). The phosphorylated 
SMAD2 and SMAD3 form a trim eric complex with SMAD4 (4) and the 
SMAD2+SMAD3+SMAD4 complex translocates into the nucleus (5) where it binds to the 
promoter regions of the DNA of target genes (6) (Ogata et aI., 1997). 
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There is an interaction between TNF-a. and TGF-~ signalling pathways and subsequent 
regulation of one by the other. For instance, TGF-~-mediated ECM deposition is inhibited 
by TNF-a.. This is mediated by the degradation of ECM proteins such as collagen and 
proteoglycans by proteases recruited as a result of TNF-a. signalling (Hui et aI., 2001, 
Knittel et aI., 1999, Lee and Rannels, 1998). The relationship between these two cytokines 
plays an important role in initiation and progression of cancers and therefore genes 
regulated by any of these signalling pathways may be modulated and cellular homeostasis 
altered, ultimately resulting in the absence of regulation of cellular growth, leading to 
cancer. 
In this project, the role played by androgens, growth factors and cytokines in the regulation 
of TIMP-3 expression in prostate cancer cells was explored. Prostatic cells were treated 
with DHT, TNF-a. and TGF-~, followed by measurement ofTIMP-3 expression levels. 
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4.2 RESULTS 
4.2.1 Regulation of TIMP-3 mRNA by OUT in Prostate Cells 
The stimulation of LNCaP cells with varying doses of DHT as well as flutamide and 
combinations of DHT plus flutamide, resulted in a significant dose-dependent down-
regulation of TlMP-3 mRNA by DHT. This effect was dose-dependent to the highest 
concentration tested of IOnM. There was no effect of the androgen receptor antagonist 
flutamide on the expression levels of TIMP-3 mRNA at 100-fold higher concentrations 
than the highest dose of DHT used, and no significant effect seen when treated alongside 
DHT i.e. 1000nM flutamide alone or 1000nM flutamide + 10nM DHT (see Figure 4.4). 
PSA mRNA increased in a dose-dependent manner in the LNCaP cells, with the greatest 
effect observed when cells were treated with IOnM DHT. This observation confirmed the 
known activity of DHT in primary prostate cancer cells (Miniati et aI., 1996). As with the 
effect on TIMP-3 mRNA expression, flutamide did not inhibit PSA mRNA expression (see 
Figure 4.5). This finding is counter-intuitive as flutamide is clinically prescribed to patients 
with androgen-insensitive prostate cancer as a therapeutic agent for management of disease 
progression (Narimoto et aI., 2010, Greenway, 1998, Eisenberger et aI., 1998, Higano et aI., 
1996). However, this result is explained by the AR mutation in LNCaP cells, which enable 
constitutive activation of the AR and subsequent pathway activation regardless of the levels 
ofPSA present (Gaddipati et aI., 1994, Suzuki et aI., 1993) 
TlMP-3 mRNA expression was eliminated in PC3 cells after treatment with DHT, the 
effect of which was not reversed by flutamide (see Figure 4.6) and PSA mRNA was hardly 
detected in the PC3 cells (results not shown). It must be borne in mind, though, that PC3 
cells produce only very small amounts of TlMP-3 mRNA (see Section 3.2). 
TIMP-3 mRNA expression was not significantly different from the control experiments in 
stromal cells BPH45, PCAF and WPMY -1 after treatment with DHT and there was also no 
modulation of TIMP-3 mRNA expression by flutamide alone or flutamide and DHT in 
treated BPH45, PCAF and WPMY -1 cells (see Figures 4.7, 4.8 and 4.9 respectively). These 
results suggest that modulation of TlMP-3 mRNA by DHT occurs in the prostate 
carcinoma cells but not in the stromal cells. 
Due to limited time and resources and previous results that showed negligible levels of 
TIMP-3 in the ECM made by LNCaP cells (see Section 3.2), it was not possible to 
corroborate expression changes seen in LNCaP mRNA by western blotting. Also, as there 
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were no significant changes in TIMP-3 mRNA expression mediated by DHT in the stromal 
cells, the TIMP-3 protein expression in these cells was not analy ed. 
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Figure 4.4: TIMP-3 mRNA expression in Treated LNCaP Cells. Cells were treatedfor 24 
hours, harvested and trypsinised as described in Section 2.6. Total RNA was extracted and 
eDNA synthesized by reverse transcription as described in Section 2.7. Relative T1MP-3 
mRNA was analysed by qPCR (Section 2.8) and expression was normalised to untreated 
controls. (a) Dose-dependent down-regulation of T1MP-3 mRNA in DHT-treated LNCaP 
(n =5) * *P=O. 0037, Kruskal-Wallis test. (b) The significant down-regulation of TIMP-3 
mRNA in JOnM DHT-treated cells was not reversed by JOOOnMjlutamide or a combination 
of J OnM DHT and I OOOnM jlutamide. 
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Figure 4.5: PSA mRNA expression in Treated LNCaP Cells. 
(a) Dose-dependent up-regulation of PSA mRNA in DHT-treated LNCaP (n =4) with 
significant effects seen at lnM DHT (**P=O.0069, Kruskal-Wallis test) and at lOnM DHT 
(**P=O.0027, Kruskal-Wallis test) (b) The up-regulation of PSA mRNA in JOnM DHT-
treated LNCaP was not reversed by lOOOnMflutamide or a combination of lOnM DHT and 
lOOOnMflutamide. 
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Figure 4.6: TIMP-3 mRNA expression in Treated PC3 Cells. 
(a) Repression oJTfMP-3 mRNA in DHT-treated PC3 at all concentrations oj DHT tested 
(n =5, *P=0.OJ44 Jor all concentrations tested, Kruskal-Wallis te t) (b) The repression oj 
T1MP-3 mRNA in DHT-treated PC3 was not reversed by 1000nM flutamide or a 
combination oj 10nM DHT and JOOOnM flutamide. Average Cr Jor TfMP-3 mRNA from 
untreated PC3 cells was 36 and Jor treated cells was 39 (close to detection limit as 
maximum number oJcycles is 40. 
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Figure 4.7: TIMP-3 mRNA expression in Treated BPH45 Cells. 
(a) There wa no significant modulation of TIMP-3 mRNA in DHT-treated BPH45 at all 
concentrations of DHT tested (n=4) (b) There was no significant modulation of TIMP-3 
mRNA expres ion in BPH45 cells upon treatment with either flutamide alone or with 
jlutamide and DHT (n =4) 
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Figure 4.8: TIMP-3 mRNA expression in Treated PCAF Cells. 
(a) There was no significant modulation of T1MP-3 mRNA in DHT-treated PCAF at all 
concentrations of DHT tested (n =4) (b) There was no significant modulation of TlMP-3 
mRNA expression in PCAF cells upon treatment with either flutamide alone or with 
flutamide and DHT (n =4). 
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Figure 4.9: TIMP-3 mRNA expression in Treated WPMY-l Cells. 
(a) There was no significant modulation of TlMP-3 mRNA in DHT-treated WPMY-J at all 
concentrations of DHT tested (n =4) (b) There was no significant modulation of TIMP-3 
mRNA expression in WPMY-J cells upon treatment with either flutamide alone or with 
flutamide and DHT (n =4). 
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4.2.2 Regulation of TIMP-3 by TNF in Prostate Cells 
All cells were treated with varying doses of TNF from 0 - 570 pM (0 - 10 ng/mL) TNF. 
There was no significant changes in TIMP-3 mRNA upon stimulation of LNCaP or PC3 
cells with varying doses of TNF (Figure 4.10) but these cells have been shown not to 
express much TIMP-3 mRNA (see Section 3.2.2). As the mRNA results were not 
statistically significant, protein expression by western blotting was not done. 
In stromal cells BPH45, stimulation with TNF resulted in a down-regulation of TIMP-3 
mRNA expression in a dose-dependent manner, with significant down-regulation upon 
treatment with 5.7 pM TNF (P=O.0072) as well as 570 pM TNF (P=0.003). These results 
were also corroborated by western blotting of ECM extracts from TNF-treated BPH45 cells 
as shown by results from densitometric analyses (Figure 4.11). However, there was no 
significant change in TIMP-3 mRNA expression in the other stromal cells PCAF nor 
WPMY-I (Figure 4.12) after TNF stimulation, and so these were not corroborated by 
western blotting. 
The above results suggest modulation by TNF occurs in the cells from the BPH stromal 
cells from a patient with benign prostatic hyperplasia, but not from cancer-associated 
stromal cells or cancer cells themselves. 
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Figure 4.10: TIMP-3 mRNA expression in TNF-treated Prostate Cancer Cells. 
Cell were treated for 24 hours, harvested and tlypsinised as described in Section 2.3. 
Total RNA was extracted and eDNA synthesized by reverse transcription a described in 
Section 2.7. Relative TlMP-3 mRNA was analysed by qPCR (Section 2.6) and expression 
was normalised to untreated controls. (a) There was 110 significant modulation of TIMP-3 
mRNA il1 TNF-treated LNCaP cells at all concentrations of TNF tested (n =4) (b) There 
was no significant modulation of TlMP-3 mRNA in TNF-treated PC3 cells at all 
concentrations ofTNF tested (n =3). 
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Figure 4.11: T1MP-3 expression in TNF-treated BPH Cells. 
Cells were treated for 24 hours, harvested and trypsinised as de cribed in Section 2.3. 
Total RNA was extracted and cD 'A synthesized by reverse tran cription a de cribed in 
Section 2.7. Relative TlMP-3 mRNA was analysed by qPCR (Section 2. 6) and expres ion 
was normalised to untreated controls. (a) There was a dose-dependent down-regulation of 
TlMP-3 mRNA with significant decrease observed both at 5.7 pM I: F (**P=O.0072, 
Kruskal-Wallis) and 570pM TNF (**P=O.0072, Kruskal-Wallis) (n=4) (b) Representative 
blot showing ECM proteins from treated cell were extracted as described in ection 2. 10. 
100,000 cells' worth of ECM proteins were ubject to SDS-PAG£, we tern blolling and 
densitometric analyses as described in Sections 2. J 2 - 2.14. Re ull hawed down-
regulation of T1MP-3 protein as shown by Ie den e bands of 23kD (- ee red arrow for 
bands) after treatment with all dose of I: F Ie ted. MWS = molecular weight tandard , U 
= untreated, X = empty lane. Results of den itometric analyses are in OD mm1 (n=2) 
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Figure 4.12: TIMP-3 mRNA expression in TNF-treated Prostate Stromal Cells. 
Cells were treated for 24 hours, harvested and trypsinised as described in Section 2.3. 
Total RNA was extracted and eDNA synthesized by reverse transcription as described in 
Section 2.7. Relative TlMP-3 mRNA was analysed by qPCR (Section 2.6) and expression 
was normalised to untreated controls. (a) There was no significant modulation of TlMP-3 
mRNA in TNF-treated PCAF cells at all concentrations ofTNF tested (n =4) (b) There was 
no significant modulation of TIMP-3 mRNA in TNF-treated WPMY-J cells at all 
concentrations ofTNF tested (n =4). 
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4.2.3 Regulation of TIMP-3 by TGF -P in Prostate Cells 
All cells were treated with varying doses ofTGF-p from 0 - 50nM (0 - I OnglmL) TGF-p. 
There was no significant changes in TIMP-3 mRNA upon treatment of LNCaP nor PC3 
cells with varying doses of TGF-p (Figure 4.13) but these cells have been shown not to 
express much TIMP-3 mRNA (see Section 3.2). As the mRNA results were not statistically 
significant, the proteins were not analysed by western blotting. 
The expression of TIMP-3 mRNA in BPH45 after treatment with TGF-p significantly 
increased in a dose-dependent manner with about 10-fold up-regulation at 50nM 
concentration after 24 hours. This was corroborated by western blotting (Figure 4.14). 
There was also a dose-dependent up-regulation of TIMP-3 mRNA in treated PCAF cells 
with about 3-fold increase observed with 50nM concentration. Western blotting results of 
treated PCAF proteins also showed an increase in TIMP-3 after treatment with TGF-p 
(Figure 4.15). 
There was no statistically significant effect ofTGF-p treatment on the expression ofTIMP-
3 mRNA in WPMY -1 cells (Figure 4.16) and so western blotting was not carried out on the 
WPMY -1 proteins. 
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Figure 4.13: TIMP-3 mRNA expression in TGF-p-treated Prostate Cancer Cells. Cells 
were treatedfor 24 hours, harvested and trypsinised as described in Section 2.3. Total RNA 
was extracted and eDNA synthesized by reverse transcription as described in Section 2.5. 
Relative TIMP-3 mRNA was analysed by qPCR (Section 2.6) and expression was 
normalised to untreated controls. (1) There was no modulation ofTIMP-3 mRNA in TGF-fJ 
-treated LNCaP cells at all concentrations of TNF tested (n =4) (2) There was no 
modulation of TIMP-3 mRNA in TGF-fJ-treated PC3 cells at all concentrations of TNF 
tested (n=3). 
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Figure 4.14: TlMP-3 expression in TGF-p -treated BPH45 Cells. 
(a) There was a dose-dependent up-regulation of T1MP-3 mRNA in BPH45 cells, with 
significant increase observed both at 0.5nM TGF-fJ (**P=0.0065, Kruskal-Wallis) and 
50nM TNF (**P=0.0026, Kruskal-Wallis) (n =4) 
(b) ECM proteins from treated cells were extracted as described in Section 2.9. 100,000 
cells' worth of ECM proteins were subject to SDS-PA GE, western blotting and 
densitometric analyses as described in Sections 2.10 - 2.12. Results showed up-regulation 
of TlMP-3 protein as shown by denser bands at - 23kD (see red arrow) after treatment with 
both doses of TGF-fJ tested. rhTlMP-3 = recombinant human T1MP-3 protein, U = 
untreated, X = blank lane. Results of densitometric analyses are in ODmm2 (n =2) 
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Figure 4.15: T1MP-3 expression in TGF-p -treated PCAF Cells 
+--23 0 
(4a) There was a dose-dependent up-regulation of TlMP-3 mRNA in PCAF cells, with 
significant increase observed at 50 nMTGF-fJ (**P=0.03J3, Kruskal-Wallis) (n =4). 
(4b) There was an up-regulation of T1MP-3 protein as shown by denser bands at ~23kD 
(see red arrow) after treatment with 50nM TGF-fJ. MWS = molecular weight standards, 
rhTlMP-3 = recombinant human T1MP-3 protein, U = untreated Results of densitometric 
analyses are in ODmm2 (n =2) 
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Figure 4.16: T1MP-3 mRNA expression in TGF-p-treated WPM Y-1 Cells. 
(5) There was no significant modulation ofTlMP-3 mRNA in TGF-/3-treated WPMY-I cells 
at all concentrations ofTNF tested (n =3) 
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4.2.4 In-silico analyses of timp-3 
This chapter has described the regulation of TlMP-3 gene expression by androgen DHT in 
prostate cancer cell LNCaP and by TNF in prostate stromal cells BPH45 and by TGF-j3 in 
prostate stromal cells PCAF and BPH45. In the light of these results it seemed essential to 
try to determine whether a secondary hypothesis was derived at this stage - does the TlMP-
3 gene have androgen, TNF or TGF-j3 response elements in its promoter region. This would 
suggest direct transcriptional regulation of the gene via androgen, TNF or TGF-j3 binding to 
a specific DNA sequence motif upstream of the promoter region of the gene. The promoter 
region of DNA is known to enhance the transcription of the genes close to it and is usually 
located on the same strand at 5' upstream of the gene to be regulated. Proximal promoters 
are usually 250bp upstream of the transcription start site of the gene and are characterised 
by the presence of CpG islands very near the beginning of the first exon of target regulated 
genes (Iannello et at, 1997, Koutsodontis et at, 2002, Desmoucelles et at, 1999). Nuclear 
receptors and transcription regulators will bind to specific response elements within the 
promoter region to initiate recruitment of co-activators or co-repressors for regulation of 
gene transcription. 
TIMP-3 is located on chromosome 22: 33192687 - 33197686. For in-silica analyses, an 
area of 5,000bp upstream of the 5' position of the TlMP-3 gene was investigated, in order 
to identify the presence of known androgen response elements, TNF response elements or 
TGF-j3 response elements. 
The general motif sequence for androgen response elements (ARE) is a loosely palindromic 
sequence consisting of 15bp arranged as 2 half sites of 6bp each divided by a 3bp spacer 
region: 5'-GGAITACA nnn TGTTCT-3' (Roche et aI., 1992). This sequence has been 
shown to be specific for androgen receptor binding and activation of gene transcription. 
Other AREs that have some of the matching nucleotides as the consensus ARE, have been 
discovered in promoter regions of genes and have been shown to be functional e.g. 
5'-AGAACA gca AGTGCT-3' and 5'-AGCACT tgc TGTTCT-3' are functional AREs 
found in the proximal promoter of PSA (Cleutjens et aI., 1997, Cleutjens et aI., 1996), 5'-
TGAAGT tcc TGTTCT -3' in the proximal promoter of mouse vas deferens protein gene 
(MVDP) (Fabre et aI., 1994), 5'-CAACTT cta TGTACA-3' in distal promoter of human 
protease activated receptor 1 (hParl) (Salah et aI., 2005) to mention but a few. Other 
putative AREs have also been discovered in the promoter regions of genes e.g. 5'-
161 
GGAACA taa GGTGCG-3' in the promoter of ADAMTS15 gene (Molokwu et al. 2010) 
although the functionality is yet to be tested . 
The sequences for TlMP-3 and 5,000bp upstream of TlMP-3 were obtained from 
ENSEMBL genome database (Hubbard et aI. , 2002). Only exonal equence for TlMP-3 
were analysed. 10 putative AREs were found in the 5000bp equence upstream of the 
TIMP-3 gene upon analysis. This 5000bp region contain the promoter region of TLMP-3 
as characterised by GC-rich region clo e to the tran cription tart ite and tran cription tart 
point on exon 1. The ARE were detected using the N UBISCA oftware (Podvinec et aI. , 
2002) and imputing the functional ARE half site : AGAACA, TGT AAC, TGTACA, 
TGTTCT, GGT ACA, AGTGCT, TGGTCA, AGTTCT, AGT ACG and GGAACA (Monge 
et aI. , 2006). The search criteria imputed into NUBISCAN for ARE prediction en ured that 
only sequences with at least 70% similarity to these functional half ite were reported. The 
putative AREs have been highlighted in Figure 4.2.4 .1. Also, a CpG i land wa identified 
in the 5000bp sequence using the CPGPLOT software (Rice et aI. , 2000) - the i land was 
proximal to the fir t ex on and the transcription tart point. Thi i al 0 highlighted in the 
Figure 4.17. 
Table 4.1 shows a comparison of the ARE in the limp-3 gene promoter region to other 
known AREs in androgen-regulated genes. The percentage of nucleotide imilarity of the 
timp-3 AREs to these reported AREs is also reported on the table. This analy i howed 
that there was 40 - 75% sequence similarity between the timp-3 ARE and the ARE of 
known androgen-regulated genes. 
GCTTGGGGGAAGGCATCGTGGCTAGGGTCTGGAGGGGAAGAGGGAGGAAAGCAAAGAGGA 
GCTTCCCTATGAGGCAACAGAAATGACAGTACCTTCTCCAGGTTGAATTTCCAAAACCCA 
GCTCTGCCCTGGAAGACTGGGACTGTGGCATCCTCTGCAGTGTTCCCAGACCGCCCTAAG 
GCCCCCAAACCAATGATTCACAACTATGTTGCTTCCCCAGAGAGCATCTCCCCCTTTGGT 
TGACATGTGGCCAGCTCAGGGGTGGAGGAGCTCCGGCAGCCACGAACCCAGACGGGATGT 
TGACTGAGAGCTTTGTGGCCATGGCAGATGGGAGGGGTGAGCTTCACCCACTCAAAGGCA 
CCCGCACCCCACCGATGAGTGTGGAATTGTGCTCTCCCGCCCTCGCAGTGAGACGACCGA 
CCAGGACTGCAGGCTGAGCAAATGGGTGTTCTCTGGCTTATAGCGCCCCCTAGCACCAGC 
CAGCGGGA TCCAAGGAGCCACCACCTGCCTGTCTGAATGCTGG 
AAAGGGGTC GGACCCATTCAACCAATACTTATTAAACTCGTTGT 
TACCAACAC CTTAGACTCCAGCAAGGGAAACAGATGGGT 
AAATAATCACATTAGAGTCAGCTAAGTATTGTCAAAGAAGTTGATACAGGGTGTTGTGGG 
GATACATGGGAGGGGAATCAGAGGAGGTTTCCCGGAGGAGGTGACATCTAAGCTGAGGTC 
TGAAGGATGTGGAAGAGTTCAGTAACTCCTGAAGACCAAAAAAATGGTGATAAAAAAGAC 
ACCTTCCTAACTTTTTAGTGCTACGATCCAAGAGACAAACAAGCAGGTGAACGCATAACT 
ACACTGGGCTCCACCATAAGCCAGAGCCTGTCTCTCCTAGGACTTTGGCATCACAATCTT 
162 
CTCTGAAATTCTGTTTTCGGCATTGATTCTTGGGGGAGGTAGCAATAT 
TGCGAAACTGATGGATGGTCTTCAGTCTTGGGTACGTTCCCATGTGTCAAACCTG 
TTTAAATGGCAGGACCCATCTCCCCTTCAGAAGCATTCACTTGTCCTACAGGATTCCCCA 
TGGAATCTTGGAGTTTTTGAGGCGAGAGGGATCCTGGATACCACTGAGTTCTATCTTTCA 
TCCAATAAACACAGAAGTGGACGCCTGGACAGGCAAAGTGACTTGACCAAGGCAGGTGCA 
CAGCTATTCTGCAACATTGGGAACAAATCTCAGGTCTTTTGATTTTTTGTTTCCACTTTA 
CTCTCTTTTCATTTCCCAGAAACAAAGTTTTCATGTGCTTTTTTTTATAGTGATATGTTT 
GGAATGCATTAGCTAGTAATTTAGGAAGGGAAAAAAATAAACACACAAGAGATAAACCTG 
TCAGGAGGACAAACCTGTATTGCTTCTGATTGGCTCAGAGGGTGATTATTATCATGGTAG 
AGAATTATTTAATCAGTGTAAGTAAAATTTCTCTGTGGGCTGGGCACTGTACAAAGACTC 
AAACGAATCTGTCTACAGATCTGAAAAGCAGATACGAGATCTGTGAATGGCTGGGGTTTC 
CAAGCCCACAGTACAAGCATGGGCCACACCTTACAGCTTGGAGGACTGAGCCCTGAAAAT 
GGGCAAGTTCCTTCACTTCTCTGAACCTTATTTTTCCCACATTTAAAACAAGGATGAGTA 
GTTTCTGAGGTCCTTTTTACGACTTCTCTTCCTACAGACTCTAGCATCCTATAACTTGAT 
ACAAAGAGGGTGGATATGAACTCACCTTTCCTAGAAAAGTTCCAGGAAAGAGAATACCAG 
GTCATCCTAGTAGGTGTGTAGACAGGCCAGATAGATCTTGAAACTTACTCAGTTCTTCCC 
AGATGTATAACTCTATCATTGTTCTTAGCTGTCAAGAGAAAGCAGGAGAGCCTGCATCTT 
CATTCTTTTTTTTTTTTTTTTTTTTTTTGGAGACGGAGTCTCACTCCATCACCTAGGCTA 
GAGTGCAGTGGCATGATCTCAGCTCACTGCAAGCTCCGCCTCCCAGGTTCACGCCATTCT 
CCTGCCTCAGCCTCCCAAGTAACTGGGACTACAGGCGCCCACCACCACACCTGGCTAATT 
TTTTGTGTTGTTAGTACAGACGG AGGATGGTCTCGATC 
CCACCTT GGATTACAGGCGTGAGCCACC 
GCACCCAGCCTGCATCTTCATTCTTACTGTTAGCCTCAGGTTCACCCCACCTAGCTTATT 
AAGTGATGTTGAATAACCAATTCTTACATATTATTAGGCTCATGGACACCATGACATCCA 
GACTGATGGGTGCCTGCTGAAGGGGGTGACCCTAGCAGGAGGACTCCCCTACGCAAGGAT 
TCATGGAGTTTGCTGTTTCTTTTCCTTAGGGTGAGAACCAAACTGCCTTCACACGGTGGG 
CAGAGGGGAACTGACTCAGGTTTGGAATAAGAGAGAACATCCCAACTGAAAAGCTCTTGG 
AATTCGCTGAACTTCAAGACACTGTGTGGACCAGCTTAGGATAGGGAGTGAGAAGAAATT 
AACCAAAAGGTAATTTCGTTACTTTTCAGCTGGAAAAAAGATCAGATTATACTTGTGCTT 
TCATAATTAAGTAGCTGCTGGAAAAAAACGCTTCAGATGCTTTCTATGAGAAAACTGCTG 
CTTGAAGTTCAGCAGAAGTTATCTACTTGATACTTATATTCCAGGCAAGGCCTTCCGTTG 
GAGAAAATATCGGCACTTTGGACAAAACTGAAATGTGAAAAGAAAGGGAAGAGAGGGCCT 
CTATCATGTAAGATGCTTATCCAAAGTGGATTTGGTCTGGAAAGTCTTCTAAAACCTTCC 
ACATGACTGTGGAATAAGTCATGTGGGGCGCGGGGATAAGCGAATCTCTCAAATTCCACC 
ACGTATGCCCTCATTCAACCTGGATCCTTAGAGTGGCCTCCAGGGCACTCTGCTCAGGAC 
TCAGTCAGCTGTTGGCCACACCCATGCTCTCCAGTCTCCTGAGACCCTATTTGGTTCTGA 
GAGGGCTAAAAAGCAGTGTGGCTAAATATCCCAGGCCTCAAAGTATTCCTACTGTGGTTG 
GGGAAGCAATAGAATCATACCCCATAAAACAATGAAAACAGTGCTAGAAAAACATCGAGA 
GACAGAAACATCTCTACGAGTTAGGCCACAGTTAGAGTGAAGGCAGGGAAGGTTTTTAAA 
GCTGGGTGGAGGGGACAAGTCAAAAAGATGTGGAAACTGGTTTCCCTTTCCTATGGCTAA 
AGTGCTCAAAGGGGAAAAAGGAGTTTCAAAAATGTTCTTGGAAATACCATCTCTCACGAA 
TTCTTCGGCCTCTGCTGTCCCAATGTCACTTGTCTGAGATGTAAACAGAGGAGTTCTGAG 
AAAGAAGCTGAACTTGCATTTCTCCC TTGTGGCATTTCTA 
ACAGGATGAAGCGGAAGAGAAAGGGAAAGAGACAAAAGTGTAGAAAGATGGAAGATCCCA 
GCTGCAAATGGCCATTTGCAGTTAGATGGAACAGCTGCTGACGTTCAGGGAAATGCATGT 
CTCTCTTCAGATGGGAAGGAGCAGTGGAAAGGGGTGACGAGTTCCTGGCTGGCCACCAAT 
CATCCCATCTTTCTGTGCCGGTTCCTCATCTGGAAAGTGGGAGTGATACTTGTGCTTGCT 
TTTCCTACCCACAAAGATTATTGTGAGAGCTATAATACGGTGAGATACAGAATCCTGCTT 
TTAAAAATACAAAGCAGAATCAAGATGTCAATAATAAGGATAGTAATTGTGTTAGTTATC 
TGCAATCATCTATTATAGCTAGTCGTCTAGGATCCTGGATCGTTCTCCTGGTTTTACTAC 
AGTTTTGGATCAGCTCACCCCCAAATCCCTTGCTGAAGGGTGGAGCTCTGTCAGCCATGG 
GCAGGGAACCACTTCCTCTTGCCTTTCTACTTTCTGTCTTTCAAACATGCCCAGGGTCTT 
CCTGCCTGGTACCTCTCTCCTGTGGCTTGCCCCAGAGCTGATCC 
TTGTCTTTGTCCACTTCTCAGCGAGGATGGCACTTCAGGGAGCCCTTCCCTTACTATCGC 
AGAGAGAGCAGGCCCTCCCCAGTCATGTCCAACCCAGAACTCTGTTTTGTTTTCTTCATA 
163 
GCCCTAGCATCACAGAAAATCACCCTGTGCATTCATGGATGTCCACGGGGGCAAGGGCTT 
TGTGTTGCTTAACCCAGCATCCTGAACCGTGTTTGTTGAATGAATACAGAACCCCGTTTG 
CTCTGGGAGAGCACAGAAAACAGTCTTCTATCATATATCATAGCCAGCTGCAAACAGCAG 
ATGGCTTCCCATATCCCAGAGAGTAAGAACCAGAGAGAGAGAGAAAGAGAGAGAGTTTGG 
GTCTTTCTCCTCTGTGCCTGCTCTCTCCAGAGAAACTGGAGGGGTAGCAGTTAGCATTCC 
CCCGCTGGTTCCACCAAGCACAGTCAAGGTCTCTAGGACATGGCCACCCCTCACCTGTGG 
AAGCGGTCCTGCTGGGGTGGGTGGGTGTTAGTTGGTTCTGGTTTGGGTCAGAGACACCCA 
GTGGCCCAGGTGGGCGTGGGGCCAGGGCGCAGACGAGAAGGGGCACGAGGGCTCCGCTCC 
GAGGACCCAGGGGCAA CACCGGTCCCGGGCGCGCCCCAGCCCACCCACTCGCGTGCCCA 
CGGCGGCATTATTCCCTAT~GGATCTGAACGATC GGGGGCGGCCCCGCCCCGTTACCC 
CTTGCCCCCGGCCCCGCCCCCTTTTTGGAGGGCCGATGAGGTAATGCGGCTCTGCCATTG 
GTCTGAGGGGGCGGGCCCCAACAGCCCGAGGCGGGGTCCCCGGGGGCCCAGCGCTATATC 
ACTCGGC CGCCCAGGCAGCG 
ATGACCCCTTGGCTCGGGCTCATCGTGCTCCTGGGCAGCTGGAGCCTGGGGGACTGGGGC 
GCCGAGGCGTGCACATGCTCGCCCAGCCACCCCCAGGACGCCTTCTGCAACTCCGACATC 
G 
TGATCCGGGCCAAGGTGGTGGGGAAGAAGCTGGTAAAGGAGGGGCCCTTCGGCACGCTGG 
TCTACACCATCAAGCAGATGAAG 
ATGTACCGAGGCTTCACCAAGATGCCCCATGTGCAGTACATCCATACGGAAGCTTCCGAG 
AGTCTCTGTGGCCTTAAGCTGGAGGTCAACAAGTACCAGTACCTGCTGACAG 
GTCGCGTCTATGATGGCAAGATGTACACGGGGCTGTGCAACTTCGTGGAGAGGTGGGACC 
AGCTCACCCTCTCCCAGCGCAAGGGGCTGAACTATCGGTATCACCTGGGTTGTAACTGCA 
AG 
ATCAAGTCCTGCTACTACCTGCCTTGCTTTGTGACTTCCAAGAACGAGTGTCTCTGGACC 
GACATGCTCTCCAATTTCGGTTACCCTGGCTACCAGTCCAAACACTACGCCTGCATCCGG 
CAGAAGGGCGGCTACTGCAGCTGGTACCGAGGATGGGCCCCCCCGGATAAAAGCATCATC 
AATGCCACAGACCCCTGA 
Figure 4.1 7: Results of in silico analysis of timp-3 plus 5,OOObp up tream of the gene. 
Blue sequences are 5,000bp upstream of the gene. Black sequences are the 5 exons 
(translated region) that make up the TIMP-3 gene. ATG underlined in exon i i the start 
codon while TGA in exon 5 is the stop codon. Red sequences are the CG repeats 
characteristic of CpG islands that are found in promoter region of gene. The grey area 
highlighted represents the CpG island proximal to the fir. t exon of the TIMP-3 gene, and 
was identified by CPGPLOT software. The CpG island wa 25 bp long with an 
observed/expected ratio of> 0.6 and a %C + %G of> 50%. The green areas highlighted 
represent the AREs both proximal and distal to the promoter region of TlMP-3 gene. (Key 
characteristics of general ARE consensus = always C at position 5 and alway G at 
position i i of the sequence.) 
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SEQUENCE B-Sl SR B-S2 % OF CONSENSUS 
CONSENSUS 1 GGAACA nnn TGTTCT 
CONSENSUS 2 GGTACA nnn TGTTCT 
PSA AGAACA nnn AGTGCT 75, 67 
MVDP TGAAGT nnn TGTTCT 75, 67 
hPAR1 CAACTT nnn TGTACA 42, 33 
1 TAATCC nnn TGTCCT 67, 58 
-
2 AGAGCT nnn TGAACT 58, 50 
3 GGAACT nnn TGTTCG 83, 75 
-
4 GTTTCA nnn TGTTAG 67, 67 
5 CTGACC nnn TGATCC 50, 50 
6 GCCTCT nnn AGTGCT 50, 50 
7 GTTTCT nnn TGTTCC 67, 67 
8 GGAACC nnn GGCAAG 50, 42 
9 GGATCT nnn CGATCC 58, 50 
10 TGCACT nnn TGTTCC 67, 67 
'iaeel~_~~==Z ",. ~== ..... a .. £=A<-.... !a2UC .. 1.£00,1_==. SU 
Table 4.1: Comparison of the putative AREs found in the 5000bp promoter region 
upstream of timp-3 gene and known AREs in androgen-regulated genes to consensus 
ARE as defined by Roche et al (Roche et aL, 1992). 
Nucleotide similarity of the 10 predicted/putative AREs in the promoter region of TlMP-3 
(labelled as 1 - 10) was compared to the nucleotide sequence of the consensus ARE. The 
functional AREs of PSA, MVDP and hPAR1 were also compared to the consensus ARE. H-
Sl = half-site 1, H-S2 = half-site 2, SR = 3bp spacer region, n = any base. The % of 
nucleotide similarity in the putative AREs in TlMP-3 promoter ranged from 50% to 83% 
for consensus 1 and from 42% to 75% for consensus 2 - this is designated as x, x 
comparing sequences versus consensus 1, consensus 2. The conserved C at position 50fH-
Sl and conserved G at position 2 of H-S2 are both underlinedfor emphasis 
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In the TNF signalling cascade, NF-kB binds to its binding site within the promoter region 
of regulated genes to initiate transcription (Borset et aI., 1996). The consensus for the 
binding site is: 
5'-GGGRNNYYCC-3' where N = any base, R = purine (AlG), Y = pyrimidine (TIC) 
(Wang et aI., 2000, Parry and Mackman, 1994). The results of the analysis showed no 
sequence matching the consensus for the binding site for NF-kB - this implies that the 
regulation of TIMP-3 expression by TNF as seen in prostate stromal cells BPH45 is not as 
a direct result of modulation of TNFINF-kB-mediated gene transcription, but could be 
using a different pathway such as MAPK. 
There are two TGF-t} response elements reported in the literature, with the following 
specific motifs: 
5'-ATCACGTGGCTGGCTGCATGCCCTGTGGCT-3 (Datto et aI., 1995) 
5' -T AGACAA TCACGTGGCTGGCTG-3' (Riccio et aI., 1992) 
None of the above motifs was found in the 5,OOObp region upstream of TIMP-3 gene, 
implying that the regulation of TIMP-3 expression by TGF-~ as seen in prostate stromal 
cells BPH45 and PCAF is due to other, as yet uncharacterised, response elements, or is an 
indirect result of modulation ofTGF-~-mediated gene transcription. 
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4.3 DISCUSSION 
This is the first study to look for modulation of TlMP-3 by DHT in prostate stromal and 
cancer cells. For the role of TlMP-3 in the progression of prostate cancer to be fully 
understood, it was important to investigate the alterations in expression of this 
metalloproteinase inhibitor since metalloproteinase expression has been shown to correlate 
with disease progression of prostate and other cancers (Mylona et aI., 2006, Vazquez-Ortiz 
et aI., 2005, Iwata et aI., 1995, Ellerbroek et aI., 1998, Islekel et aI., 2007, Riddick et aI., 
2005) 
TIMP-3 mRNA expression was significantly down regulated in LNCaP cells after 
treatment with DHT (Figure 4.4). The loss of TlMP-3 in LNCaP cells may be the reason 
for their known increase in their expression of metalloproteinases compared to normal 
prostate cells (Aalinkeel et aI., 2011). DHT -mediated prostate cancer cell proliferation and 
cell survival is androgen receptor (AR)-dependent (Arnold et aI., 2007, Wu et aI., 2007, 
Klus et aI., 1996). However, there was no reversal of the effect of DHT on TIMP-3 mRNA 
expression when LNCaP cells were treated with flutamide, an anti-androgen (see Figure 
4.4). This result is counter-intuitive as flutamide is clinically administered to patients with 
lymph node metastatic prostate cancer as an androgen receptor antagonist, the mode of 
action of which is inhibiting the binding of androgen to the AR (Eisenberger et aI., 1998, 
Greenway, 1998, Higano et aI., 1996). Although the down-regulation ofTIMP-3 mRNA by 
DHT was not verified by western blotting due to difficulty in detecting the TIMP-3 protein 
in LNCaP cells, the loss of the transcript may be contributing to the loss of TlMP activity 
observed with LNCaP protein extracts as discussed in the next chapter. 
The activity of the DHT used in these experiments was confirmed by analysing the 
expression of PSA (Figure 4.5) - a serine protease that is androgen-dependent and is used 
as a diagnostic marker for prostate cancer progression (Downing et aI., 2003). PSA mRNA 
was up-regulated by DHT in a dose-dependent manner in LNCaP cells, as previously 
demonstrated (Montgomery et aI., 1992). This result also confirms that the activity of the 
mutant androgen receptor in the LNCaP cells can be enhanced in-vitro by addition of DHT, 
and this in turn enhances the signalling cascade involved in transcription of androgen-
regulated genes such as PSA (see figure 4.1). Flutamide did not reduce PSA mRNA 
expression in LNCaP cells (see Figure 4.5) - again, this is counter-intuitive as PSA is 
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routinely measured in patients' serum for evidence of decreased levels as an indication of 
better prognosis of prostate cancer (Yu and Lai, 1998, Mettlin et al., 1994). 
Also, in this study, the expression of the small amount of TIMP-3 mRNA expressed by 
PC3 cells was completely eliminated after DHT treatment (Figure 4.6). This result was 
unexpected, as these cells do not possess an AR (Marcelli et aI., 1995) and should not 
respond to nuclear receptor activation by DHT ligand. The existence of alternative 
pathways by which these cancer cells are able to respond to androgen treatment has been 
investigated, one of which is transcriptional activation by a cell surface receptor (Kampa et 
al., 2002, Hatzoglou et al., 2005), where the inhibition of LNCaP cell growth by BSA-
coupled testosterone was demonstrated to occur via a membrane androgen receptor in-vitro 
and in nude mice. Their results suggest that the potentially pro-tumourigenic AR-
independent effect of DHT-mediated reduction in TIMP-3 mRNA expression in the 
prostate cancer cell line PC3 may be via a membrane receptor. As with LNCaP cells, there 
was no reversal of the effect of DHT on TIMP-3 mRNA expression when the PC3 cells 
were treated with flutamide (Figure 4.6). 
In the stromal cell lines BPH45, PCAF and WPMY -1, there was no statistical difference in 
TIMP-3 mRNA expression between treated and untreated cells nor between untreated, 
DHT-treated and DHT+flutamide-treated (see Figures 4.7, 4.8 and 4.9 respectively), 
implying that DHT-mediated regulation ofTIMP-3 may be cancer cell-specific. 
Elevated levels of TNF have been observed in the serum of prostate cancer patients 
(Nakashima et aI., 1998) and this may be as a result of recruitment and activation of 
macrophages by necrotic cells in the tumour mass in response to the hypoxic conditions. 
The macrophages subsequently elicit the production of pro-inflammatory cytokines in 
tumours. In this study, TIMP-3 expression was down regulated in prostate stromal cells 
BPH45 by TNF treatment, in a dose-dependent and statistically significant manner (see 
Figure 4.11). There were no significant changes in TIMP-3 mRNA expression after cell 
treatment in the cancer cells LNCaP and PC3 (see Figure 4.10), nor stromal cells WPMY-l 
and PCAF cells (see Figure 4.12). It is likely that that the stromal cells produce the bulk of 
the TIMP-3 in the tumour microenvironment, as has been reported previously (Mylona et 
al., 2006). A decrease in TIMP-3 expression in response to increased TNF expression may 
favour increased proteolytic activity and subsequent tumour metastasis and disease 
progression. The effect seen in BPH45 (Figure 4.11) is probably due to the fact that these 
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cells produce large amounts of TlMP-3 and they originate from a highly fibrotic condition 
that results in hyperplasia and hypoxia. 
Despite the name "tumour necrosis factor", the levels of circulating TNF required to 
antagonise tumour growth may be toxic to the patient (Balkwill, 1992) and could also act as 
an agonist under certain conditions (Szlosarek et aI., 2006). 
The expression of TIMP-3 was significantly up regulated by 5 ng/mL (50 nM) TGF-~ in 
the prostatic stromal cells PCAF (Figure 4.15) and at 50 pglmL (0.5 nM) and 5 ng/mL (50 
nM) concentrations in BPH45 (Figure 4.14). These results are in line with studies 
undertaken by Cross et al (Cross et aI., 2005) who showed a dose-dependent up-regulation 
of versican, a component of ECM, and TlMP-3 in the prostate stromal cells BPH 31, 33, 44 
and 45 after TGF-~ treatment. Increase in ECM deposition will subsequently lead to 
increase in sequestering of TlMP-3 and may alter the proteinase: inhibitor balance in favour 
of the inhibitor, TlMP-3. 
In-silica analysis of TlMP-3 revealed 10 putative AREs in the promoter region (Figure 
4.17). A key feature of the putative AREs obtained was the conserved C at position 5 of H-
Sl and conserved G at position 2 of H-S2. This occurrence is also seen with the PSA ARE 
but only the G is conserved in MVDP and hPARI AREs. This conserved G has been shown 
to be essential for the binding of androgen receptor to the DNA sequence for functionality 
of ARE and activation of gene transcription to occur (Fabre et aI., 1994, Claessens et aI., 
1989, Crossley et aI., 1992). The results from this project showed down-regulation of 
TlMP-3 transcript by 10nM DHT. The presence of putative AREs in the promoter region of 
this gene could mean that it is directly regulated by androgen. Although functional studies 
have not been carried out to validate these putative AREs as a result of limited time and 
resources, the presence of the conserved G at position 2 of the second half-site makes it 
more likely that these AREs are functional and may be regulating the transcription of 
TlMP-3. Also, the degree of sequence similarity of the putative AREs to the consensus 
ARE plus their conserved G further increases their chances of being actual AREs. 
There was no identified TNFINF-kB response elements or TGF-~ response elements in the 
promoter region of TlMP-3, suggesting that the regulation of TIMP-3 expression by TNF 
and TGF-~ occur via mechanisms other than those investigated. 
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In conclusion, the effects ofDHT, TNF and TGF-~ on the expression ofTIMP-3 in nonnal 
prostate, prostate stromal cells and prostate cancer cells clearly reflect two different 
patterns; a DHT -mediated cancer-cell specific modulation of TIMP-3 and a cytokine-
mediated stromal cell-specific modulation of TIMP-3. The results from this project are 
important in light of the fact that the tumour microenvironment consists of both cancer and 
stromal cells co-existing and co-migrating and an overall increase in TIMP-3 will favour 
reduced proteinase activity and subsequently may prevent metastasis of the tumour and vice 
versa. 
In the next chapter, the effect of artificial TIMP-3 modulation was investigated in order to 
understand if reduction of TIMP-3 expression has functional consequences for the cells 
indeed affect migration of the tumour as well as other biological functions. 
170 
CHAPTER 5: siRNA-MEDIATED DOWN-
REGULATION OF TIMP-3 FOR FUNCTIONAL 
STUDIES 
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5.1. INTRODUCTION 
The occurrence of short interfering double-stranded RNA molecules in living cells plays a 
vital role in the regulation of gene expression and control of biological processes. Short 
interfering RNAs (siRNAs) are small double-stranded molecules of about 25 nucleotides 
that have been important in the analyses of gene functions. They were first observed in 
plants as regulators of post-translational modifications and have since been widely studied 
in other organisms, including humans (Hamilton and Baulcombe, 1999). siRNAs act by 
binding to specific mRNA molecules in living cells and effectively blocking the 
transcription of the target gene and down-regulating the expression of the gene products. 
This involves a cascade of reactions that are important for successful gene regulation 
(Lipardi et aI., 200 I). 
The knowledge obtained from studying these natural dsRNA molecules has led to the 
production of commercially available siRNAs that have been designed to target different 
genes in humans (Gruber et aI., 2004, Davidson and Harper, 2005, Grayson et aI., 2006, 
Endsley et aI., 2008). These have now been widely used for mode of action as well as loss 
of function studies (Endsley et aI., 2008, Molhoek et aI., 20 II, Elbashir et aI., 2002) and for 
the study of the role(s) played by different genes in disease progression. For use in in-vitro 
studies, siRNA is introduced into the cells by the process of transfection. There are several 
ways to achieve effective transfection, some of which have already been discussed in 
Section 5.2. In the course ofthis study, several optimization experiments were carried out 
to obtain the best transfection efficiency with minimal toxicity to the cells. The best 
protocol was the calcium phosphate transfection method as described in Section 5.2.1. 
For this project, commercially available TIMP-3 silencing siRNA was purchased so as to 
silence the gene and study the changes in biological functions in prostate cells. The timp-3 
silencer siRNA (AM 16708, Ambion) targets the fifth ex on of timp-3 gene and was shown 
by the manufacturer to effectively down regulate timp-3. 
First, the gene silencer siRNA is introduced into the cells by the calcium phosphate 
transfection. It enters the cells and binds to an RNA-induced silencing complex (RISe), 
which contains active RNAse. One strand of the siRNA is incorporated into the complex 
and the other strand is degraded. With siRNA incorporated, the RISe is now active 
(aRISe) and able to recognize timp-3 mRNA, which it binds to and degrades via the action 
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of RNAse. aRISe dissociates from the destroyed mRNA and is available to bind to more 
mRNA for destruction, thereby continuing the silencing cycle (Elbashir et aI., 2001b, 
Elbashir et aI., 2002, Elbashir et aI., 2001a). Eventually, there is sufficient inhibition of 
gene transcription leading to inhibition of translation and protein expression. The cells can 
then be analysed for changes in biological behaviour and compared to control un-
transfected cells or cells that have been transfected with non-targetting siRNA. 
A schematic representation of the process of gene down regulation is shown in Figure 5.1. 
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Figure 5.1: Schematic Diagram of the mode of action of siRNA in gene silencing. siRNA 
is introduced into the cells (1) and this binds to RiSe (2), leading to its activation and 
subsequent cleavage of double stranded siRNA; one strand is completely degraded and the 
other is incorporated into the activated RiSe (aRIse) complex (3). aRiSe recognizes and 
binds to a specific mRNA and initiates the degradation activity of RNAse, leading to 
inhibition of transcription (4) and release of aRiSe (5), which is recycled back into the 
mRNA silencing cycle (6). 
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Several biological functions are important in the survival of a cell. There should be 
homeostasis between proliferation and apoptosis in tissues and this is made possible by the 
inherent characteristics of the individual cells that make up the tissue. In cancer, there is an 
altered balance in the tissue in favour of proliferation (Backus et aI., 2002, Evan and 
Vousden, 2001, Butler et aI., 1999) and this causes uncontrolled growth of the tissue and 
formation of a tumour. If malignant, the tumour grows in size and cancer epithelial cells 
break out of the primary site with the help of the increased proteinases present in them and 
those produced by the accompanying stromal cells (Wroblewski et aI., 2002, Itoh and 
Nagase, 2002, Cockett et aI., 1998). The cells intravasate into the blood stream and migrate 
to neighbouring regions and other organs of the body. Some studies have also shown that 
the cancer epithelial cells also co-migrate with some stromal fibroblast cells. Eventually, 
the cells extravasate and invade other organs and form a secondary site and co-habit with 
the cells in that part of the body (Vande Broek et aI., 2008, Wernert, 1997). Proteinases are 
thought to playa key role in the migratory and invasive potential of several cancers. An 
increase in their expression has been observed in several advanced stage cancers (Porter et 
aI., 2004, Molokwu et aI., 2010). Again, the balance between these proteinases and their 
inhibitors is altered in favour of the former. As TIMP-3 is a tissue inhibitor of many 
extracellular metalloproteinases, the effects of siRNA-mediated down regulation of this 
inhibitor on biological functions such as proliferation, cell survival and apoptosis, 
migration, invasion and proteinase inhibition were investigated. In previous experiments in 
Chapter 3, it was observed that the prostate stromal cells produce very high levels ofTIMP-
3 compared to prostate cancer cells and that this expression was reproducible across 3 
different types of stromal cells. The effect of down regulation of TIMP-3 in the prostate 
cancer-associated fibroblasts (PCAF) and compared the results to those obtained from non-
prostate cancer-associated fibroblasts (WPMY -1) was therefore investigated. As the 
availability of BPH stromal cells was limited, the effect of down regulation of TIMP-3 
could not be investigated in these cells, even though they had previously been available and 
had been used for previous experiments (Chapters 3 and 4). The experiments set up to 
investigate any changes in biological functions post-TIMP-3 down-regulation included: 
proliferation assay, apoptosis assay, migration assay, invasion assay and MMP inhibition 
assay. 
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5.2. RESULTS 
5.2.1 Optimisation of Transfection 
There were three methods of reverse transfection employed in this study, as described in 
Section 2.13. These were carried out in order to determine the optimal conditions of siRNA 
transfection that gave the best gene knockdown. The methods include: electroporation, 
lipid-based Dharmafect-2 and calcium phosphate transfection methods. With all three, there 
was a degree of transfection complex-mediated loss of gene transcript compared to 
untransfected control (see Figure 5.2 and 5.3) in both PCAF and WPMY-l cells. 
The calcium phosphate transfection gave the best results, with <20% toxicity of the 
transfection complex and so this was used for subsequent transfection experiments. In 
PCAF (Figure 5.2) and WPMY-l (Figure 5.3) cells, there was -19% knockdown oftimp-3 
mRNA with the calcium phosphate transcription complex alone and - 85-89% knockdown 
of timp-3 mRNA with timp-3 targeted siRNA (n=4). The net knockdown, taking the effect 
of transfection complex into consideration, was therefore -70% - this level of knockdown 
was still sufficient for protein depletion in the ECM of cells, as measured by western 
blotting (see Figures 5.4 and 5.5). The electroporation and Dharmafect-2 transfection 
transfection methods gave unfavourable loss of gene transcript with transfection complex 
alone (between 35 and 45% loss) in both cell lines so were not pursued further. 
The data sets for these optimisation experiments were n=2 (Figures 5.2 and 5.3) so it was 
not possible to do reliable statistical analyses on the results. However, for the subsequent 
experiments, the data sets were at least n=3 (Figures 5.4 onwards) and statistical analyses 
were carried out. 
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Figure 5.2: Transfection of PCAF cells using different transfection method. 
100,000 cells were reverse-transJected as described in Section 2.13 and the Iran cription 
complex was maintained in the cells Jor 24 hours after which the medium was changed to 
antibiotic-free, serum-containing media for another 3 days. The cells were then uplifted 
from the ECM, RNA extracted, eDNA prepared and mRNA produced via qP R a 
described in Section 2.6 - 2.9. (A) There was - 40% down-regulation oj timp-3 mRNA with 
the transJection complex alone (Mock) and this remained unchanged with the non-targeting 
siRNA (NTsiRNA). There was - 70% down-regulation oj timp-3 mRNA with timp-3 
targeting silencer siRNA (timp-3 ssiRNA) (n =2). (B) There was - 25% down-regulation oj 
timp-3 mRNA with the transJection complex alone (Mock) and thi remained unchanged 
with the non-targeting siRNA (NTsiRNA). There was - 70% down-regulation oj timp-3 
mRNA with timp-3 targeting silencer siRNA (timp-3 ssiRNA) (n =2) (C) There was - 19% 
down-regulation oj timp-3 mRNA with the transJection complex alone (Mo k) and thi 
remained unchanged with the non-targeting siRNA (NTsiRNA). There wa - 5% down-
regulation oftimp-3 mRNA with timp-3 targeting silencer siRNA (timp-3 iRNA) (11=2). 
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Figure 5.3: Transfection of WPMY-l cells using different transfection methods. 
(A) There wa - 45% down-regulation of timp-3 mRNA with the transfection complex alone 
(Mock) and this remained unchanged with the non-targeting siRNA (NTsiRNA). There was 
- 70% down-regulation of timp-3 mRNA with timp-3 targeting silencer iRNA (timp-3 
ssiRNA) (n=2). (B) There was - 30% down-regulation oftimp-3 mRNA with the transfection 
complex alone (Mock) and this remained unchanged with the non-targeting siRNA 
(NTsiRNA). There was - 70% down-regulation of timp-3 mRNA with timp-3 targeting 
silencer siRNA (timp-3 ssiRNA) (n=2) (C) There wa -20% down-regulation of timp-3 
mRNA with the transJection complex alone (Mock) and this remained unchanged with the 
non-targeting siRNA (NTsiRNA). There was - 89% down-regulation oj timp-3 mRNA with 
timp-3 targeting silencer iRNA (timp-3 ssiRNA) (n=2). 
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5.2.2 Down regulation of TlMP-3 in Prostate Cells 
PCAF and WPMY - I cells were grown to - 80% confluence and afterward harve ted for 
reverse transfection using the calcium phosphate method. The tran fection complex was 
maintained in the cells for 4 days to allow for better ilencing effect and afterward the 
cells were uplifted from the ECM and counted. The ECM wa harve ted a de cribed in 
Section 2.10 and subjected to SDS-PAGE and western blotting. RNA wa extracted from 
the cells and subjected to rever e tran cripta e PCR for cD A production and qP R for 
quantification of timp-3 mRNA. The control for the e et of experiment were the cell 
transfected with the non-targetting siRNA ( T iRNA) and the te t experiment were the 
cells transfected with limp-3 silencer siRNA (timp-3 iRNA). 
Duplicate experiment were al 0 set up in order to monitor change in TIMP-3 expre ion 
by immunocytochemistry as previously de cribed in Section 2. I 7. The cell were grown on 
glass slides after reverse transfection for 4 days and formaldehyde-fixed onto the lide 
prior to staining with primary mouse anti-TIMP-3 antibody and counter tained with 
fluorescent anti-mouse antibody. The fixed cells were also counter- tained with the DAPl 
nuclear stain to differentiate nuclear from cytopla mic and ECM taining. 
The results from the experiments showed a ignificant down regulation of timp-3 mRNA in 
PCAF cells (n=4, p=0.0286 Mann-Whitney) and in WPMY - I cell (n-, =0.0294 Mann-
Whitney) transfected with timp-3 ssiRNA when compared to cell tran fect d with 
NTsiRNA. These results were also corroborated at the protein level by we tern blotting of 
PCAF and WPMY-I ECM extracts (see Figures 5.4 and 5.5 re pectively and by 
immunostaining of duplicate PCAF and WPMY-I cell (ee igure 5.6 and 5.7 
respectively). The expre ion of TIMP-3 in immuno tained cell wa cytopla mic to a 
small extent and largely extracellular, supporting it expre ion predominantly in the 
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Figure 5.4: siRNA Silencing oftimp-3 in PCAF cells. 
23kD 
100,000 cells were reverse-transJected as described in Section 2.13 and the transcription 
complex was maintained in the cells for 24 hours after which the medium was changed to 
antibiotic-free, serum-containing media for another 3 days. The cells were then uplifted 
from the ECM, RNA extracted, eDNA prepared and mRNA produced via qPCR as 
described in Section 2.6 - 2.9. (a) There was significant down regulation oftimp-3 mRNA 
in timp-3 siRNA transfected PCAF cells compared to NTsiRNA transfected (control) cells 
(n=4, p=0.0286, Mann-Whitney). 
(b) ECM was extracted as de cribed in Section 2.10 and 100, 000 cells' worth of ECM was 
immuno-blotted for T1MP-3 as described in Section 2.11. 5 nM of recombinant human 
TIMP-3 was also loaded as contro/. The western blots were analysed by densitometry as 
de cribed in Section 2.12. There was a loss oj TIMP-3 protein in the ECM after TIMP-3 
down regulation in PCAF cells (see red arrow at the 23 kD area) when compared to ECM 
from NTsiRNA transfected control cells. MWTS = Molecular weight standards, rhT3 = 
recombinant human TIMP-3, TS = ECM from Non-targetting siRNA transfected cells, 
T3SS = ECMfrom timp-3 silencer siRNA transfected cells (n=3) 
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Figure 5.5: siRNA Silencing oftimp-3 in WPMY-) cell . 
(a) There was significant down regulation of timp-3 mRNA in timp-3 iR 'A Iran ifecled 
WPMY-J cells compared 10 NTsiRNA transfecled (control) cells (n =4, p =O.0294, Mann-
Whitney), n=3 
(b) There was a loss of TlMP-3 protein in the ECM after TlMP-3 down regulation in 
WPMY- J cells (see red arrow at the 23 kD area) when compared 10 ECM from T. iRNA 
transfected control cells. MWTS = Molecular weighl tandard, NTS = ECM from on-
targetting siRNA transf ected cells, T3SS = ECM f rom timp-3 ilen er iRNA Iran rfi. led 
cells. n=3 
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Figure 5.6: Immunocytochemistry and Imaging of Transfected PCAF Cells. 
The above is a representative example of results from 4 experimental repeats. 25,000 cells 
were reverse Iransfected as described in Section 2.13 and seeded into chambers on a glass 
slide. The transcription complex was maintained in the cells for 24 hours after which the 
media was changed 10 anlibiotic-/ree, serum-containing media for another 3 days. 
Afterwards, the cells were subjected to immunocytochemistry as described in Section 2.17. 
The cells were incubated with mouse anti-TlMP-3 antibody for 24 hours and green 
fluorescent anti-mouse secondary antibody for 1 hour. The cells were imaged using a 
fluorescent microscope at lOX objective. There was loss of the green fluorescence in timp-3 
ssiRNA transfected PCAF cells compared to the control NTsiRNA transfected cells as 
shown in the bottom 4 images. Scale bar = 100 um. 
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Figure 5.7: Immunocy tochemistry and Imaging of Transf ected WPMY-I Cell . 
The above is a representative example of results from 4 experimental repeat . 25,000 cell 
were reverse transfected as described in Section 2.13 and seeded into chamber. on a gla 
slide. The transcription complex was maintained in the cells for 24 hours after which the 
media was changed to antibiotic-free, serum-containing media for another 3 day . 
Afterwards, the cells were subjected to immunocytochemi try as described in Section 2.17. 
The cells were incubated with mouse anti-T1MP-3 antibody for 24 hour. and green 
fluorescent anti-mouse secondary antibody for 1 hour. The cell were imaged using a 
fluorescent microscope at lOX objective. There wa a 10 s of the green fluore cence in 
timp-3 ssiRNA transfected WPMY-lcells compared to the control NT. iRNA tran ifecled 
cells as hown in the bottom 4 images. Scale bar = 100 um. 
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The proliferation assay was carried out using the coulter counter method as described in 
Section 2.16.1. The cells were counted after being uplifted from the ECM using the coulter 
counter 4 days post transfection. There was no significant difference in the number of 
NTsiRNA and timp-3 ssiRNA transfected PCAF and WPMY-I cells (see Figure 5.8). 
The apoptosis assay was carried out using the Annexin-v-FITC/PI method as discussed in 
Section 2.16.4. The cells, 48 hours post-transfection were stained with Annexin-V IFlTC to 
detect apoptotic cells and counter-stained with PI to exclude cells that were necrotic. The 
results from this project showed a significant increase in apoptosis in PCAF cells after 
down regulation of TlMP-3 (n=3, p=0.0265 Mann-Whitney) compared to cells that had 
been transfected with NTsiRNA (see Figure 5.9). This increase in cellular apoptosis was 
not detected in timp-3 ssiRNA-transfected WPMY-l cells (see Figure 5.10). 
The migration assay was carried out using the 3D trans-well Boyden chamber method 
without Matrigel as described in Section 2.15.2. After transfection with timp-3 ssiRNA, the 
cells were seeded onto the upper compartment of the Boyden chamber and were allowed to 
migrate towards the chemo-attractant (complete medium with serum) in the lower chamber. 
The number of cells that migrated was counted 48 hours post-seeding via cellular staining 
with crystal violet. These results showed significantly lower migration of timp-3 down-
regulated PCAF cells when compared to the control NTsiRNA cells (n=4, p=0.0294, Mann-
Whitney) (see Figure 5.11). The opposite result was observed in timp-3 down regulated 
WPMY -1 cells where a significant increase in the migration potential was seen in 
comparison to the control cells (n=4, p=0.0294, Mann-Whitney) (see Figure 5.12). It is 
worth mentioning, at this point, that the PCAF cells are cancer-associated fibroblasts and 
the WPMY -1 cells are non-cancer associated fibroblasts. 
The invasion assay was carried out using the modified Boyden chamber method as 
described in Section 2.15.3. - this is similar to the migration assay as above but the 
membrane dividing the upper and the lower compartments of the Boyden chamber is 
layered with growth factor-reduced Matrigel. This system therefore artificially mimics the 
barrier that cells will come across when invading tissues by crossing a basement membrane. 
There was significantly lower invasion of timp-3 down-regulated PCAF cells when 
compared to the control cells (n=4, p= 0.0265, Mann-Whitney) (see Figure 5.13). Again, 
the opposite result was observed in timp-3 down-regulated WPMY -1 cells where a 
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significant increase in the invasive potential was seen in comparison to the control cells 
(n=4, p=0.0265, Mann-Whitney) (see Figure 5.14). 
The proteinase inhibition assay was carried out as described in Section 2.16. The ECM was 
extracted from transfected cells and analysed for its MMP-inhibitory properties. The rate of 
MMP inhibition was measured using the Flusys Software, where a deviation from a ViN 0 
of <1 was regarded as inhibition of MMP activity. The NOLB buffer used had little or no 
MMP inhibitory property (see Figure 5.15). As a positive control, 5 nM rhTIMP-3 was also 
made up in NOLB and tested for its activity on MMP and inhibited MMP-2 by 79% (see 
Figure 5.15). ECM extracts from PCAF and WPMY -I cells inhibited MMP-2, by 48% and 
45%. When the timp-3 mRNA was knocked down, these values were reduced to 17% and 
20% respectively. The results from PCAF cells are shown in Figure 5.16. 
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(a) 
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WPMy.1 CEllS" PAYS PosT .TBANSfECTION 
Figure 5.8: Coulter Counter Proliferation Assay of Transfected PCAF and WPMY-l 
cell. 100,000 cells were reverse-transfected as described in Section 2.13 and the 
tran cription complex was maintained in the cells for 24 hours after which the media was 
changed to antibiotic-free, serum-containing media for another 3 days. Afterwards, the 
cell were uplifted from the ECM and counted as described in Section 2.15.1. The counts 
from timp-3 ssiRNA transfected cells were normalized to counts from NTsiRNA transfected 
cells. Results showed no significant proliferative difference between timp-3 ssiRNA 
transfected cells when compared to control for both PCAF and WPMY-1 cells (a) and (b) 
respectively. 
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Figure 5.9: Apoptosis Assay of Transf ected PCA F Cell. 
(b) 
100,000 cells were reverse-transfected as described in Section 2.13 and the Iran cription 
complex was maintained in the cells for 24 hours after which the media was changed to 
antibiotic-free, serum-containing media for another 3 days. Afterward, the cell were 
uplifted from the ECM and stained with Annexin-V-FITC and Propidium Iodide (PI) Jor 
FACS analysis as described in Section 2.15.4. (a) The count from timp-3 siRNA 
transJected cells were normalized to counts from T. iRNA tran ifecled cell . There wa a 
significant increase in the number of apoptolic PCAF cell after Iran ifec/ion with timp-3 
siRNA relative to NTsiRNA control cells (n =3, p=0.0265, Mann-Whitney) . 
(b) A shift to the right side of the graph repre ents an increase in apoptotic Annexin- V-
FITC positive cells while a shift to the lop oj the graph repre enls an increa e in necrotic 
PI-positive cells. In both TsiRNA and timp-3ssiRNA transJecled PCAF cell , a proportion 
of the cells displayed a necrotic profile (top left and right quadrant) bUI in the laller, there 
was a shift of non-apoptotic (bottom left) towards apoptosi (bot/om right - indicated b 
blue arrow). This population of cells were analysed and count graphically repre ented a 
in (a). n=3 
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Figure 5.10: Apoptosis Assay of Transfected WPMY-1 Cells. 
(a) There was no significant level of apoptosis in NTsiRNA and timp-3ssiRNA-transfected 
WPMY-l cells. This is also indicated by the minimal number of counts in the bottom right 
quadrant (blue arrow) of timp-3 ssiRNA transfected WPMY- l cells when compared to 
TsiRNA transfected control cells 
(b) In both NTsiRNA and timp-3ssiRNA transfected WPMY-1 cells, there were minimal 
necrotic cells (top left and right quadrant) but in the latter, there was a slight but non-
statistically significant shift of non-apoptotic (bottom left) towards apoptosis (bottom right 
- indicated by blue arrow). This population of cells were analysed and counts graphically 
repre en ted in (a). n=3 
187 
(a) (b) 
PCAf NTslRNA 
~ I 
II: • 
• ~ 
z 
e 
~ I 
~ 
i 
2 
~ 
z 
j 
j 
u • 
~/ 
Figure 5.11: Migration Assay of Transf ected PCAF Cell. 
After reverse transfection of the cells for 4 days, the cell were uplifted and ozlnted. 25,000 
transfected cells were seeded onto the upper compartment of the Boyden hamber, as 
described in Section 2.15.2. The migrated cells were tained 4 hour po f- eeding. The 
counts from timp-3 ssiRNA transfected cell were normalized to count from T. iRNA 
transfected cells. There was a significant decrea e in the number oj migrated P 'AF ell 
after transfection with timp-3 siRNA relative to T. iRNA control cell (n =4, p=0.0294, 
Mann-Whitney) - this is represented graphically in (a) and pictorially in (b) n=3 
(a) 
MIGRADON ASSAY Of Ijmo:3 '!RNA·IBANSFECTEP 
WPMY·l CELLS 4 PAYS POST.IBANSFECDON 
(b) 
WPMY·1 NTslRNA 
WPMY·1 tlmp-3sslRNA 
Figure 5.12: Migration Assay of Transfected WPMY-l Cells. 
After rever. e transfection of the cells for 4 days, the cells were uplifted and counted. 25,000 
transfected cell were seeded onto the upper compartment of the Boyden chamber, as 
de cribed in Section 2.15.2. The migrated cells were stained 48 hours post-seeding. The 
counts from timp-3 siRNA transfected cells were normalized to counts from NTsiRNA 
Iran ifected cells. Re ult hawed a significant increase in the number of migrated WPMY-1 
cell after tran ifection ... ·dth timp-3 ssiRNA relative to NTsiRNA control cells (n=4, 
p =0.0294, Mann-Whitney) - this is represented graphically in (a) and pictorially in (b). 
n=3 
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Figure 5.13: Invasion Assay of Transfected PCAF Cells. 
PCAf-1 NTslBNA 
PCAf rlmp-3ss lBNA 
After reverse transfection of the cells for 4 days, the cells were uplifted and counted. 25,000 
transfected cells were seeded onto the upper compartment of the 8 0 den hamber, a 
described in Section 2.15.3. The cells that passed through the mat rigel were tained 4 
hours post-seeding. The counts from timp-3 ssiRNA transf ected cell were normalized to 
counts from NTsiRNA transf ected cells. Re ult howed a significant decrease in the 
number of invasive PCAF cells after transfection with timp-3 ssiRNA relative to T. iRNA 
control cells (n =4, p =0.0265, Mann-Whitney) - this i represented graphicall in (a) and 
pictorially in (b) n=3 
(a) 
IN'IASION AssAY OF CimP:3 .IRNA·TRANSFECTED 
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(b) 
WPMY·1 NTslRNA 
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Figure 5.14: Invasion Assay of Transfected WPMY-1 Cells. 
After reverse transfection of the cells for 4 days, the cells were uplifted and counted. 25,000 
Iran ifected cells were seeded onto the upper compartment of the Boyden chamber, as 
described in Section 2.15.3. The cells that passed through the matrigel were stained 48 
hours post-seeding. The counts from timp-3 ssiRNA transfected cells were normalized to 
counts from NTsiRNA transfected cells. Results showed a significant increase in the 
number of invasive WPMY-1 cells after transfection with timp-3 ssiRNA relative to 
TsiRNA control cells (n =4, p =0.0265, Mann-Whitney) - this is represented graphically in 
(a) and pictorially in (b) n=3 
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Figure 5.15: Control Experiment/or the Protein a e Inhibition A ay. 
3 uM o/the non-denaturing lysis buffer (, DLB) was added to the cuvelte at von the graph 
and had minimal effect on the activity of MMP-2 
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Figure 5.16: Proteinase Inhibition Assay of ECM from Transfected Stromal Cells. 
Cell were re\'er e transfected and after 4 days, ECM was extracted and subjected to the 
proteinase inhibition assay as described in Section 2.16. 5 nM of recombinant human 
TiMP-3 (rhTiMP-3)(A) or 100,000 cells' worth of ECM was added to the substrate-MMP-2 
mixture and the change in rate of sub trate breakdown measured (V}) . A Vi Vo value of 
0.21 wa achieved by rhTIMP-3, meaning that there was 79% inhibition of MMP-2 activity. 
A Vi/ Va \'Olue of 0.52 with ECM of PCAF transfected with control NTsiRNA., implying a 
4 1:10 inhibition of MMP-2 activity. With ECM from the timp-3 ssiRNA transfected PCAF 
and WPMY-1 cells, the V/Vo was 0.83, implying 17% inhibition. 
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5.3. DISCUSSION 
To my knowledge, this is the first investigation of the role of TIMP-3 in biological 
functions in prostate cells by using siRNA to down-regulate the expression of TIMP-3. It 
enhances the body of knowledge available to improve on therapy by focusing on other 
factors apart from the known 'culprits' responsible for poor prognosis of prostate cancer. It 
is also the first study to look closer into the expression patterns and role(s) played by 
prostate stromal cells in the progression of prostate cancer. TIMP-3 is an endogenous tissue 
inhibitor of many metalloproteinases involved in the progression of many cancers, and the 
study of its pattern of expression and modulation would greatly enhance our understanding 
and management. 
In this project, siRNA-mediated down regulation of timp-3 in cancer-associated PCAF and 
non-cancer associated WPMY -1 prostate stromal cells was carried out successfully using 
the calcium phosphate reverse transfection method (Figure 5.2 and 5.3), with significant 
down-regulation of timp-3 gene transcription and protein expression (Figure 5.4 and 5.5) 
achieved 4 days post-transfection. These results were also corroborated by 
immunocytochemistry (Figure 5.6 and 5.7). Although the expression of timp-3 mRNA was 
successfully down-regulated in prostate cancer cells LNCaP at the first trial (data not 
shown as n= 1), it was decided not to carry out further experiments with these down-
regulated cells as only about 50% down regulation was achieved and the LNCaP cells do 
not produce a lot ofTIMP-3 in the first instance, as shown in Figure 3.8. The LNCaP cells 
also do not lay down much ECM and TIMP-3 has been undetected in the little ECM that 
they make. PC3 cells produce negligible timp-3 mRNA and protein as well, so it was not 
feasible to use them in these sets of experiments. Instead, the readily available PCAF and 
WPMY -1 prostate stromal cells were studied, in light of the literature at the time that 
suggested a tumour-stroma migration and interaction, and in light of previous results from 
this project showing a decrease in the expression of TIMP-3 in both of the prostate stromal 
cells PCAF and WPMY -1 after co-culturing with prostate cancer cells LNCaP (see Figures 
3.22 and 3.23). It was important to understand the implication of the loss of this 
endogenous proteinase inhibitor on certain physiological processes in the stromal cells that 
were the major producers of this inhibitor. 
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Proliferation is an important biological occurrence in all living cells and a major factor in 
the initiation and progression of all cancers. Cells have inherent mechanisms by which they 
regulate their rate of growth and an outcome of one of several possible alterations in these 
mechanisms can cause uncontrolled proliferation of epithelial cells, leading to the first 
stage of cancer e.g. in prostate cancer, the cells develop androgen independence via 
mutations in their androgen receptor, leading to uncontrolled cell growth (Kabalin et aI., 
1995, Morote et aI., 1997). These cells co-habit with surrounding stromal cells and may 
influence their behaviour and their protein expression profile (Olumi et aI., 1999, Shimao et 
aI., 1999, Stuelten et aI., 2005, Kaminski et aI., 2006, Pal and et aI., 2009). Therefore, I 
wanted to investigate whether TIMP-3 had any direct role to play in the rate of growth of 
the prostate stromal cells, especially as they produce more TIMP-3 than prostate cancer 
cells. The results of the proliferation assay showed no significant difference in the rate of 
growth of cells with down regulated TIMP-3 expression when compared to control cells. 
Although there was always a lower number of a PCAF cell after TIMP-3 down regulation 
in comparison to the control cells, the numbers were never statistically different (see Figure 
5.8). This implied that the reduction of available TIMP-3 in the tumour microenvironment 
might not affect the total number of cells present. This is somewhat contrary to other results 
in the literature where an over-expression of TIMP-3 in tumour cells led to a reduction in 
overall tumour cell size (Vizoso et aI., 2007) Although this was an in vivo study, one would 
expect that under-expression would give the opposite result i.e. increase in the rate of 
growth of cells with lower levels ofTIMP-3. It must be borne in mind that some cells also 
have compensatory mechanisms whereby the loss of a pathway partner/protein could lead 
to the production of a substitute or increased production of a co-pathway partner, such that 
the absence or reduction of the protein does not manifest in an early alteration in 
physiological processes. As the transfections set up in this project were transient, it was not 
possible to investigate changes in the rate of proliferation outside of 4 days post 
transfection. 
Apoptosis is also a regulated process necessary for the balanced homeostasis of cells in an 
organ. Alterations in the mechanism of regulation of cell death may result in a 'switch off' 
of cell death and 'switch on' of unchecked cell survival. The results obtained in this project 
showed a significant increase in the number of apoptotic PCAF cells after down regulation 
of TIMP-3 (See Figure 5.9). This implied that the loss of TIMP-3 sensitised the cells and 
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initiated apoptosis in these cells. This result is in line with studies that showed an increase 
in the rate of cellular apoptosis in the epithelial mammary gland of TIMP-3-deficient mice 
(Fata et aI., 2001), highlighting its role as an important survival factor, albeit in mouse 
cells. The results from this project are contrary to other studies that show TIMP-3 as a pro-
apoptotic protein in several cancers such as fibro sarcoma, lung cancer (Baker et aI., 1999, 
Finan et aI., 2006, Lee et aI., 2008). However, cancer cells are mostly epithelial (excluding 
fibrosarcomas) and this assay involved stromal cells - this may account for the counter-
intuitive results obtained with these cells. It could also be that by virtue of the previous 
proximity of these cells to prostate cancer cells, they may no longer be able to efficiently 
regulate their cell cycle balance, leading to the increase in apoptotic cells observed. 
There was no significant apoptosis in the WPMY-I cells after down regulation ofTIMP-3 
when compared to the control cells (see Figure 5.10). As these cells are not malignant, the 
compensatory mechanisms that regulate the cell cycle balance may still be intact, allowing 
for recovery of the imbalance caused as a result of the loss ofTIMP-3. 
Migration and invasion are important processes observed in advanced cancers where the 
cancer cells detach from the primary tumour, are released into the blood stream and migrate 
to neighbouring parts of the primary site as well as to distal organs. It is therefore important 
to understand the factors that mediate these processes. When cancer cells migrate, they 
carry along with them stromal fibroblast cells from the primary site and these stromal 
fibroblasts enable the cancer cells to invade and 'home' in their new secondary site 
(Shimao et aI., 1999, Eck et aI., 2009). With this in mind, I set out to investigate the 
changes in migratory and invasive potential of TIMP-3 down regulated stromal cells. The 
results from this project showed a significant down regulation of both migration and 
invasive potentials of PCAF cells when compared to their control cells (see Figs. 5.11 and 
5.13 respectively) and, on the opposite hand, a significant increase in the migration and 
invasive potentials in WPMY-I cells (see Figs. 5.12 and 5.14 respectively). There is not 
much data available in literature on expression pattern of TIMP-3 in prostate stromal cells 
grown in vitro and while the results from the WPMY -1 cells in this project are in line with 
other studies that show a decrease in the invasive potential of cancer cells that were over-
expressing TIMP-3 (Miyazaki et aI., 2004, Baker et aI., 1999), the results from the PCAF 
cells are contrary to literature. In one study where thyroid tumour cells were subjected to 
TIMP-3 silencing, an increase was observed in the migration and invasive potential of 
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NIM 1 thyroid carcinoma cell line when compared to control cells (Anania et al., 2011) -
this is in line with the increase in invasive potential seen in TIMP-3 down regulated 
WPMY -1 cells. The reason for the contrary behaviour of the PCAF cells upon down 
regulation of TIMP-3 remains unclear - again it may be that their previous proximity to 
cancer cells has altered their mechanism of maintenance of the proteinase-inhibitor balance. 
A proteinase inhibition assay was carried out as previously described (Knight et al., 1992). 
Due to the age of the Flusys machine and lack of availability of reagents and printing 
facilities to connect to the machine, the amount of data collected was small, compared to 
the other assays in this project. Because similar results were obtained from ECM of PCAF 
and WPMY -1 cells, only the PCAF experiment data are shown, as these were the only ones 
that could be printed from the machine. These have been scanned and reported in this 
Chapter. As shown, there was no interference of the buffer on the assay, indicating that the 
results obtained from the protein extracts were real effects of the contents of the extracts 
see Figure 5.15). Commercial recombinant human TIMP-3 was also able to show an 
inhibitory effect on the MMP-2 activity on the QF substrate, up to approximately 80% 
inhibition. The ECM extracts from the control cells transfected with NTsiRNA showed a 
total MMP-2 inhibitory effect of approximately 50% while the ECM from the TIMP-3 
down regulated cells showed only approximately 20% inhibition of total MMP-2 activity 
(see Figure 5.16). This implied that the reduction of the amount of TIMP-3 present in the 
ECM of the stromal cells after TIMP-3 down regulation resulted in an overall loss of 
inhibition of MMP-2 activity. TIMP-3 is strongly sequestered in the ECM (Langton et al., 
1998, Leco et al., 1994, Anand-Apte et al., 1996) and so it can be inferred that the loss of 
MMP-2 activity seen in this assay may be as a result of the siRNA-mediated reduction in 
TIMP-3 levels in the ECM of transfected cells. This is in line with the study where an 
increase in the levels of TIMP present in conditioned medium from prostate stromal cells 
resulted in an increase in MMP inhibition (Cross et al., 2005). 
In conclusion, the importance of TIMP-3 in the tumour microenvironment is key to 
elucidating better diagnosis and treatment or management of prostate cancer. The stromal 
cells that produce the bulk of the available TIMP-3 that is in the ECM may play a role in 
progression of prostate cancer. The complexity of events within a tumour makes it difficult 
to pin point one determining factor for tumour development, migration and invasion out of 
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the primary site. Direct and indirect feedback mechanisms are all at work in ensuring 
continuity of cancer progression and TIMP-3 has proven a worthy protein to be studied as a 
potential anti-tumourigenic agent and a candidate for new therapy. 
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CHAPTER 6: GENERAL CONCLUSIONS AND 
LIMITATIONS OF RESEARCH 
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This research has focused primarily on investigating the role(s) of tissue inhibitor of 
metalloproteinases-3 (TIMP-3) in prostate cancer. The first sets of experiments were 
carried out in order to investigate the expression levels of TIMP-3 in prostate cells, both at 
the transcript and protein levels. The first port of call was to compare the TIMP-3 levels in 
available androgen-dependent LNCaP and androgen-independent PC3 prostate cancer cell 
lines as well as benign prostatic hyperplasia stromal cell line BPH45 as a control. As a 
result of emerging literature at the time, which showed higher expression of TIMP-3 in 
stromal compartments of several cancers, it was important to investigate whether TIMP-3 
was expressed in normal stromal cells as an additional control. Therefore, a transformed 
prostate stromal cell line, WPMY -I was purchased from A TCC and profiled for expression 
of stromal markers in order to confirm its reported stromal fibroblast characteristics 
(Webber et aI., 1999). True to the literature, WPMY -I cells expressed vimentin, which is a 
marker for fibroblasts (Webber et aI., 1999) (see Appendix). At the time of the project, our 
collaborator at the University of Sheffield, Dr. Colby Eaton, kindly donated some stromal 
fibroblast cells isolated from primary prostate tissue, designated as PCAF cells so in total, 
there were 3 stromal cell lines and 2 cancer cell lines available for comparison. 
Our collaborators also kindly donated prostate tissue samples comprising normal prostate 
tissues, BPH tissue and primary prostate cancer tissues for analyses and so this enabled 
immunohistochemical analyses to be carried out alongside the immunocytochemical 
analyses using the cell lines available. 
The first set of experiments involved analysis of modulating factors on the expression of 
TIMP-3. The effect of androgen, TNF and TGF-f3 on the levels of TIMP-3 in all the cell 
lines was analysed. Also, siRNA-mediated down-regulation of TIMP-3 was employed in 
order to study the changes in migration and invasive potential of the cells and to investigate 
the effect of loss of this inhibitor on proliferation and apoptotic processes in the cells. The 
primary function of TIMP-3 in tissues is the inhibition of metalloproteinases and so it was 
also important to study the effects of siRNA-mediated down-regulation of TIMP-3 on its 
proteinase inhibitory characteristics. This was carried out using a previously described 
method (Knight et aI., 1992). 
Part of the tissue samples donated included tissue microarray samples collected from 
patients with different Gleason scores. This proved very useful in experiments aimed at 
correlating the expression of TIMP-3 with tissue Gleason grading and progression of 
prostate cancer. There were also other tissue samples available - these were obtained from 
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liver and spleen samples and were very useful as control tissues for the 
immunohistochemical analyses of the prostate tissues. 
There were limitations to this project and these are discussed later on in this Chapter. 
6.1 TIMP-3 EXPRESSION IS HIGHER IN PROSTATE STROMAL CELLS 
THAN IN PROSTATE CANCER CELLS 
To my knowledge, this is the first report showing the expression of TIMP-3 in the prostate 
stromal cells WPMY -1 and the first report to compare the levels of TIMP-3 in this cell line 
to other prostate cell lines in vitro (see Section 3.2.2). 
The results obtained in this study showed significantly greater TIMP-3 mRNA expression 
in prostatic stromal cells, PCAF, WPMY -1 and BPH45, relative to LNCaP and PC3 cells 
(Figure 3.4). There was also higher expression of TIMP-3 mRNA in the BPH45 stromal 
cell line compared to the normal stromal cells WPMY -1 and the cancer associated stromal 
cells PCAF. This may be as a result of the fibromatous characteristics of BPH which results 
in an overgrowth of the stromal compartment of the prostate (Di Silverio et aI., 1993) 
suggesting differentiation of the stromal fibroblasts to myofibroblasts (Lovelock et aI., 
2005, Tuxhorn et aI., 2002) thereby leading to concomitant increase in the total amount of 
TIMP-3 sequestered in the BPH cell line. Studies by Mylona et al (Mylona et aI., 2006) 
have showed that TIMP-3 is expressed abundantly in the stromal cells adjacent to the breast 
tumour. Also, studies carried out by Cross et al (Cross et aI., 2005) demonstrated increased 
expression of TIMP-3 mRNA in stromal cells BPH3I, -33, -44 and -45, relative to the 
cancer cells PC3 and LNCaP. As shown in this study, the expression of TIMP-3 in the 
androgen-dependent prostate cancer cell line LNCaP was IOO-fold higher than expression 
in androgen-independent prostate cancer cell line PC3 (see Figure 3.4) This suggests that 
expression of TIMP-3 may inversely relate to staging of prostate cancer as the LNCaP cells 
were originally obtained from a patient with local metastasis and the PC3 cells from a 
patient with distant metastasis (Sobel and Sadar, 2005b). Also corroborating the results 
from this project, when TIMP-3 was cloned and transfected into the metastatic breast 
cancer cell line MDA-MB-453, there was a reduction in its metastatic potential, in 
comparison to untransfected cells (Han et aI., 2004). The results from this project showing 
higher expression ofTIMP-3 in prostate stromal cells compared to prostate cancer cells, are 
also in line with studies by Karan et al (Karan et aI., 2003) who carried out analyses of 
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TIMP-3 expression in prostatic stromal cells, prostatic cancer cells LNCaP-C33 (androgen-
dependent) and LNCaP-C81 (androgen independent). They demonstrated greater 
expression ofTIMP-3 in the stromal cells, relative to the LNCaP-C33 cells, and expression 
was undetectable in the LNCaP-C81 cells. Riddick et at (Riddick et aI., 2005) also obtained 
similar results when analysing the components of prostatic tissue that are associated with 
prostate cancer. Stromal cells are likely to be important in the control of proteolytic activity 
within the tumour microenvironment, perhaps as a result of their increased expression of 
TIMP-3, and as the stromal-epithelial ratio reduces in cancer, this control is less likely to be 
complete. At the protein level, the expression of TIMP-3 is corroborated in the stromal cells 
relative to expression in LNCaP. As a result of the negligible levels of TIMP-3 mRNA in 
PC3 cells, comparative western blotting was not carried out on their cell lysates. 
Immunocytochemical analyses also corroborated the expression of TIMP-3 in prostate 
stromal cells PCAF and WPMY-l, with negligible levels ofTIMP-3 detected in the LNCaP 
prostate cancer cells (see Figure 3.6). TIMP-3 staining was also localised primarily in the 
ECM - this is in line with its known ECM-adherent characteristics (Lee et aI., 2007) 
6.2 TIMP-3 EXPRESSION IS CONTROLLED BY PARACRINE 
SIGNALING IN CO-CULTURES OF PROSTATE STROMAL AND 
CANCER CELLS. 
In this study, the levels ofTIMP-3mRNA expressed in stromal cells PCAF and WPMY-l 
more than doubled significantly upon co-culturing with prostate cancer cells LNCaP (see 
Chapter 3, Figure 3.22) and the low expression of TIMP-3 in the LNCaP cells was 
completely lost post-co-culture with both PCAF and WPMY-l stromal cells (see Figures 
3.22 and 3.23). There appear to be some paracrine crosstalk between the cells, making them 
behave differently, as opposed to when the cells are grown independently. This type of 
paracrine effect has been previously reported (Arnold et aI., 2(08) whereby the expression 
levels of PSA were significantly increased in androgen-dependent LAPC-4 prostate cancer 
cells when co-cultured with cancer-associated prostate stromal cells. It is also possible that 
the cancer cells LNCaP may be secreting excess proteinases and, via paracrine signalling, 
activating the defence mechanism in stromal cells, resulting in an increase in the amount of 
TIMP-3 expressed by the cells. TIMP-3 will sequester in the ECM and protect the tissue 
from proteinase degradation. It is also likely that TGF-~ normally produced by prostate 
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cancer cells LNCaP (Ishii et aI., 2011) resulted in an increase in TIMP-3 expression by the 
stromal cells due to transformation to myofibroblasts. The results from this study show a 
significant up-regulation of TIMP-3 expression in PCAF cells by TGF-p in a dose-
dependent manner. Another example ofparacrine synergy between stromal and cancer cells 
was demonstrated by Hinsley et al who showed that when pro-tumourigenic endothelin-I is 
elevated, as is the case in several cancer epithelial cells (Granchi et aI., 2001), there is a 
concomitant up-regulation of ADAM-I 7 IT ACE activation and/or expression which in tum 
stimulates the production of epidermal growth factor receptor ligands amphiregulin and 
HB-EGF in oral fibroblasts. These ligands activate EGF signalling in neighbouring head 
and neck squamous cancer cells by binding and activating the EGF receptor on the cell 
surface of the cancer cells which in tum mediates elevated motility, increase in pro-
migratory COX-2 expression and migration of the cancer cells out of the tumour micro-
environment (Hinsley et aI., 2012). These reports support the importance of tumour-stromal 
interactions in the initiation of cellular migration leading to tumour progression. However, 
the results from this project suggest that this interaction is likely to inhibit overall tumour 
migration as a result of the increase in stromal cell production ofTIMP-3 upon contact with 
cancer cells (see Section 3.2.5). 
6.3 TIMP-3 EXPRESSION IS HIGHER IN NORMAL AND BPH 
PROSTATE TISSUES THAN IN PROST ATE CANCER TISSUE 
The expression of TIMP-3 in BPH tissue was higher than in normal prostate tissue (see 
Figures 3.12 and 3.13). In primary prostate cancer tissue, the expression of TIMP-3 was 
low (see Figure 3.10). Upon analysis of the normal prostate tissue, the localization of 
TIMP-3 was observed both in the ECM and cytoplasm (see Figure 3.13). However, the 
cytoplasmic expression of TIMP-3 was much lower in primary prostate cancer tissue (see 
Figure 3.14). This suggests that the transformation of normal epithelial cells to malignant 
carcinoma cells may inversely correlate with expression of TIMP-3. This also corroborates 
the results obtained in cell lines where there was a significantly higher level of TIMP-3 
expression in LNCaP cells (early lymph node metastatic cell line) in comparison to PC3 
cells (advanced bone metastatic cell line). 
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Tissue microarray samples were kindly donated by our collaborators and information such 
as patient Gleason score, tissue Gleason grade and PSA levels of the patient was also 
supplied. As a control, liver tissue samples were also made available. Results from this 
study showed the expression of TIMP-3 in all tissue samples, irrespective of disease state. 
However, the intensity of expression and localisation patterns varied with disease state and 
tissue Gleason grade. There was negligible expression of TIMP-3 in the liver tissues in 
comparison to prostate tissue (see Figure 3.17). This is in line with results obtained in 
previous studies that investigated the expression of genes in several tissue types and 
showed TIMP-3 gene transcripts were expressed at a higher degree in prostate tissues, 
when compared to liver tissue (Wu et aI., 2009a). There was higher expression of TIMP-3 
in cancer tissue with Gleason grade of 4, in comparison to tissue with Gleason grade of 7 
(see Figures 3.18 and 3.19 respectively). This suggests there is an inverse correlation 
between expression of TIMP-3 and malignancy in prostate cancer. The localisation of 
TIMP-3 was primarily glandular, although staining was still observed in the stromal 
compartment. The lower expression of TIMP-3 in the prostate cancer tissue with high 
Gleason grade was concomiatant with loss of a huge amount of epithelial glandular 
expression of TIMP-3 in the prostate cancer tissue. This predominantly epithelial 
expression of TIMP-3 has also been demonstrated in breast carcinoma tissue where 
expression of TIMP-3 correlated inversely with histological grading of the tissue (Mylona 
et aI., 2006) as well as non-small cell lung cancer (Mino et aI., 2(07) and glioblastoma 
samples (non-epithelial cancer) (Nakamura et al., 2005a). It is possible that the epithelial 
localisation ofproteinases responsible for glandular degradation results in co-localisation of 
TIMP-3 inside the epithelium as well as in the stromal cells where it is produced in high 
quantities. Upon loss of glandular epithelia, there could possibly be a concommitant loss of 
TIMP-3, leading to results such as ones seen in this project. However, as co-localisation 
experiments of proteinases with TIMP-3 in these prostate tissues were not done, it is not 
possible to confIrm that the epithelial localisation of TIMP-3 is as a response to presence of 
proteinases. 
Taken together, the importance ofTIMP-3 in progression of cancer, including cancer of the 
prostate, cannot be over-emphasized. Measures targeting cancer associated fIbroblasts, as 
well as increasing total levels of TIMP-3 in the prostate microenvironment may prove 
invaluable for the management of prostate cancer. This may also be applicable to other 
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cancers that have shown an inverse correlation between TIMP-3 expression and 
malignancy. 
6.4 TIMP-3 IS MODULATED BY DUT IN PROSTATE CANCER CELLS 
The down-regulation of TIMP-3 mRNA in LNCaP cells after treatment with DHT (Figure 
4.4) and its elimination in PC3 cells (Figure 4.6) suggests that there may be an increase in 
metastatic potential of prostate cancer cells with loss of TIMP-3. The LNCaP cells are less 
metastatic than the PC3 cells (Sobel and Sadar, 2005b), and their loss of this inhibitor may 
increase proteolysis and initiate tumour metastasis. DHT -mediated prostate cancer cell 
proliferation is androgen receptor (AR)-dependent. However, in this study, there was no 
reversal of the DHT effect on TIMP-3 expression by flutamide. This agent is clinically 
administered to patients with lymph node metastatic prostate cancer, as they are androgen 
receptor antagonists that act by inhibiting the binding of androgen to the AR. The ICso of 
Flutamide with regards to inhibition of the androgen receptor, is approximately 175nM 
(Peets et aI., 1974) so at approximately 5x ICso concentration, there was no inhibition of the 
AR by Flutamide in LNCaP cells. The caveat to this experiment is that the activity of the 
stock of flutamide used cannot be verified, as there was no reversal of the increase in PSA 
mRNA levels observed after DHT treatment in LNCaP cells (see Figure 4.5). 
In this project, the expression of TIMP-3 mRNA in the PC3 cells was completely depleted 
after DHT treatment (Figure 4.6). This result was unexpected, as these cells do not possess 
an AR (Marcelli et aI., 1995). The results suggest that the potentially pro-tumourigenic 
effect of DHT -mediated reduction in TIMP-3 expression might be AR-independent. The 
effect of DHT on down regulation of TIMP-3 was seen at 10nM; a concentration that 
allows for optimal proliferation of LNCaP cells (Lin et aI., 1998, Zhu et aI., 2003). At 
concentrations that only allow for binding of DHT to the AR (dissociation constant of 
approximately O.lnM) (Wilson and French, 1976), there was no significant effect on the 
levels ofTIMP-3. This suggests that the DHT-mediated effect on TIMP-3 down regulation 
was 'switched on' where there are higher levels of circulating DHT, to enhance cellular 
proliferation and not just for the binding of the DHT ligand to its receptor. The existence of 
alternative pathways by which these cancer cells are able to respond to androgen treatment 
has been investigated and could be due to aromatase action (Tsugaya et aI., 1996) or a cell 
surface receptor, as shown by Hatzoglu et al (Hatzoglou et aI., 2005); they carried out 
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studies that demonstrated the inhibition of LNCaP cell growth by BSA-coupled 
testosterone via a membrane androgen receptor in-vitro and in nude mice. TIMP-3 is 
implicated in cell cycle progression (Airola et ai., 1998) and inhibition of cell growth may 
correlate with a reduction in TIMP-3 expression in the LNCaP cells treated with DHT in 
the Hatzoglu et al study. The activity of DHT used in this project experiments was 
confirmed by co-analysing the expression of PSA - a serine protease that is androgen-
dependent and is clinically used as a diagnostic marker for prostate cancer progression 
(Downing et ai., 2003) (Figure 4.5). 
In the stromal cells, there was no statistical difference in TIMP-3 mRNA expression 
between treated and untreated cells (Figures 4.7, 4.8 and 4.9), implying that DHT-mediated 
regulation may be cancer cell-specific. As the levels of TIMP-3 in protein extracts from 
LNCaP cells were undetectable, it was not possible to corroborate the DHT-mediated 
down-regulation ofTIMP-3 mRNA observed. 
In silico analyses of the promoter region ofthe TIMP-3 gene revealed 10 putative androgen 
response elements (ARE) in its promoter region (see Figure 4.17). The sequence similarity 
was comparable to AREs found in known androgen-regulated genes like PSA (Cleutjens et 
ai., 1997, Cleutjens et ai., 1996), hPAR 1 (Salah et aI., 2005) and MVDP (Fabre et aI., 
1994), all of which had 40 - 85% sequence similarity to the general ARE consensus (Table 
4.1). This result opens the possibility that TIMP-3 may be an androgen-regulated gene 
specifically in prostate cancer cells. TIMP-3 may also be androgen-regulated in prostate 
epithelial cells, although I did not test this. The results from this project also showed that 
the prostate stromal cells did not alter their TIMP-3 mRNA expression upon treatment with 
DHT, again buttressing the cancer cell or perhaps epithelial specific modulation of TlMP-3 
in prostate. Also, the functionality of the putative AREs discovered in the promoter regions 
was not validated as a result of financial and time constraints during the course of the 
project. Several studies have shown the occurrence of putative AREs in the promoter region 
of genes and have validated their functionality. These include the Janne el aJ study which 
showed that ornithine decarboxylase was regulated by androgen in murine epithelial cells 
and demonstrated the functionality of the putative ARE in murine epithelial cells (Janne et 
al., 1991). Also, the putative 5' ARE half site of ARE in the promoter region of human 
kallikrein-2 gene hKLK-2 was shown to be functional in PC3 cells upon transfection with 
AR and the promoter region of the hKLK-2 gene (Murtha et aI., 1993). Work with our 
collaborators also revealed that the ADAMFS-/5 gene was modulated by DHT and we 
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found that within the proximal and distal promoter regions of the ADAMTS-J5 gene, there 
were several putative AREs, although their functionality was not confirmed (Molokwu et 
aI., 2010). There has also been a study by Villar et at who discovered novel putative AREs 
in the promoter region of the gonadotropin regulated testicular RNA helicase gene (GRTH) 
and demonstrated that treatment with an AR antagonist prevented the transcription and 
production of GRTH and also that point mutating one of the AREs resulted in repression of 
androgen-mediated transcription ofGRTH (Villar et aI., 2012). 
Taken together, the existence of AREs in the promoter region of TIMP-3 may be indicative 
of its androgen-regulation. Further experiments targeted at demonstrating the functionality 
of the 10 putative AREs discovered would be necessary in order to confirm this hypothesis. 
6.5 TIMP-3 IS MODULATED BY TNF IN PROSTATE STROMAL CELLS 
Elevated levels of TNF have been observed in the serum of prostate cancer patients 
(Nakashima et aI., 1998) and this may be as a result of recruitment and activation of 
macrophages by necrotic cells in the tumour mass as a result of hypoxic conditions and 
subsequent production of pro-inflammatory cytokines in response. In this project, TIMP-3 
mRNA and protein expression were down regulated in prostate stromal cells BPH45 by 
TNF treatment, in a dose-dependent and statistically significant manner (see Figure 4.11). 
There were no apparent changes in TIMP-3 mRNA expression after cell treatment in the 
stromal cells PCAF and WPMY -1 cells nor in cancer cells LNCaP and PC3 (see Figures 
4.10 and 4.12). As NF-lCB signalling is elevated by stromal fibroblasts in BPH, it is possible 
that TNF signalling is driving the cells' resistance to apoptosis and promoting hyper-
proliferation. As TNF induces the expression of MMP-2 in BPH tissue (Konig et aI., 2004), 
it is quite possible that the balance between MMPs and TIMPs has been altered in favour of 
proteolysis. 
In silica analysis of the TIMP-3 gene did not reveal the presence of any of the known NF-
KB response elements (Section 4.2.) implying that the TNF-driven modulation of TIMP-3 
in the stromal cells BPH45 may be an indirect effect on other mediators in the non-
canonical TNFI NF-KB signalling pathway in the cells, leading to a possible inhibitory 
effect on the production of TIMP-3 in these. 
Overall, it is possible to include TlMP-3 as a potential target for the management of BPH 
by gene therapy to incorporate or activate the pro-apoptotic TIMP-3 gene in BPH tissue. 
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6.6 TIMP-3 IS MODULATED BY TGF-B IN PROSTATE STROMAL 
CELLS 
The expression of TIMP-3 mRNA was significantly up-regulated by 50nM TGF-~ I in the 
prostatic stromal cells BPH45 and PCAF (see Figures 4.14 and 4.15). This result is in line 
with studies undertaken by Cross et al (Cross et aI., 2005) who showed the up-regulation of 
versican and TIMP-3 transcripts in the prostate stromal cells BPH 31, 33, 44 and 45. The 
results from this project suggest there may be an altered balance in favour of higher TIMP-
3 expression in the stromal cells in the prostate, which could potentiate inhibition of 
proteolysis and subsequent metastasis of tumours from the prostatic primary site. There was 
no effect ofTGF-p on TIMP-3 expression in normal prostate stromal cells WPMY-I after 
TGF-p treatment, implying that the up-regulation of TIMP-3 by this cytokine is related to 
pathology (disease) rather than physiology (normal tissue homeostasis). 
In silico analysis of the TIMP-3 gene did not reveal any TGF-p response elements in the 
promoter region of the gene, implying that the effect ofTGF-p on TIMP-3 expression was 
not via direct modulation of transcription or was via unknown direct mechanisms. One 
hypothesis is that TGF-p may modulate other proteins that interact with TIMP-3 thereby 
modulating the total levels in the stromal cells. One such example is demonstrated in 
bovine chondrocytes where TGF-p significantly increased the expression of TIMP-3 via a 
mechanism thought to involve protein kinases, and also showed that inhibition of serine 
and tyrosine kinases in the cells reversed the increased TIMP-3 expression observed (Su et 
aI., 1998). Other examples have also been published for TIMP-3 modulation by TGF-p 
(Airola et aI., 1998, Canovas et aI., 2008) so this potential indirect modulation ofTIMP-3 is 
not novel. 
6.7 DOWN-REGULATION OF TIMP-3 IN PROSTATE STROMAL CELLS 
RESULTS IN ALTERED BIOLOGICAL FUNCTIONS 
The RNAi-mediated down-regulation of TIMP-3 mRNA expression in both prostate 
stromal and cancer cells was successful via previously described electroporation, lipid and 
calcium phosphate transfection methods (see Section 2.13). As the total level ofTIMP-3 in 
208 
LNCaP cells was negligible, it was not possible to validate the down regulation by western 
blotting in LNCaP cells. However, this was successfully done in stromal cells PCAF and 
WPMY -1 (see Figures 5.4 and 5.5). To follow up on this, the effect of down-regulation of 
TIMP-3 in the stromal cells on biological functions such as cell proliferation, apoptosis, 
migration, and invasion and proteinase inhibition was investigated. This was important in 
elucidating the role(s) TIMP-3 plays in prostate cancer progression, since stromal cells 
have been shown to secrete soluble factors that enhance the migration and invasive 
potential of cancer cells from their primary site to distal sites (Kaminski et aI., 2006, Mi et 
aI., 2011, Nomura et aI., 2008, Barone et aI., 2012). Stromal fibroblasts play an anti-
tumourigenic role in nonnal tissues but once activated during carcinogenesis, activated 
stromal fibroblasts have also been shown to co-exist with migrated cancer cells from 
several cancers e.g. ovarian cancer (Zhang et aI., 2011) and multiple myeloma (Vande 
Broek et aI., 2008). 
Proliferation of the stromal cells PCAF did not change after siRNA-mediated down 
regulation of TIMP-3 although there was a trend towards slight loss of cell number in 
PCAF cells (see Figure 5.8). There was, however, a significant increase in the number and 
percentage of apoptotic PCAF cells (Figure 5.9), which may explain the slight decrease in 
number of PCAF cells counted, post-transfection. This suggests that the effect of TIMP-3 
is not primarily by enhancement of the proliferation of activated stromal fibroblasts in the 
tumour microenvironment. In contrast, there were no changes in number of proliferating 
WPMY -1 cells post TIMP-3 down-regulation (Figure 5.8) and no increase in the 
percentage of apoptotic cells when compared to the control cells with non-targeting siRNA 
(Figure 5.9). The results from this research are in direct opposition to the known anti-
tumourigenic effects of TIMP-3 in cancer cells and have not previously been reported in 
any other cancer-associated fibroblasts. It is possible that epigenetic changes have occurred 
in the PCAF cells due to their previous existence with cancer cells and, whilst the inhibitor 
TIMP-3 is still being expressed, it may be interacting with pathways that mediate cell 
survival in the cancer associated fibroblasts. Human fibroblasts are characteristically 
known to secrete elevated levels of growth factors such as TGF-~ (Thannickal et aI., 1998, 
Strutz et aI., 2001) and FGF (Yamazaki et aI., 1997) so their proliferation may have become 
overly dependent on the survival pathways mediated by these secreted factors. 
This effect may not be present in nonnal fibroblasts like the WPMY -1 cells that still have 
their regulatory pathways intact. 
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Migratory and invasive potential of activated cancer-associated fibroblasts PCAF was 
significantly inhibited after siRNA-mediated down regulation of TIMP-3 (see Figures 5.11 
and 5.13). This is in contrast to previously described studies such as one by Coulson-
Thomas et al who demonstrated an increase in activated stromal cell migration after being 
in contact with metastatic prostate cancer cells DU 145 and PC3 (Coulson-Thomas et aI., 
2010). However, in their studies, the fibroblasts used were normal non-cancer associated 
but attained an activated myofibroblastic phenotype when co-cultured with bone-metastatic 
PC3 and brain-metastatic DU-145 prostate cancer cell lines. Also in this project, the origin 
of the fibroblasts is prostatic so whether this confers alternate characteristics to the 
fibroblasts in comparison to what prostate cancer cells would confer to bone marrow and 
brain-derived fibroblasts used in the Coulson-Thomas study, is unknown. It would be 
interesting to investigate the effect on migration on these brain and bone marrow derived 
fibroblasts upon down regulation ofTIMP-3. The migration of cancer associated fibroblasts 
is not alien and has been reported in colon carcinoma associated fibroblasts via FGF-
mediated 'switch on' of migration (Sonvilla et aI., 2008) as well as in a directed fibroblast-
led matrix-degrading and migratory pattern (Gaggioli et aI., 2007). Therefore, inhibition of 
matrix-degrading proteinases should, in theory, reduce this migration of cells and vice 
versa. In this project, TIMP-3 down regulation in the cancer associated fibroblasts resulted 
in decreased migration. There was an increase in the migratory and invasive potential 
observed in the normal prostate stromal fibroblasts WPMY -1 after down-regulation of 
TIMP-3 (see Figure 5.12 and 5.14). This would support the anti-migratory properties of 
MMP inhibitors and would subsequently result in reduced invasion of cells. As these 
WPMY -1 cells have not undergone any previous oncogenic selection leading to potential 
epigenetic alterations, they may not have the 'over-compensatory' mechanism in them. 
This, however, is speculatory. In order to confirm that the down-regulation of TIMP-3 in 
the prostate cells also resulted in an increase of total MMP activity, an in vitro proteinase 
assay was carried out to test this. As TIMP-3 is a known MMP-2 inhibitor (Visse and 
Nagase, 2003), it was chosen for the assay. Recombinant MMP-2 was shown to cleave the 
substrate leading to release of a fluorescent group (see Figure 5.15) as previously described 
(Knight et aI., 1992). Apparent MMP-2 inhibition was observed with control recombinant 
TIMP-3 (79% inhibition) as well as ECM lysates from NTsiRNA-transfected PCAF and 
WPMY-I cells (48% inhibition) while only 17% inhibition remained in ECM lysates from 
TIMP-3 ssiRNA-transfected PCAF and WPMY-1 cells (Figure 5.16). This confirmed that 
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TIMP-3, the only TIMP to be sequestered in the ECM, was functioning as an MMP-2 
inhibitor in prostate stromal cells and that the loss of the expression of TIMP-3 in the 
stromal cells led to a loss of MMP-2 inhibition. This result supports the previously 
characterized MMP-inhibitory function of TIMP-3 and strengthens the proposal for 
therapies targeted at increasing the levels of TIMP-3 as a means of management of cancer. 
6.8 LIMITATIONS OF THIS RESEARCH 
There were some limitations that prevented additional experiments to be carried out. The 
major limitation was time and it would have been interesting to do several follow-up 
experiments to further understand the mechanism of regulation of TIMP-3 in prostate 
cancer and its specific role(s) in the cancer progression. Also, it would have been ideal to 
carry out some xenograft studies in vivo, including injection of LNCaP cells into athymic 
mice so as to follow their growth, migration and invasion of tissues upon siRNA or 
shRNA-mediated modulation of TIMP-3 in-vivo, in comparison to wild type LNCaP cells. 
These LNCaP cells have been previously successfully injected into mice and they 
successfully grew into tumours (Ryo et aI., 2005) 
Also, it would have been useful to carry out more comprehensive prostate tissue microarray 
analyses to have a diverse comparison of TIMP-3 expression and Gleason grades 1, 2, 3 4 
and 5. Comparison of the expression of TIMP-3 and clinical PSA level would have proved 
useful as well but both of these actions were hindered by the limited availability of time and 
tissue samples for me to carry out the experiments. The limited experiments carried out 
using the available tissue microarray were not included in the main body of my thesis due 
the loss of nuclear images obtained from the microscope (see Appendix). 
6.9 PROPOSALS FOR FOLLOW-UP RESEARCH 
The following experiments are proposed as follow-up research to complete the body of 
work already carried out in this project and would enable better understanding of the role(s) 
of TIMP-3 in prostate cancer progression: 
• Investigation of the expression ofTIMP-3 in normal prostate epithelial cells such as 
RPWE cells (CRL 2853, ATCC). This would enable better comparison of TIMP-3 
expression between non-malignant and malignant prostate cancer cells, and verify if 
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the DHT -mediated modulation was cancer cell specific or characteristic of all 
prostate epithelial cells. 
• Investigation of paracrine modulation of TIMP-3 expression in co-cultures of 
prostate cancer and prostate stromal cells. This is to detennine if the co-culture-
mediated modulation of expression of TIMP-3 required cell-cell contact or if it was 
as a result of cancer cells secreting soluble factors that stimulated the elevation of 
TIMP-3 in cancer cells. 
• Investigation of the pattern of growth, migration and metastasis of LNCaP cells 
with and without accompanying stromal cells in athymic mice with and without 
inducible shRNA-mediated down regulation of TIMP-3 in the cells using 
commercially available lentiviral vectors like TRIPZ shRNA vectors (Thenno 
Fisher Scientific, U.S.A». This would enable transfer of the in vitro experiments to 
in vivo scenario and demonstration of the differences seen in migration and invasion 
between normal and cancer associated stromal fibroblasts. 
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APPENDIX 
FIGURE AI: IMAGES FROM TISSUE MICROARRAY ANALYSES WITHOUT 
DAPI NUCLEAR STAINING 
Gl + G1 
= GS2 
PIN 
NT 
TIMP-3 Staining in Matched Prostate Cancer (GS 2), PIN and Normal Prostate (NT) 
Tissue Samples. 
Note the higher intensity of TlMP-3 staining in the GS2 samples compared to the PIN and 
NT samples 
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G2+G2 
= GS4 
NT 
TIMP-3 Staining in Matched Prostate Cancer (GS 4) and Normal Prostate (NT) Tissue 
Samples. 
Note the intensity of TIMP-3 staining is similar in all tissue samples. No matched PIN 
tissue jar this sample set. 
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G3 + G2 
= GS 5 
PIN 
TlMP-3 Staining in Matched Prostate Cancer (GS 5), PIN and Normal Prostate (NT) 
Tissue Samples. 
Note the higher intensity of staining in the PiN and NT samples compared to the GS 5 
sample 
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G3 +G3 
= GS6 
NT 
TIMP-3 Staining in Matched Prostate Cancer (GS 6), PIN and Normal Prostate (NT) 
Tissue Samples. 
Note the higher intensity of staining in the NT samples compared to the G 6 and PI 
samples 
247 
G3 + G4 
=GS 7 
NT 
TIMP-3 Staining in Matched Prostate Cancer (GS 7), PIN and Normal Prostate (NT) 
Tissue Samples. 
Note the higher intensity of staining in the NT samples compared to the GS 6 and PIN 
samples 
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ABSTRACT 
Pro cancer is a m jor eau .. of mortality. rgely a eonsequence of nd 
transtonn lion to androgen-independenl growth. Mloprot ' are imp!' ed in c:aneer 
progression. A di ' ntegrin and me lIoprot 'n. with thromboepondin motifs (AOAMTS) ,.. 
expreSMd in prostate cane .. eells, with AOAMT5-1 a'ld ADAMT5-15 being the mo t bun-
dan!. AOAMTS-15 but not AOAMT5-1 eJl~ion downregul ed by androgen in P 
prostate eancer eells. po 'bfy through androgen response eMments • .oc:i with the gene. 
ADAMT5-15 exp,.. Ilion is predictive for survival in bre eancer, and the duation may be 'm-
ilar in prostate caneer, .. androgen independent. I uauaJly due to aberrant ' jng through 
ita receptor. 
INTRODUCTION 
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properties (191. ADAMTS-5 bas been implicaled iD cartiJaae 
breakdown in anhritis CZO. 21 I. ADAMTS-2. ADAMTS-3. and 
ADAMTS-14 ~ procolla,en N-peplidases (22), and 
ADAMTS-13 has been identified as the von Willebrand factor 
clenin, protease that is an important part of the blood coagula-
tion cascade (23). Expression levels of ADAMTS ~s in 
prostaIr cancer and stromal cells have been reported previously 
(24). ADAMTS-I and ADAMTS-15 we~ the most lbundantly 
exprnsed in each of the prostate cancer and stromal cell lines 
invesligllled. but their role in prostate cancer developmenl and 
progression is DOl known. 
<>Winl to homology wilh ADAMTS-I. ADAMTS-15 is pre-
dk1ed to have protcoglycanase properties (25). However the 
ADAMTSs underio C-~nal proIeoIytic proceuiRl! (26). 
which affects their locaIizaion and activities. and the multi-
ple domains could be playing diff~nt roles. as is the cue with 
ADAMTS-I. in which the proteolytic domain is responsible for 
~anasc activity. while the C -Imninal domains ~ required 
for antian~ic activity (27). 
Decreased ADAMTS-IS expression in malignanl b~asl tu-
mors comlales with poor patient prosnosis (28). susgesling that 
ADAMTS-15 may be playing a proI«Iive role in ~ cancer 
patients. As is the case with prostaIe cancer. ~ cancer is a 
disease in which hormone deprivation plays a role in rnanq:e-
menL with the use of estrosen receptor aotagonists In patients 
with esIfOIet\-R!CCplor-positive tumors (29). 
In order to funhcr understand the pocential roles of 
ADAMTS-I and ADAMTS-15 in prostate cancer ~ion. 
we set out 10 test the hypothesis that the expression of ADAMTS-
I and ADAMTS-15 is rqulaled by androgens in prostaIe cancer 
cells. 0wiRl! to their possible proteolytic and antilllgiogenic ef-
fects. such a scenario might sugesl that these proIeases play 
important roles in prostate cancer prosression. 
MATERIALS AND METHODS 
Cell culture 
The androtJen-sensitive LNCaP prostate cancer cell line (30) 
was used to t.esl the effects of DHT on ADAMTS e~on. 
The «115 were plated into 24-well cultu~ plates at I density of I 
)( l<r cell5lwell for RNA extractioo and in 6-well cu~ plates 
at 5 )( 104 celJsIwcll for protein exlnlction. Cells were l!fOWD to 
IppI'Oxillllldy fiOII confluence in Dulbecco's modification of 
Eagle's medium supplemented "'Ith l()<l· fetal calf serum. 100 
uDitslmL penicillin. 100 IlglmL SlRptomyc:in. and 0.25 IlgImL 
amphotericin B. III 31'''(" iD a humidified almD5phe~ of 5% 
~. Medium was chansed to serum-free OC'CM (Biotopcal 
Industries. K.lbbuU 8eit HaEmet. Isnel). suppiemelllCd wilb 2 
roM L..,lutmnine • .ad cells w~ allowed to acclimlli7.e 10 the 
new medium for 48 hr. The medium was then 1'eIIKWed • .ad 
cells were treated in frail DCCM medium for 24 hr with DHT 
(SIJIIII) or with ftutamide (Silma. Poole. UK). a oonsteroidaI 
androl!m m:eplOr antatonist. LNCaP cell prolifention is max-
imally stimulated by DHT III eOCICeftInItioDs between I and 10 
oM (8. 30-32). To cmer the ranse between clIUale levels .ad 
maximal DHT lItilNllalioo. I"*ment doses of OJ, 1.0. UId 10 
oM DHT we~ used. To ddennine whether an excess of ftu-
!amide would inhibit the effect of DHT. [.NeaP cells were allO 
trealed with I 14M RUlamide or 100M DHT + I IlM Rutamide. 
DHT and Rutamide we~ dissolved iD 0.1'* ethanol. The con-
trol ann was lrea&cd with 0.001% ethanol. as Ibis was the final 
concenlrallon of ethanol In the treatment arms. 
RNA rxtraction and eDNA synthesis 
For mRNA expreuion analysis, DHT treatment was carried 
oul for 24 hr. This time point was used because previous experi-
ments anaIyziRl! rqulllion of ADAMTS-l S h.a shown respon-
sive changes in expression by Ibis time poinl (24). The medium 
was ~moved, and TRI Req:ent (SI,ma) was applied to the wells 
to lyse the «lis. usin, the supplier's protocol. The resuhing cell 
lysate was stored II -8O"C. awaiting RNA exlnlCtion. Total 
RNA was moerse-transcribed to eDNA with ~venc lmIscrip-
lase 0 (Invitrogen. Paisley. UK) using the suppIier's protocol. 
Reactions for eDNA synthesis wc:te run 00 a GeneAmp PCR 
System 9700 (Applied Biosystems). The thennaI cycle was set 
at 2500C for 2 min. 42"C for 50 min. and 7()1>C for 15 min 
and was then cooled to 4u C. furthcrrnoR. eDNA was IlIlR'd 
at - 2O"C until ready for use in maHime reverse-traOIIcriptue 
polymerase chain reactions (RT-PCRs). 
Real·time RT·PCR 
Real-time RT-PCR was nm in IO-Ill reactions In dupli-
cate. using 384-well plates on the ABI Prism 7900HT se-
quence detector with SDS 2.1 5Oft~ (Applied Biosystrms). 
TaqMan Jene expression assays (Applied Blosystems) were 
used. Each assay contained a proprietary primer p'Obe with 
I t.-c.boxyftuorescdn repoct.er and a quencher. Further. 5 
ilL of TaqMan master mix (Applied Biosystems. Warri"lton. 
UK). O.S ilL 0( TaqMan Fne expasioa assay. 2.5 "l of 
difthylpyrocarbonat.e-treated wat.er. and 2 Il L of eDNA were 
mixed In each welt. The thennal cycle was set It 9SoC for S 
min. and then 40 cycles we~ set at 95°C for 15 s and 6O"C 
for 60 I. Independent eDNA samplei were also analyzed us-
Ing SYBR Gnlen assays (Applied BI05yslernsl. Each reaction 
consisted of Sill of 2>< SYBR Gnlen mastermix as supplied. 
SO-.I.OOO oM of each primer, and I III of eDNA .ad made up 
to a final n:actioa volume 0( 10 ilL with diethylpyrocarbonate-
trealed wiler. 
Glyceraldehyde-3-phospha1e dehydrogenase (GAPDH) or 
RNA polymerue II (RNAP) we~ used II the endogenous 
houset~RI genes to normalize between samples (33). Assay 
IDs 0( TillMan assay, were as follows: HsOOl99608..mL 
f(]l' ADAMTS-I. Hs0037352O...JDL for ADAMTS-IS. 
HdM268S9-aL for prostatc-speciftc nlsen (PSA), 
HI99999905..mL for GAPDH. and HiOO99280Lml for RNAP. 
Primer sequences for SYBR Gnlen experiments wc:te IS follows: 
for ADAMTS-I. forward 5' ~ACI'OCAAGGCGTAGGAC 
and ~vene 5' -AAGCATGGTrJ'CCACATAGCG; for 
ADAMTS-15. forward 5'-TCCI'CITCACCAGGCAGGAC 
and R!\'ef1e 5' -GGTCACACATGGTACCCACATCA; and for 
-
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GAPOH. rOfWW 5' -GC.TCCTCCTGlTCGACAGTCA and 
~vene ~'·AAC1TCCCCATGGTGTCTOA. Elpreuion!nels 
of mRNA in die I~ celli ~lllive 10 die control celli were 
detenniml usln, die 2' AAO method (34). Thil allowed die 
nonnaiil.alion of die Clpreuion levell of die Jene of Inleresl ill 
Individual elpcrimmts. 
Prolrin rxlroclion 
For procdn t'lttadioa. celli werr ue.Icd with DHT and 
Outll'ftide for 72 hr. Ifter which medium WIS I'CmOWld and 
celli were I't'fIlIy wuhcd with photphatr·buffemi saline. Tria· 
huffemi gline WIS mllcd with 0.01.., Triton X·IOO at 4"C In I 
volume ratio or 100: I with pro&eue inhlbllor cocktail (SI,ma) 
"-unt.lnl,,, 4-(2-lmllkldhylbenunesulConyl ftuoride. pepUlia 
A. IlesUlUn. leupcplin. 1IpI'OIinln. and 1rM.-epolysucclayl-l-
lcucylam6doC4-p .. ido)-bulMe (£-64) accordlllJ 10 die 1Up-
pIier'l pmocoI. EKh ~II WIS applied with 200 #,L of die 
millure for I hr at 4°C 10 Iy .. die cells. The Iyllle wu ccn-
IIiIUJCd 1112.000 x, for 10 min at 4'C. The supcmUIlt WIS 
~fIIO\'ed and gved, while die pellet containln, cell debris WIS 
dlsc.ded. The supematanI WIS Ilorcd at -4O"C. IwllitillJ pro-
lein quIIIIIlficadon and WesIem bIoIIIIlJ. P'rruin quanIlficlllon 
WIS achieved uRllJ the MIcro8CA .... y (Pim:e. LouJhbor· 
ou .... UKI accordin, 10 the IMIIUf8Cblft!l', pmcocol. 
C"orodrri'l.olion oJon o",ibod, 10 '''r 
proprplidr of ADAMTS·15 
We 1ft U"'IR' of lIlY publlcatlons dclcribillJ the sped-
IlcilY of 10 antibody 10 ADAMTS-I5.11 wu ~fore esICftliaI 
that we llna chanKleriud I conunerciaJ Iftllbody before we 
could 80 on 10 Ult' II In thi.lIIUdy. This wu act\It'vcd by alRNA 
knockdown of ADAMTS-15 ellftsalon and then analysis of 
dlanp In pro&eIn n!ftUioa by Wellem bIotti ... ual .. I rab-
bil antibody diR'!Cted llpillll the propepIkIe of ADAMTS-15 
(Abeam. Cunbridae. UK. ~7).ln addIlion. alGENOME 
SMARTpool alRNA apI .... ADAMTS-15 _ synlhesiud by 
Dt..nucon (Epiom. UK). &dI SMARTpooI siRNA vial con· 
tained I pool of four dUferclll alRNA JeqIIt'ftCCI diR'!Cted aplnII 
the Fne of InlcR:lI (Table I I. GAPDH wu knocked dowtt to 
_ IS I poIitive conIroI. IIId allOalalJC!liaJ siRNA ICIqIIt'IIce 
(NTCI be8riRl no Idenllty 10 IIIY.equence ill the human ~ 
wu ....... ectcd illlO cells ill a ...,.,.ae ... or well. IS I neplive 
SecII*ICI 
6'-GCGCOGACCUGGAACAI.J\MUU 
'~
S'-cuocGACGCUGCUUCtMUUUU 
'·~
5'-CCAAGCGUUUCGUGIJClWJUU 
5'~'ACGCUUGGUU 
5'-GCMGAAGGI~ 
Ii'-AGUCCAGUCACCUU 
COI'IIIOJ. The sequences of the positive and the nepdve control 
were proprietary. GAPOH and NTC elpcrimeatl were canted 
out ualllJ aICONTROL GAPO (ell. no. D-001140-0I..o5) and 
s;CONTROL 1IOI1IaIJCli", siRNA (cat. no. D-001~13) re-
spcctiWlIy. The cells werr transfected in DhmnaFECT 2 T ...... 
fedion ReqenI (Dhannacon) accordin,lo the maauflCl1Rr', 
protocol. The androaen-Indcpendml. LNCaP«rivcd C4-2b4 
cell Une (351 WIS used for validali", die aati-ADAMTS·J5 
antibody. The cells were detached usi", trypsln-EDTA. IIId I 
small amounl of sennn-Q)IUJnillJ medium wu added to the cell 
IUspeaaIon 10 illlCliVlle the IIypsin. The cells were ccnIIirulcd 
at 1.000 x I for 5 min. and the medium wu ~1IIO¥ed from the 
cell pellet. The celli were ~suspcndcd in the medium contain-
IIlJ I()II (vlv) fetal calf serum wilhoul anlibiotk:s and ~ 
Wells of I 96-well poIysI~ne plate were used to ~ the 
ft'lIFDb for the tnnIfmiOll5. In one ~II. 2.5 #'8 of siRNA WIll 
added to 10 III of &enlm-r~ mcdllllQ, and In a sepIII1IIe well. 
0.4 III of DharmaFECT 2 wu added to 19.6 III of saum-f~ 
medium. The coaIeatl of the lina well _~ added 10 the ICC-
and, and the mllIU~ WIll left at ambient temperatu~ for 20 min. 
befon! beillJ pJaced into the weill of I 48-well pille. A IoIaI of 
3 x 10' cell. wen: added 10 eacb of the weill contaIni .. the 
alRNA milture. and die ftnal volume of each well WIS made up 
to 200 III with the medium containlaa no aadbiollcs. Kooct· 
down of taIJCt alRNA _ .... yzcd by rQJ-dmc RT·PCR at 
72 hr posUraaIfection. and protda knoctdowa WIS aaaJyllCd at 
120 Iv posUranIfection by Western bloUin, IS described below. 
Protein umples were prepared by hcatinalo 9S·C for ~IO 
min ill redudna IIII!pIe buffer 162.5 mM TriI-HCI; 25 .. (vlv) 
Ilycerol: 2fI. (wlv) sodium dodecyllUlfaae: 0.01'10 bromophe-
nol blue: 350 mM dIthIoIbreitoJ. pH 6.11. SodIum dodecyl 
sulf*'1JOlyacryWaide ad C~I wu pelformed .... 
IIlJ I()II. (wlv) polyacrylamide It'll. Each well WIll Joatcd with 
100 III of proCcin. aad the ,el' were eleclrophoresed for I Iv 
at a c:oIIMII wJuac of 200 V. Protein rrom the ad wu thea 
tnasfermlto a poJyvlayledeae ftuoride membrane at I constMI 
cunenl of 400 A ror 10 min at pH 11.0. The membrallC WIll 
bJoctcd for I br In blockIaJ ball'er 16'1- (wlv) cuein, O.ns .. 
Twcco-20 ill TBS (T8ST)1. After blockin,. the IIICIIIInne WIll 
probed for6 hrusi .. the rabbit anli-ADAMTS-15 antibody (Ab-
eam. ab4SOC7) ndJcd .... DIIthe propcpIide of ADAMTS- 15, 
at • dilution of I :S.OOO (200 1IIImL) In bIockina buffer. After 
dne wuheI ill TBST. the mcmbnIne _ probed for I Iv wIda 
c. ................ 
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a honcndIsh-pnnddue-i.'OOjup&ed (HRP<onjutlkd) lwine 
antirahttit l,ci antibody (DaLo Cytomatlon. POJ99. Ely. UK, 
at a dilution of I: 3.000 ( 113 nt/ml. I. HRP detection wu done 
with Eel. Plus WCllcm NatUn, dd«tlon ... It (Amrntt.m. lJllk 
Chalfont. UK, an-ordllll to the manuracturrr's protorol. "y-
pMilm ECI. (Amenhaml X-ray 111m wu ullCd to ellpole .nd 
deYclop the membranes. 
fof repmbi",. the p"ly\'iny~ Ruoride me"""-_ 
washed th~ times In mST and IUipprd or antl-AOAMT'S-
I ~ antibody by qitlllion It ""C for 6 hr in mST broIIaht to 
pH 2.0 with He!. GAPDH wu probed with rabbit polyeloMl 
anti-GAPDH 1'<; (Abeam. ab9oUI~h III a dilution 0( I: 1.000 (I 
pt/mLl. Secondary antibody probin, and HRP dd«tion _ 
done u de~:ribed cutler. 
Drns;lomdry 
Bands detected on X-ray I1lms rrom Western bIoIllnl elpn-
imenls ~ KIIIiquantitati\'ely .... Iy/~ by densitomdl'y uline 
a GS-710 Callbrattd Imqin, DmJilomdtr (Bin-Rail. Hemel 
Hc:~ UKI runnina on Quantily One ~III 4.'.1 IOR-
ware (Bio-Radl. A boundary wu drawn around eactl blftd ror 
anaIy,!IO. 'J'he adjusted area and density (\,olumel or the bud 
rrom each treatment sampk wu ''()~ with the band !'rom 
the control sample. lneaJurcd u optical delllily )( mm'. and w. 
defined by the wftware as the sum or the Intenlilie5 of the parb 
(in optical demily I within a mlume boundary multiplied by the 
area of a ,In,k piael (In mm: I minUi the backJRlUftll \'OIume. 
AOAMTSI5 Rrnr 11I.1I1,,5;S 
'J'he ,enom\c ~ of the ADAMTSI and AllAMTSI5 
FfteS were obtained from the Ensembl JeIlOlllC dalabue. Re-
Jc.oasc49 (www.emembl.OfJI(lfl). 'J'he F.IIsembl online 1001 was 
u~ 10 determine the "-Rankin. sequence conIainl", the lent 
rqulatory rqlon. the transcription Mart poi .. (TSPI. and the 
FfIC ~ with intron and ClIon Infonnalion. UIi", an ill sil-
ica approach with the online nuclear recqltor bindi", site search 
1001 NUBISc.., """Inn 2.0 (www.nubiscan.uniNI.I:fll (7). a 
mIlrili wu crewd consisti", or the rollowi", nine ARE haIf-
IIIn: AGAACA. TGTACC. TGTACA. TGTTCT. GGTACA. 
AG'T'GCT. TGGTCA. AGTTCT. and AGTACG. f..ach half-lite 
hu previoully been shown to be runctional ( I J I. A can:b "nIl-
C!JY wu desi.ned 10 search ror putati"" AREa CUftIIII*'d or 
dirtlCl tqJCalJ (DRs). IIM!f1cd tqJCalJ (IRaI.Iftd CMI'ted ~ 
IERil or theIe half-sites IlUrpoIN by a lIOftIPCCilk 3-bp 1('-
qllt'1lC(!. rormi", a complete IS-tIp ARF~ A ttweshoId _ or 
0.8 wu Id to minimU.e rabc-posili\'e Pft'dictionI. Thta ttftsh· 
old Idtlna ensuml that only puUU"" AREa with teqUentn 
conapondi", to 10-1 (X)IlI. similarity with the half -"lei in the 
mIlril ftt'e del«ttd. 'J'he frequency and position of ARF.a 
thIl met the MWCh crilit'ria were m:onkd. for aJIIII*Uon. 
the promoIef rqions and .equences of PSA (human .... lIlkreln 
3.ItXLXJ) Iftd prost __ 1pCCi1k memhnne anti1ft' crollit' by-
droluc I. FOUl I I Jt'I'CI were allO lDaIy /.Cd ull", the ... 
llI'aIeIy. ItXUCJ aene espreuion il known to be upn:autMcd by 
aodroFn.1ftd the promoter r"elion cont.aiDi the fUlldJoMl ARE 
(AGAACAFaAOTGCTl. -170 bp from the TSP (31). The 
C'lpIftIlon of the FOIlII JftIl' II dowlftlul*d by IIIIdIupA 
1J91. 
.",,,,IIIIC',,III""I.,.,, 
'J'he Kntlkall- Walli. It'll wu ulCd to IdenUFy siplac.tl elr-
rerenct'l between !he mcdiana of eacb lrr ..... 1f'OUP. OIff«-
t'IIL'eI in t'lIPftIIInn Ineh _ Iakd for si •• Ik--=e with dw 
Duna', multlple-Comswilllll It'll. whktl aMlY1ir1 dllIeftoncft 
in ,..... sum between Nd'I tIftImenl JR", and C'OIIIroI. 'J'he 
Grut!tI'. !ell wu uled to IdenUry Iftd I'C'IIIOW ..... 1' .... ..a-
pia where appn"n.c. AIlIeIb ftt'e pet1ormC'd on Grlf!bPlld 
Priun S.O (GrIfIIIPId SonWaR Inc. I s..&lllkally ..... lkant elU-
f('f'('fttft were dC'ftned by P ~OS 
RESULTS 
R""I",/o" 0/ AOA.4ITS·1 ""tI ADAMTS.15 
",RNA rx,rruio" ".' "HT 
'J'hedfect o(DHT .... ~""t'lI~oI AOAMTS-
I and ADAMTS-" mRNA was ....,., .. uIiftI ..... ,,_ RT· 
PC.1t OHT tralmenl ctid no( siplk_ly rep'* e~ 
or ADAMTS-I mRNA • any 0( the ClIIaah'lliunl ul&.'d ,fit, 
ute I( al\. In ~ to \bI1, DHT w ....... dlM ........... 
the eapl\'llioR 0( ADAMTS-IS dNA. ADAMTS-15..aNA 
wu dowIIIqullkd by .,... .... 70"1 wtdI tIftlInCIIII 01 01 
.ad I 11M DHTrapma\'ely If",," Ubll. The K ........ W1IIIh 
tell demonIInIed .... the ....... bed a MplftQnd)' dUrer-
ent m.na: I, = .(022). nu.·'IIIU~ 1rII .. 
uled to ... IYle dlffemKn .. ,... ... betWfta C'&'b u.t-
mmt pt .. , Iftd ,,*roI. ADAMTS-IS mRNA ('I ........ 
Ij,Rilkantly dI"" ... ""'" ... ifni ..... 01 0.1 11M DHT tp 
<.OSI. I 11M DHT VI <.(1)11. I I'M ........ tp <.011 .... 
10 11M DHT with I pM Itu&uIIMte cp < .051. Cump.i .. dII: 
10 AM DHT ......... I"*P wtth!he 10 AM DHT .... I ,.M 
IhamIdr ..... IMIP IIbowcd no ..... AanI dllfCII'ftIW In 
ADAMTS-" eJ.prnaion. GnIt!b', tell was ...... to II1II 10 
nM DHT trNl ... fIOUII to .... fy .... rrlllP'e .. 0lIlIyUIt 
sample. after ........ the dllf~ In tile ..... ADAMTS-15 
mRNA elpmllioa bdweea Ihr alIIIIUI .... the 10 aM DHT 
IfOUP was si.-taM tp <.051.1 ....... eDNA ........ 
(II = 5) from lNCaP c:etlilmled with DHT and ....... ~ 
lDaIyted ... ", SYBR Gnen UU)'I. Retulb rmlll tIIetc eapcrl-
menIIlho Ibowcd ~ of ADAMTS-I~ .aNA by 
DHT thII .u DOl ..... tIIIed by ~ (cilia_ Ihowftl. AI 
a poUtiw control. ,.1Ilioft of PSA IIIRNA by DHT .. all" 
anaIyted. A. eapeded. PSA naIlNA eapmaioa ........ 
by DHT In a ~_. C'ompMId .Ida CODbUI. 
lISA mRNA was IIIWI'd'" .... row by 0.1 aM DHT. 9-fold hy 
I nM DHT,Iftd 4.HoId by 10 aM DHT (cilia"" "'"",. 
AII,lbotI, .. 1114.';8" 
AI we railed to hit ctw.neriI..- 01 Allo\fIn'S-I' ..... 
bodIn in the ~. _ ......... ~ of die 
IIdHt, 01 CIne IIUICb aatftIody • .....,.,.7. nil ......... a ... 
AlI ........... ' " : .. ....,.,., •• .-.-c... 
'" 
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FIgIn t. ~Of ADMITS-llf1d -15 mAHAlI'I I..NCIP CIIII.-dwlhDHT IfId ....... aiIIIlfIdiIogIn ............. c.II 
... ....., lor 24 IIrwlh .. .-:tIIddc-.. 01 OHT ar ...... IfId .......... Ifldc:DNA_.,......,tar ... ~ ....... RJ:PCR. 
Eactl dIM ~ ..... _ 1II1idW11M1 .... 01 cONo\. The harIzIInIIIbM dlnalllII iMdIIII C$I 1111111 ..... tar emt __ ...... 
EJpqIIiarI ..... 1I'I -....cI CIIIII .......... fI*I dIIrVII ..... 1D ccnftIIL (8) AlUla (II - 15) c:aIIIId ..... 15 __ ....... 
1tIOIIq"1IIPI'I1111lII1IMI 01 ADMIfS.1 mANA In lie -....cI CIIIII .... 10 C$IIIIICII.1n .....,CIIIICXIr*OO.i») AlUla c:aIIIId ..... 
11 ...... ~ In - 11).1turIng" ............... Of ADUlTS-15111ANA 11'1 .. ......, CIII ....... 10 .......... , In--.. 
cell (c:cI*oI). The .......... UIed It .. .,., 10 dInaII ....... gftqlllI'I "'*II '-"":'11'1 C$I II'e" ......... 1D OIII'MII .. 
• ~ • ....,.,... rp < .06. "p < .01. -p ~. 001). 
of die propeptide of ADAMTS-I S. C4--2b4 ails ~ 
more ADAMTS-I S IbM did LNCaP ails In petimiury npa'-
imenb (fiJift 2). lIIIki..,abe effect 0{ knoctdown more readily 
ddccgble oa I Wesaem blot. We them<ft utilized abe former 
cell line In Ihese c:IwacteriDIioa SIUdieI. ADAMTS-I S rnRNA 
esprnliOll in C4-2b4 proItaIe cancer ails was ilDllitcd by 
8()Il. (± I~." = 3) by siRNA specific for ADAMTS-IS. Pro-
lein expRSIioII_ 8IIIIyzed by WesIem bIoai .... IbodI of SO 
kDI were detected In aDdle IMes. but die bead WII IIIeI!UIInf 
in !hi: ails baled wid! ADAMTS-I S siRNA. Denlitometric 
MaI"si, 01 !hi: 5O-kDI bud showed IhIt ilS e~ _ 
knocbd down by over l1)li (FiJUR 3). To coaIroI ror erruB ill 
UIIIpIe ao.diaI. die meillllnne WII IIIripped ... thea rqJRIbed 
willi 1UII.i-<IAPDH _body. &.nds of 34 kDI wen! cIe&eded 
wiIb equal inImIity in die Pn'C lad ADAMTS-I S kDoctdowa 
J.nes. The bind was Ibtenl in die GAPDH tnockdowa J.nr 
(fipre 3). The dNcIioa 0{ ~ expralioa oldie 
5O-w. bind by die IIIIibocIy In die cdIIlR*:d willi IiRNA 10 
die AIJ,UITS/5 pne vailird * specildl)' 01 die IIdIocIy lad 
iIIuInkd ..... dIe lap prodIIcI rlOllllhele c:dIs WIll form 01 
die enzyme oI...,roliJDlldy SO UlL 
.'6-I.ti." of ADAMTS·15 prot,;" ,xpreuio" 
b,DHT 
To MIIyze die e&d 01 DHT ....... 011 An.uns-
IS protda expalioll. LNCaP celli weft! ~ wiIb DIn 
willi IDd ........ II ......... for n hr. WetIem bIoaiItt willi !be 
c. ............ 
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50 kD. 
37kO. 
25kDl 
F1gun 2. ADAMTS- I S expressJO/1 ., breast and prosta!e cancer 
eel ines probed WI Abeam ab4S047 arG-ADAMTS-15 antibody. 
Each ne was loaded 100 ,,0 01 proIBWl Bands 01 so kDa 
were deteded on Western bklIs 
SOkO'-.............. 
37kDe-
21'0.-
ADAMTS-15-
expression 
FIgIn a. VII 01 the spealicly 01 the ADAMTS-15 antilody 
ADNlTS-15 expresslon In C4-2b4 pro&ta cancer cells was Iran-
SlenIIy knock.ed oown. Western bIottrlg was pertormed WIth the 
cell !ysatBS. Each lane was loaded wth 100 ,,0 01 protHl. Lane 
1 was 1he tysate ~ moc:II-transl8cted eels (NrC) . Lane 2 was 
1TOm ADAMTS-IS knockdoWn eels: and Lane 3 !rom GAPOH 
knockdoWn cells The ~ panel Is an ImIge 01 the Iiot prob-
Ing the AD4MTS-15 anIIlodY A ro.kDa bind was detected In 
elCh lane The lower panel 15 an Image of the same membrane 
It had been s1rWed and fllP'obed anb-GAPDH antibody 
34-kDI bands were deteded ., Lanes 1 and 2 01 aquall'llenslty 
shoWIng thai the cItIererot In tntensay when the rnembrlw1e was 
probed br ADAMTS-15 was no! due to III8qUaI sample Ioadng. 
GAPOH knoc:tIdoWn led ID cornpIIMe absence 01 • band I'l Lane 3 
on the lower panel. These resltls .... represen 01 two 8lCP8I1-
ments 
IQ)e 
50 
37 
50 -
37-
=-1 :.: 1 :-r3\:-:\ ::1\:'\::7 
........ 0.1'-' 1.-. 10Il104 110M 10nM 
- . FIol 1,.. 
Figure 4. Etleclof DHT on AOAMTS-15 protein 8ICPfB$SIOn. West-
ern blotting was used to detect AOAMTS-1 5 expressIOn In lNCaP 
cells lreated lor 72 hr wIIh control. 0.1 nM DHT. 1 nM DHT. 10 nM 
DHT. 1 I'M n amide. and 10 nM DHT plus nutarnlde Cell layers 
were lysed WIth Triton X-l00 for protetn I!ldl'actlon. and protein was 
quantilled will !he MicroBCA assay. Each lane Joaded with 
100 " oof protein Bands of SO kDa were detected. The I!l(p9t'I'Ilent 
Is representative of two. with similar restJIts 
anu-ADAMTS- IS anubody reve led [I SO-kD b nd in all the 
lane (Figure ~ l. These b311ds w~e analyzed den ilometry. 
and in keeping with the mRNA d • ADAMTS-15 rr lein w 
downregul d by DHT in a d -dependent manner (Tabl 2). 
Th effect ~ no( inhibited b OUlamide. In [I. had been 
ob eved al lhe mRNA I vel. tre tm nt \l.uh nutnrmde I 
aI used downregul lion f ADAMTS-15 P tein. 
Pulati,'C' {mdro en rC'~poll e de", nl 
The DA fTSI5 gene h not been prevl Iy de ribed 
an androgen-regulated gene U ing the NUBI n online nu-
clear receptor binding ite search tool. the ADAM TS15 gene 
p moter and gene u n were screened to identif put · 
th AREs. We identified I ARE In the ADAAfTSI5 promoter 
and 12 10 the gene uen . ADAMTS· l mRl'lj ex· 
pre I n w oot regul ed by DHT 10 r cxperimen . 1be 
ADA}'fTSl gene h d 00 pulalhc AR in the prom ter region 
but had two In the gene sequence. l' ble 3 give the po ill n. on-
en lion. sequence. and score for the putati\'e REs identified. 
For pansoo. ~e pc~ rmed the search on the I,KUJ 
g ne. whi h i uprcgulQled by androgen. nod n the FOUl 1 
g ne. whi h i downregul ted b and gen (li Ie ~). Figure 
5 h . a hemllli repre ntati n of the AR identified 10 
the ADAMTSI. DA ITS15. and IIKLKJ genes_ The RE de-
tected ilion 169 of the hKLKJ promoter region I known 
~ the functi nal PSA ARE ucnce AGAACAgcaAGT-
ocr (35). The hKLKJ promoter had pproxlm tel d bl the 
ARE-to-bp rail mp d With the DAMTSI5 and FOUlI 
promoters. and the hXLK) gene sequence had appro 1m tl"1 
1.5 lime the rntio found in the ADA fTSI5 d FOUl I gene 
uence and ppro imatel 3 time the ratio in the AD. fT'SJ 
gene sequence. 
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T ... 2. OIIl.IDI'ftIIn: AnIIyIII '" BIndI DIIIctad on WIItBm BIDII ParIDnnId on ~ From 1WD Expar:maIIII. will ~ VDIIInI III 
III BandI 0UInIIIIIcI1IId ~WIllI ConboI 
Lana 8 
line 1 line 2 Lana 3 line 4 lineS OHT 10 11M .. 
ConboI OHTO.111M OHT 1 11M OHT 10 11M FIIamIda 111M FUllmldeluM 
ExpeI1menI 1 
A4UItId dIr1IIDmRIc volume (00 ~) 0.2025 0.1238 0.0806 0.0483 0.0668 0.066 
A4UItId volume raIaIM 10 conWoI 0.8 0.4 0.2 0.3 D.3 
ExpeI1menI 2 
A4UItId dIr1IIDmRIc volume (00 II11II') 0.2038 0.2231 0.0217 0.0022 0.05 0.0083 
A4UIIId volume raIIIIva 10 CDMDI 1 1.1 0.1 0.01 0.2 0.05 
Tllllle3. ~. 0rIen&IIIDn. ~. IIId SImIIIrIy Scont "'III AREa DIIIctad In lie ADAMTSf IIId ADAMTSJS Genae 
PDIIUDn (5nncII AIPeII 0rIIIatI0n ARE 5equance san 
ADMITS' 
PromoIIt 
Sequanoe 4833(·) OR OOTGCnIcaTGTGCT 0.112 
1878(+) OR TOOTCAlcaTGTTCT 0.111 
ADAMTS'S 
PIoInDeIIr ·2319(+) ER GGAM:~aGGTGCG 0.81 
5equencI 914 (+) OR ~TACT 0.111 
914 (_) ER AGCACCc:coAGTACT 0 .• 
914(.) IR AGCNXa:gNlTACT D.81 
928(. ) OR AGTACTcggGGTGCT 0 .• 
2367(_) ER GGCACAgclAGTCCC 0.111 
ee84(.) OR AGTGCTc:lgAGTGCA 0.87 
853(-) OR AGTGCCgagAGTGCT 0.84 
7038(+) IR TGTGCTgccTOOACT 0.88 
128110 (-) OR TGTCCCcICAGTGCC 0.81 
,.,23 (_, OR TGAACCgItAGTTCA 0.112 
,.,23( ) ER TGAACCgItAGTTCA 0.811 
19183 (f) IR AGCACTotcTGMCT 0.81 
lt1nH OR AGTTCAQlgAGTGCT 0.90 
247VO (f) IR AGTGCA8cfTGCACC 0.84 
, ..... 8ummIry "'lilt ARE o.ta lor ADAMTS,. ADAMTS,6. "KLK3.111d FOLHf GeMa 
ADMITSI AOIUITSIS hKLK3 FOUIl 
Gene Ioc:IIIDn 211121.3 111124·3 19q13.33 l1pl'.t 
AndIogIn I8gLIIIIon Nell fIIIIAIId 00wnraguIIIad IJpIegIMIId ~
PromoIIr 
lIngII (lip) 1.788 
AREa 0 
AREaperbp 0 
~ 
lIngII (lip) 9.121 
AREa 2 
AREaperbp 0.00022 
DISCUSSION 
Hormone Ihenp)' ror locally IdVllllCCd and IIIdUtalk 
prostlle canm' euenaJaily consists of iowerin, cin:ullllin. 111-
droFn ~I1InIliOft In order 10 silence andfoaen rKepIOr 
sianaHna. In our eqJetimenl5. we analyzed Ihe expression of 
ADAMTS-I and ADAMTS-I.5 undet d1tremlt c:onceIIInlions 
2,578 2.434 2.818 
1 2 1 
0.00038 0.000II2 0.00038 
24.848 6,860 82,033 
III 4 l!6 
0.00048 O.oooee 0.0004 
of DHT in ID aodroFn-retpOIIIive cell One. LNCaP. ADAMTS-
I mRNA expression was not siplfic:1DtIy fClUllIICd by DfIT. By 
conttul.. DHT downqulated die expression of ADAMTS-I.5 
mRNA and protein. Tbe AIlUffS15 JCIIe has not pcnioully 
been reponed 10 be .ndrupn fClUllIICd. II il known 10 be ex-
pressed In proItIIe cancer cell UI1CI (24). and III expreuion in 
bacUI cancef' is • aood ladic:ator of paliena survival (2'). ThII 
C. N.1IaIakwu II ... 
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hI<LIU --:;.F. .. ''''--... -------ec-• ., 
-I III-I II1II ... 
• • • 
TP 
~f,------~r~~~--------~----------~ .. ~·----.w------------...... ·· .111+) tMC·) 1IIlt.,....... ' .... . ,~., '''II(., . ~ 
...... ~ "'IIC-I '''771-' ,...., 
• • • 
TP 
r 
• • • 
F1guN .. NIIM AREs ........ In .. ADMITS'. MJAMTSJI. IIId MUC3 gil*. TM •• ..,.... at pan (T1Pt dIrIOIII .. 1IId ~ 
.. pn:IIIIOIIr end ...... ~ .. gInI ~ TM 1IQIIIOnI.1 of .. AREs,..... tD .. TIP .. 1ndIcIIICt ( .,1IId ( I dInaII ... 
8IId 1nIMNe ....... ~. 
rUin the possibility !hit ADT could be Uprqulllina ADAMTS-
15 cllpn:ssion In pro5taIe CMCer ~1I1 and InhibiUna tumor pro-
,mUon .• 1 \eul unIll the ~lIs bel."CJI'M andnJtet'I indepmbll. 
The relationship between lumorellpn:lSton of ADAMTS-15111d 
IUl'VlvaJ bas not yet been ItUctied in proMIIIe ~ ~. 
OUr ellperilDC'flls .110 showed !hit rather m.n inhibilina 
the action of DHT. ftutamidr actually had • limn. effect 15 
DHT In dowIlqulaliRJ ADAMTS-15 Cllpreuion. This aup-
ports prn10ul lindinp that mutaJons In the androfea ~ 
of proslIIe cancer cell. could lead to aberranl actIVIIion by 
.. naIl1eruids and ~ IIIdrotm rcceplof ..u,onilb 
(40-42,. LNCaP ~1I1 have. mutation in the andnJten Ilaplor 
Ii,and-bindin, domain in w_-II tllmmine I. c:hanaed 10 alInine 
at position an mm A 1.leadl.., lo IIIIdnlten ~ actlWliotl 
by nUWDidr (401. Other ancJroFn recepIOr mullliom hlw beetI 
identified In lumors of pallelU with proIlate cancer (43). Up lo 
68~ of JII'OIl* cancer pIllenb with dheue pI'OIfftIion while 
on treIlaIelll wllb nUlamide nperience diRuc mnilliotl when 
lluWDidr I. wilbdrawn (44-47). Thi. phenomenon. known 15 
the llablmide wlthdrrnl IYndrome. provIcb clink" evidence 
thai mutaUona In !he IIIIdroFn n:cqJlor of pnlIIIIIC caIICft eells 
could Ie .. to abemIIl actiVllion by tlutanlide. 
Activak!d androJen ~ bind to AREs In promoIer re-
,1oaI of lladluFn-rquIakd aaa. where &ranJaipUotI factoR 
II'C recruited by the n:cqJlOI'-Upnd complex (48). 1'ranIcrlp-
lion faclors roald be eUher coactIQIon or COftIII"IO"L Ie-
aultmeftl 01 coactIY1IIUrI by !he ~ wUl Ie ... lo IncreIIed 
tranlatplKJft of mRNA. while of ~ INdIa 
to dec:reued tnuIIcription (481. UIiIII .. ill UlinJ IIfIIIIU&it 
we .:Iftned !he AllU/TSI and ADAMTSU ..... for puI8. 
liw ARF... One ARE .. fOWld In tIw promoI« retloll of 
AllUITSI' but none In the II"-*' rep. 01 AlMIITS I. We 
.110 round IIeWfaI putadw AREa dowftIlreIM rlthe TSP 0( 
the AIlAMTS" .... ". railea tile poaINUIy ... OIl&! or 
100ft 0( IheIe AREa rouId be actina ... CIII\aftm. Unlib 
,me ~ .. eabancen ~_ be ~ .... tUllY ..... 
sand tip UpIUnm or dcJWIIIlftUI 0( the TIP (~I The ItKLXJ 
... hal IUd\ .. eahIAa:r CCIIlIW", .. ARE ... is ~ .. 
4.Dl tip upilft'am of die TSP (50). and 1nmII ..... MW 
found that proponionaIeIy IIkW AREa II'C IoC'aIed •• the .. 
ICIqUMCe &hie lei die ptoIIIIJI« rep. of andrufan· ........ 
Jeftft (511. whkb III In -... wtdl our ......... The ",..,-
k..n of tile ARE lo tip rIlio wtdI mpect 10 IIIIIImtea upI'CI' 
ulllioa or downftpIIIion is not Uowa. Our analylillIhowed 
that the ItKLXJ promoIer NJIoII had Ift:e tile ..... y of 1*-
tIllw AREa as Ihe FOUII and AllUITSH fIIOIIk*R 1'IlINr 
4 I. Thil may __ that IIIlW AREa are R'lqUinld 10 .eembIr 
coectIqIOf ~ "- II'C .. ired for die UItIIIbIy or 
corepIaIOr compieU!l. A ItaU_ .... lur 0Iher tnMCrip-
tion factor bindl", .. tea In dw pmmaIer retiona 0( AlltIlTSI . 
..... ... " ... ...."., .......... cw.. .,. 
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.) 
b) 
c) 
d) 
N·TennnuI C·TennlnuI 
2 .17 
1- 5Ion,1 peptide, 2- propeptlde doma n, 3- proteolyt c domain, . - dIsImegr1n4lke 
dom In, ! . tI1rombospondln do e.cyslein&-r1ct1 dol1'llln, end 7-sp&Cer regIOn 
Fur1n cleavage de jAto"'. Pile 
0:"8" .'::I:J, lC=>~~~ 
~M------~II ~I'--------------""'--""'''''''''''~M 
23 to. 10 kDa 
Predicted tINv &it. 
(Pro'-. Cys", 
l~~1(I1 
60IIDa IS IIDa 
Figure .. DonIakI structure of ADAMTS-16 and simIarIty 01 predicted eleavaOe products with ADAMTS-l , (a) A schemallc dIaIJam of the 
domains of I~ AOAMTs-15, (b) The IurIn cleavage 5 e and the prOOJc1s that would result. 0.. W ern bloCs <Id not detect a propepIJde 
fra~1 of 23 IIDa as would be expected from cleavage al this e. (e) The approxlmate posl1Ion of the predicted cleavage &lie that would 
produce a 6O-kDa ~ fragment detected on Western blois, and the slru<:tlKe of the C-lenninaJ region that would be released. (d) A 
SChematic ~ of the C-termlnal region lhal ls responsible lor the anllanglogenlc actMty 01 AowrS-l . The predicted C-Iennlnal deavage 
product lrom AOAMTS-15 (e) Is sJmIlar In structure to the antIangIogenIc region 01 AOAMTS-l , 
lbcpropcptide 
C. N. 1Ioiokwu' ..... 
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ADUG'8-1'. 
_1-1. '.~ .. :~:~===== .. .. ...... ..................... . 
:: :;'::::'::1 :=~::.wc::==== 
... .. .......... . ...................... . 
AfaMJ'1- 1 I, 
_1-1. All ."_"'-_ftA\IUOVIIII_""~~'" ... _  ...-___ IIIr__ -.no 
.. ........ . . ........... ~~ .... . 
~: ========E= :t:=: ....... ............ • ..... ... ....... t •••• 
n~ _aJ..IIY ........ __ .... I'I .. ~..,.,~ ..... . 
., •• ....,."..··N..,.lNn ..... Ko2' .... ~JCih. • .... --
.. ..... .. . .... .... . . 
1113 "--"'-~_"""IGCM~ 
... ------------~III. 
.. .. ...... ...... .. 
~-l', 
___ I, 
13'==-=::1 .. ., .. 
. .. ... . 
FIIIIn 7. PrI*IIn I8QU8IICIIIgmIenI Ollie predicted C-tarmnI CIIeIIQI procu:t 01 ADMITS-l& Ind lie --IIIIDUIIIII: C-..,...ngmn 
01 ADAMTS-l, The proI8In 18QI8IC8I'" oIlIIIned tom lie E....u WIb III ( .... ...a.org) Ind ....... __ ..-a .. 
cdN 8IQI8lC8111CPn1n1 tool SlM (WWW.IICPMY.chIIooIiII.Un-p.l*nI). The 001_ wei cyIIIN ~.. hIftIU.s ., CJIIJ 
5imilarity of ADAMTS-IS and ADAMTS-I (2S) sugetls tMl 
!he ADAmS-I S disintegrin-like domain. where we predict the 
clcavqe site lies. Is also a ~Ine-rich domain willi no disin-
tepin activity. 
ADAMTS enzymes are known to be C -tennlnally processed 
(26.56). and il is likely that !he form of ADAM1'S-1S we de-
tected has lost its C -tennlnal ancillary domains but retains the 
propeplide and catalytic domainL The propeptjde domain is 
thought 10 mlnlain the lalellc)' of the cllalytk domain. and IC-
tivllion of the caIaIytk domain is medialed by cleav.,e by pro-
protein convertase. such as furin (16). Retention of the propep-
tide implies Ihallhe catalytic domain of ADAM1'S-15 rmIIiRS 
inactive. and thus the proteolytic activity II muted, It is poasiblc 
lIIail calIlyticaily active fonn of ADAMTS-15. willi the prupep-
tide removed. Is also etpreSSed by LNCaP cells. u such a fOl11l 
would not have been detected by the anlibody used In our study. 
Analo8ously. the full Ienglll ADANTS-I and the C-tenninal 
qion of ADAMTS-I are reponed to display prometastalic and 
antimdaStlltic properties respcclively (27. S7). The C -tenninal 
qion containing three Ihrombospondin repealS and I spacer 
(figure 6) is responsible ror the antlanpOFnic properties of 
ADAMTS-I (S7). This qion of ADAMTS-I II very simi-
lar to the C -terminal rqion thai we pmlict il cleaved from 
ADAM'TS-IS (Fiaures 6 and 7). leavin, the pmpeptlde and 
the cIlaIylic domain of 50 kDa thai we ddected on our West-
ern blots. It is conceivable dial the potential proteolytic IC-
livity of the fOl11l of ADAMTS-15 tMl we have idftld8cd 
Is muted because the propeptide remains bound to the cal· 
alytic domain. and the C-tenniMI half of die molecule il reo 
leued 10 runction u an Inhibilor of aRJioIcncail in the tumor 
rnicruenvironmenl Somadc mutallOIII of ADAMTS15 "W 
been identified in bcaII and cololmal canca' celli (58--M). 
Analysll of the ADAMTSI5 mutadons In colorectal aIft-
cer cells predicl that shortened ........ forms or ADAMTS· 
15 are produced (60). No ..... ions of ADAMTS-15 .. ve 
been reponed in prostaIe cancer cdls. but In addition 
10 protcolytic processin,. this could be .nher pouIble 
elplanation for the delection of a 5O-kDa ADAMTS·15 
protein, 
It is ,meraI1y accepted that prostaIe and breal cancer .,.10-
aenesli correlates willi disease severity (61-63). and. 00Ied 
eartier. breast canca' patients with rcIalively blah« tumor ex-
prnsion of ADAMTS-15 have better survival (28). ~ 
undetJOlna AM evelllUally ~ to hormone refl'lClOfY 
pruilaIe cancu (HRPC). In HRPC. by m«hanlams whldl are 
not yet clearly undrrItood. andmten ~ _palin, resumes 
despise diminished Ineb of circu .... IIIdroFn (64). On the 
basil of our ftndiap. !his II likely to resull In downreaulaUon 
of ADAMTS-15 in the tumor rnicroenvlmnme-. c:oatribuUna 
10 the poor prognosis of palicnI5 who develop HRPC. 
In conclulion. we haw showII that ADAMTS-15 elpmsion 
II dowflnllUlated by androaen. sugesdn, thai ADT 1eads to 
269 
increased expression or ADAMTS-I!I in Ihe tumor microenvi-
ronment. and mutations in Ihe androgen receptor leading 10 an 
androgeo-independenl SIaIe may resull in constitutive cIownrea-
ulalion of ADAMTS-I!I. Its role in lRast cancer sugest.s thai 
ADAMTS-I!I has a cancer-repressive role. 
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